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A B S T R A C T
Background
This is an updated version of the original Cochrane Review published in Issue 11, 2006 of the Cochrane Database of Systematic Reviews.
Epilepsy is a commonneurological condition inwhich abnormal electrical discharges from the brain cause recurrent unprovoked seizures.
It is believed that with effective drug treatment up to 70% of individuals with active epilepsy have the potential to become seizure-free,
and to go into long-term remission shortly after starting drug therapy with a single antiepileptic drug (AED) in monotherapy.
The correct choice of first-line AED for individuals with newly diagnosed seizures is of great importance. It is important that the
choice of AEDs for an individual is made using the highest quality evidence regarding the potential benefits and harms of the various
treatments.
Carbamazepine or lamotrigine are recommended as first-line treatments for new onset focal seizures and as a first- or second-line
treatment for generalised tonic-clonic seizures. Performing a synthesis of the evidence from existing trials will increase the precision of
the results for outcomes relating to efficacy and tolerability and may assist in informing a choice between the two drugs.
Objectives
To review the time to treatment failure, remission and first seizure with lamotrigine compared to carbamazepine when used asmonother-
apy in people with focal onset seizures (simple or complex focal and secondarily generalised) or generalised onset tonic-clonic seizures
(with or without other generalised seizure types).
Search methods
We conducted the first searches for this review in 1997. For the most recent update, we searched the Cochrane Epilepsy Group
Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online
(CRSO), MEDLINE, Clinical Trials.gov and the WHO International Clinical Trials Registry Platform on 26 February 2018, without
language restrictions
Selection criteria
Randomised controlled trials comparing monotherapy with either carbamazepine or lamotrigine in children or adults with focal onset
seizures or generalised onset tonic-clonic seizures
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Data collection and analysis
This was an individual participant data (IPD) review. Our primary outcome was time to treatment failure and our secondary outcomes
were time to first seizure post randomisation, time to six-month, 12-month and 24-month remission, and incidence of adverse events.
We used Cox proportional hazards regression models to obtain trial-specific estimates of hazard ratios (HRs) with 95% confidence
intervals (CIs), using the generic inverse variance method to obtain the overall pooled HR and 95% CI.
Main results
We included 14 trials in this review. Individual participant data were available for 2572 participants out of 3787 eligible individuals
from nine out of 14 trials: 68% of the potential data. For remission outcomes, a HR of less than one indicated an advantage for
carbamazepine; and for first seizure and treatment failure outcomes, a HR of less than one indicated an advantage for lamotrigine.
The main overall results were: time to treatment failure for any reason related to treatment (pooled HR adjusted for seizure type: 0.71,
95% CI 0.62 to 0.82, moderate-quality evidence), time to treatment failure due to adverse events (pooled HR adjusted for seizure type:
0.55 (95% CI 0.45 to 0.66, moderate-quality evidence), time to treatment failure due to lack of efficacy (pooled HR for all participants:
1.03 (95% CI 0.75 to 1.41), moderate-quality evidence) showing a significant advantage for lamotrigine compared to carbamazepine
in terms of treatment failure for any reason related to treatment and treatment failure due to adverse events, but no different between
drugs for treatment failure due to lack of efficacy.
Time to first seizure (pooled HR adjusted for seizure type: 1.26, 95% CI 1.12 to 1.41, high-quality evidence) and time to six-month
remission (pooled HR adjusted for seizure type: 0.86, 95% CI 0.76 to 0.97, high-quality evidence), showed a significant advantage
for carbamazepine compared to lamotrigine for first seizure and six-month remission. We found no difference between the drugs for
time to 12-month remission (pooled HR for all participants 0.91, 95% CI 0.77 to 1.07, high-quality evidence) or time to 24-month
remission (HR for all participants 1.00, 95% CI 0.80 to 1.25, high-quality evidence), however only two trials followed up participants
for more than one year so evidence is limited.
The results of this review are applicable mainly to individuals with focal onset seizures; 88% of included individuals experienced
seizures of this type at baseline. Up to 50% of the limited number of individuals classified as experiencing generalised onset seizures at
baseline may have had their seizure type misclassified, therefore we recommend caution when interpreting the results of this review for
individuals with generalised onset seizures.
The most commonly reported adverse events for both of the drugs across all of the included trials were dizziness, fatigue, gastrointestinal
disturbances, headache and skin problems. The rate of adverse events was similar across the two drugs.
The methodological quality of the included trials was generally good, however there is some evidence that the design choice of masked
or open-label treatment may have influenced the treatment failure and withdrawal rates of the trials. Hence, we judged the quality
of the evidence for the primary outcome of treatment failure to be moderate for individuals with focal onset seizures and low for
individuals with generalised onset seizures. For efficacy outcomes (first seizure, remission), we judged the quality of evidence to be high
for individuals with focal onset seizures and moderate for individuals with generalised onset seizures.
Authors’ conclusions
Moderate quality evidence indicates that treatment failure for any reason related to treatment or due to adverse events occurs significantly
earlier on carbamazepine than lamotrigine, but the results for time to first seizure suggested that carbamazepine may be superior in
terms of seizure control. The choice between these first-line treatments must be made with careful consideration. We recommend that
future trials should be designed to the highest quality possible with consideration of masking, choice of population, classification of
seizure type, duration of follow-up, choice of outcomes and analysis, and presentation of results.
P L A I N L A N G U A G E S U M M A R Y
Lamotrigine versus carbamazepine monotherapy (single medication treatment) for epilepsy
This is an updated version of the Cochrane Review previously published in Issue 11, 2016 of the Cochrane Database of Systematic
Reviews.
Background
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Epilepsy is a common neurological disorder in which abnormal electrical discharges from the brain cause recurrent seizures. We studied
two types of epileptic seizures in this review: generalised onset seizures, in which electrical discharges begin in one part of the brain and
move throughout the brain; and focal onset seizures, in which the seizure is generated in and affects one part of the brain (the whole
hemisphere of the brain or part of a lobe of the brain). Focal seizures may become generalised (secondary generalisation) and move
from one part of the brain throughout the brain. For around 70% of people with epilepsy, a single antiepileptic medication can control
generalised onset or focal onset seizures.
This review applies to people with focal seizures (with or without secondary generalisation) and people with generalised tonic-clonic
seizures, a specific generalised seizure type. This review does not apply to people with other generalised seizure types such as absence
seizures or myoclonic seizures, as the recommended treatments for these seizure types are different.
Objective
Carbamazepine and lamotrigine are first-choice treatments for individuals with recently diagnosed epilepsy. The aim of this review was
to compare how effective these drugs are at controlling seizures, to find out if they are associated with side effects that may result in
individuals stopping the medication, and to inform a choice between these medications.
Methods
The last search for trials was in February 2018. We assessed the evidence from 14 randomised controlled trials comparing lamotrigine
with carbamazepine. We were able to combine information for 2572 people from nine of the 14 trials; for the remaining 1215 people
from five trials, information was not available to use in this review.
Results
The results of the review suggest that people are more likely to withdraw earlier from carbamazepine than lamotrigine treatment. The
most common medicine-related reason for withdrawal was side effects: 52% of total withdrawals in participants on carbamazepine and
36% of total withdrawals in participants on lamotrigine. The second most common medicine-related cause for withdrawal was seizure
recurrence: 58 of 719 total withdrawals (8%) on carbamazepine and 105 of 697 total withdrawals (15%) on lamotrigine.
The results suggest that recurrence of seizures after starting treatment with lamotrigine may happen earlier than treatment with
carbamazepine. They also suggest that freedom from seizures for a period of six months may occur earlier on carbamazepine than
lamotrigine. The majority of the people included in the 14 trials (88%) experienced focal seizures, so the results of this review apply
mainly to people with this seizure type.
The most common side effects reported by participants during the trials were dizziness, fatigue, gastrointestinal problems, headaches
and skin problems. These side effects were reported a similar number of times by people taking lamotrigine or carbamazepine.
Quality of the evidence
For people with focal onset seizures, we judged the quality of the evidence to be high for the outcomes of seizure recurrence and
remission of seizures and we judged the quality of the evidence to be moderate for the outcome of treatment failure. The design of
the trials (specifically, whether the people and treating clinicians knew which medication they were taking) may have influenced the
rates of withdrawal from treatments. Up to 50% of people in the trials used in our results may have been wrongly classified as having
generalised seizures; for people with generalised onset seizures, we judged the quality of the evidence to be moderate for the outcomes
of seizure recurrence and remission of seizures and low quality for the outcome of treatment failure.
Conclusions
For people with focal onset seizures, lamotrigine and carbamazepine are effective treatments and a choice between these two treatments
must be made carefully. More information is needed for people with generalised onset seizures. We recommend that all future trials
comparing these medications, or any other antiepileptic medications, should be designed using high-quality methods. Seizure types of
people included in trials should also be classified very carefully to ensure that the results are also of high quality.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Lamotrigine compared with carbamazepine for epilepsy
Patient or population: adults and children with focal onset or generalised onset seizures (generalised tonic-clonic with or without other generalised seizure types)
Settings: outpat ients
Intervention: lamotrigine
Comparison: carbamazepine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Carbamazepine Lamotrigine
Time to treatment fail-
ure (any reason related
to treatment)
All participants
Range of follow-up: 0 to
2420 days
The median t ime to
treatment failure was
1144 days in the carba-
mazepine group
The median t ime to
treatment failure was
1813 days (669 days
longer) in the lamotrig-
ine group
HR 0.71 (0.62 to 0.82)a 2481 (9 trials) ⊕⊕⊕©
moderateb
HR of less than 1 indi-
cates an advantage for
lamotrigine.
Treatment failure due
to adverse events
also occurred signif i-
cant ly earlier on car-
bamazepine compared
to lamotrigine: HR 0.54
(95% CI 0.45 to 0.65,
P<0.00001)
There was no dif fer-
ence between lamotrig-
ine and carbamazepine
in terms of treatment
failure due to lack of ef -
f icacy: HR 1.03 (95% CI
0.75 to 1.41, P=0.86)
4
L
a
m
o
trig
in
e
v
e
rsu
s
c
a
rb
a
m
a
z
e
p
in
e
m
o
n
o
th
e
ra
p
y
fo
r
e
p
ile
p
sy
:
a
n
in
d
iv
id
u
a
l
p
a
rtic
ip
a
n
t
d
a
ta
re
v
ie
w
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Time to treatment fail-
ure (any reason related
to treatment)
Subgroup: focal onset
seizures
Range of follow-up: 0 to
2420 days
The median t ime to
treatment failure was
1149 days in the carba-
mazepine group
The median t ime to
treatment failure was
1699 days (550 days
longer) in the lamotrig-
ine group
HR 0.74 (0.64 to 0.86) 2182 (9 trials) ⊕⊕⊕©
moderateb
HR of less than 1 indi-
cates an advantage for
lamotrigine.
Treatment failure due
to adverse events
also occurred signif i-
cant ly earlier on car-
bamazepine compared
to lamotrigine: HR 0.56
(95% CI 0.45 to 0.68,
P<0.00001)
Treatment failure due
to lack of ef f icacy was
not calculated for fo-
cal onset seizures sub-
group due to small num-
bers of individuals with-
drawing f rom treatment
for lack of ef f icacy
Time to treatment fail-
ure (any reason related
to treatment)
Subgroup: generalised on-
set seizures
Range of follow-up: 0 to
1446 days
The 25th percent ile* *
of t ime to treatment
failure was 57 days
in the carbamazepine
group
The 25th percent ile* *
of t ime to treatment
failure was 510 days
(453 days longer) in the
lamotrigine group
HR 0.51 (0.33 to 0.78) 299 (6 trials) ⊕⊕©©
lowc,d
HR of less than 1 indi-
cates an advantage for
lamotrigine
Treatment failure due
to adverse events
also occurred signif i-
cant ly earlier on car-
bamazepine compared
to lamotrigine: HR 0.49
(95%CI 0.27 to 0.88, P=
0.02)
Treatment failure due
to lack of ef f icacy was
not calculated for fo-
cal onset seizures sub-
group due to small num-
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bers of individuals with-
drawing f rom treatment
for lack of ef f icacy
* Illustrat ive risks in the carbamazepine and lamotrigine groups are calculated at the median t ime to treatment failure (i.e. the t ime to 50%of part icipants failing or withdrawing
f rom allocated treatment) within each group across all t rials. The relat ive ef fect (pooled hazard rat io) shows the comparison of ’t ime to treatment failure’ between the
treatment groups
* * The 25th percent ile of t ime to treatment failure (i.e. the t ime to 50% of part icipants failing or withdrawing f rom allocated treatment) is presented for the subgroup with
generalised seizures as less than 50% of part icipants failed / withdrew f rom treatment, therefore the median t ime could not be calculated
Abbreviations: 95% CI: 95% conf idence interval; HR: hazard rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a. Pooled hazard rat io for all part icipants adjusted for seizure type.
b. Downgraded once due to high risk of bias due to the open-label design of f ive trials included in the analysis (Eun 2012; Lee
2011; Nieto-Barrera 2001; Reunanen 1996; SANAD A 2007); the design of the trial may have inf luenced the withdrawal rates.
c. Downgraded once due to high risk of bias due to the open-label design of three trials included in the analysis (Lee 2011;
Reunanen 1996; SANAD A 2007); the design of the trial may have inf luenced the withdrawal rates.
d. Downgraded once due to potent ial m isclassif icat ion of generalised onset seizures in up to 50%of part icipants in the trials.
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B A C K G R O U N D
This review is an update of a previously published review in the
Cochrane Database of Systematic Reviews (Issue 11, 2016) on ’Lam-
otrigine versus carbamazepine monotherapy for epilepsy: an indi-
vidual participant data review’ (Gamble 2006; Nolan 2016a)
Description of the condition
Epilepsy is a common neurological condition in which abnormal
electrical discharges from the brain cause recurrent unprovoked
seizures. Epilepsy is a disorder of many heterogenous seizure types,
with an estimated incidence of 33 to 57 per 100,000 person-
years worldwide (Annegers 1999; Hirtz 2007; MacDonald 2000;
Olafsson 2005; Sander 1996), accounting for approximately 1%
of the global burden of disease (Murray 1994). The lifetime risk
of epilepsy onset is estimated to be 1300 to 4000 per 100,000
person-years (Hauser 1993; Juul-Jenson 1983), and the lifetime
prevalence could be as large as 70millionpeopleworldwide (Ngugi
2010). It is believed that with effective drug treatment, up to 70%
of individuals with active epilepsy have the potential to go into
long-term remission shortly after starting drug therapy (Cockerell
1995; Hauser 1993; Sander 2004), and around 70% of individ-
uals can achieve seizure freedom using a single antiepileptic drug
(AED) in monotherapy (Cockerell 1995). Current National In-
stitute for Health and Care Excellence (NICE) guidelines rec-
ommend that both adults and children with epilepsy should be
treated with monotherapy wherever possible (NICE 2012). The
remaining 30% of individuals experience refractory or drug-re-
sistant seizures, which often require treatment with combinations
of antiepileptic drugs (AEDs) or alternative treatments, such as
epilepsy surgery (Kwan 2000).
We studied two seizure types in this review: generalised onset
seizures, in which electrical discharges begin in one part of the
brain and move throughout the brain; and focal onset seizures, in
which the seizure is generated in and affects one part of the brain
(the whole hemisphere of the brain or part of a lobe of the brain).
Description of the intervention
Carbamazepine was amongst the earliest ’traditional’ medications
licensed for the treatment of epileptic seizures and has been com-
monly used as monotherapy for focal onset and generalised onset
seizures for over 30 years (Shakir 1980). Lamotrigine is among a
’second generation’ of AEDs, licensed asmonotherapy for epileptic
seizures following demonstrations of efficacy compared to ’tradi-
tional’ AEDs such as carbamazepine (Brodie 1995; Brodie 1999;
Reunanen 1996).
Comparative trials have shown newer AEDs such as lamotrigine to
be to be generally well tolerated asmonotherapy in both adults and
children, and related to fewer adverse events, fewer serious adverse
events and fewer drug interactions with concomitant AEDs and
other concomitant medications than ’traditional’ first-line AEDs
such as carbamazepine (Brodie 1995; Brodie 1999; French 2007;
Reunanen 1996).
Evidence regarding teratogenic effects (disturbances to foetal de-
velopment) of carbamazepine and lamotrigine is conflicting and
uncertain. It is thought that the risk of congenital malformation
may be higher for women taking carbamazepine compared to the
general population (Meador 2008; Morrow 2006), and carba-
mazepine has been shown to be associated with neural tube de-
fects (Matlow 2012). The risk of malformations is thought to be
lower for women taking lamotrigine than carbamazepine (Meador
2008), but the risk of malformation may increase with an increas-
ing dose of lamotrigine (Morrow 2006). It is unclear whether tak-
ing carbamazepine or lamotrigine during pregnancy has any neg-
ative neurodevelopmental effects on the child (Bromley 2014).
Current NICE guidelines for adults and children recommend car-
bamazepine or lamotrigine as first-line treatments for new onset
focal seizures and as second-line treatments for generalised tonic-
clonic seizures (NICE 2012). Lamotrigine is considered a suitable
first-line treatment for new onset generalised seizures if sodium
valproate is considered unsuitable. Carbamazepine may be a suit-
able second-line treatment for generalised onset seizures but may
exacerbate myoclonic or absence seizures (Liporace 1994; Shields
1983; Snead 1985).
How the intervention might work
Antiepileptic medications suppress seizures by reducing neuronal
excitability (disruptionof the usualmechanisms of a neuronwithin
the brain, which may lead to an epileptic seizure) (MacDonald
1995). Lamotrigine and carbamazepine are broad-spectrum treat-
ments suitable for many seizure types, and both have an anti-
convulsant mechanism through blocking ion channels and bind-
ing with neurotransmitter receptors, or through inhibiting the
metabolism or reuptake of neurotransmitters (Brodie 1996; Lees
1993; Ragsdale 1991).
Why it is important to do this review
With evidence that up to 70% of individuals with active epilepsy
have the potential to go into long-term remissionof seizures shortly
after starting drug therapy (Cockerell 1995; Hauser 1993; Sander
2004), the correct choice of first-line antiepileptic therapy for in-
dividuals with newly diagnosed seizures is of great importance. It
is important that the choice of AEDs for an individual is made
using the highest quality evidence regarding the potential benefits
and harms of various treatments. It is also important that the ef-
fectiveness and tolerability of AEDs appropriate to given seizure
types are compared to one another.
Therefore the aim of this review is to summarise efficacy and toler-
ability from existing randomised controlled trials comparing lam-
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otrigine and carbamazepine, two current first-line recommended
treatments for use in monotherapy for epileptic seizures. Perform-
ing a synthesis of the evidence from existing trials will increase
the precision of the results for outcomes relating to efficacy and
tolerability and may assist in informing a choice between the two
drugs.
There are difficulties in undertaking a systematic review of
epilepsy monotherapy trials as the important efficacy outcomes
require analysis of time-to-event data (for example, time to first
seizure after randomisation). Although methods have been devel-
oped to synthesise time-to-event data using summary informa-
tion (Parmar 1998; Williamson 2002), the appropriate statistics
are not commonly reported in published epilepsy trials (Nolan
2013a; Williamson 2000). Furthermore, although most epilepsy
monotherapy trials collect seizure data, there has been no uni-
formity in the definition and reporting of outcomes. For exam-
ple, trials may report time to 12-month remission but not time
to first seizure or vice versa, or some trials may define time to
first seizure from the date of randomisation while others use the
date of achieving maintenance dose. Trial investigators have also
adopted differing approaches to the analysis, particularly with re-
spect to the censoring of time-to-event data. For these reasons,
we performed this review using individual participant data (IPD),
which helps to overcome these problems. This review is one in a se-
ries of Cochrane IPD reviews investigating pair-wise monotherapy
comparisons (Marson 2000; Nevitt 2017b; Nolan 2013b; Nolan
2013c; Nolan 2016b; Nolan 2016c; Nolan 2016d). These data
have also been included in IPD network meta-analyses of anti-
epileptic drug monotherapy (Tudur Smith 2007; Nevitt 2017a)
O B J E C T I V E S
To review the time to treatment failure, remission and first
seizure with lamotrigine compared to carbamazepine when used as
monotherapy in people with focal onset seizures (simple or com-
plex focal and secondarily generalised) or generalised onset tonic-
clonic seizures (with or without other generalised seizure types).
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomised controlled trials (RCTs) using either an
adequate method of allocation concealment (e.g. sealed, opaque
envelopes) or a ’quasi’ method of randomisation (e.g. allocation
by date of birth).
• Trials may have been double-blind, single-blind or
unblinded.
• Trials must have included a comparison of lamotrigine
monotherapy with carbamazepine monotherapy in individuals
with epilepsy.
Types of participants
• We included children or adults with focal onset seizures
(simple focal, complex focal or secondarily generalised tonic-
clonic seizures) or generalised onset tonic-clonic seizures, with or
without other generalised seizure types (in other words, those
who had only generalised tonic-clonic seizures and those who
had both generalised onset tonic-clonic seizures and generalised
seizures of other types (e.g. absence, myoclonic etc.)).
• We excluded individuals with other generalised seizure
types alone without generalised tonic-clonic seizures (e.g. those
who had only absence seizures without any generalised clonic
tonic-seizures) due to differences in first-line treatment
guidelines for other generalised seizure types (NICE 2012).
• We included individuals with a new diagnosis of epilepsy,
or who have had a relapse following antiepileptic monotherapy
withdrawal.
Types of interventions
Carbamazepine or lamotrigine as monotherapy.
Types of outcome measures
Below is a list of outcomes investigated in this review. Reporting
of these outcomes in the original trial report was not an eligibility
requirement for this review.
Primary outcomes
Time to treatment failure (retention time). This was a combined
outcome reflecting both efficacy and tolerability, as the following
may have lead to failure of treatment: continued seizures, side ef-
fects, non-compliance or the initiation of additional add-on treat-
ment. This is an outcome to which the participant makes a contri-
bution and is the primary outcome measure recommended by the
Commission on Antiepileptic Drugs of the International League
Against Epilepsy (ILAE 1998; ILAE 2006).
Time to treatment failure is considered according to three defini-
tions:
1. Time to treatment failure for any treatment related reason
(continued seizures, side effects, non-compliance or the
initiation of additional add-on treatment)
2. Time to treatment failure due to adverse events (i.e. side
effects)
3. Time to treatment failure due to lack of efficacy (i.e.
continued seizures)
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Secondary outcomes
• Time to first seizure post randomisation.
• Time to achieve six-month remission (seizure-free period).
• Time to achieve 12-month remission (seizure-free period).
• Time to achieve 24-month remission (seizure-free period).
• Incidence of adverse events (all reported whether related or
unrelated to treatment) and adverse events leading to treatment
failure.
Search methods for identification of studies
Electronic searches
The first searches for this review were run in 1997. Subsequent
searches were run in July 2014, December 2015 and October
2016. For the most recent update we searched the following
databases.
• Cochrane Epilepsy Group Specialized Register (26 February
2018) using the search strategy set out in Appendix 1.
• Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies Online
(CRSO, 26 February 2018) using the search strategy set out in
Appendix 2.
• MEDLINE (Ovid, 1946 to 26 February 2018) using the
search strategy set out in Appendix 3.
• ClinicalTrials.gov (26 February 2018) using the search
terms ’Lamotrigine AND carbamazepine | Epilepsy’.
• WHO International Clinical Trials Registry Platform
(ICTRP, 26 February 2018) using the search terms ’ Lamotrigine
AND carbamazepine AND Epilepsy’.
We imposed no language restrictions.
Searching other resources
We reviewed the reference lists of retrieved studies to search for ad-
ditional reports of relevant trials. We contacted Ciba Geigy (man-
ufacturers of carbamazepine), GlaxoSmithKline (manufacturers of
lamotrigine) and the original investigators of relevant trials iden-
tified by our search.
Data collection and analysis
Selection of studies
Two review authors (SJN and AGM) independently assessed trials
for inclusion, resolving any disagreements by mutual discussion.
Data extraction and management
We requested the following individual participant data for all trials
meeting our inclusion criteria.
Trial methods
• Method of generation of random list
• Method of concealment of randomisation
• Stratification factors
• Blinding methods
Participant covariates
• Gender
• Age
• Seizure types
• Time between first seizure and randomisation
• Number of seizures prior to randomisation (with dates)
• Presence of neurological signs
• Electroencephalographic (EEG) results
• Computerised tomography/magnetic resonance imaging
(CT/MRI) results
Follow-up data
• Treatment allocation
• Date of randomisation
• Dates of follow-up
• Dates of seizures post randomisation or seizure frequency
data between follow-up visits
• Dates of treatment withdrawal or treatment failure and
reasons for treatment withdrawal or treatment failure
• Dose
• Dates of dose changes
For each trial for which we did not obtain individual participant
data (IPD), we carried out an assessment to see whether any rele-
vant aggregate level data had been reported or could be indirectly
estimated using the methods of Parmar 1998, and Williamson
2002. Where graphical time-to-event data (e.g. Kaplan Meier
curves) were published with or without corresponding effective
numbers at risk, we used a Microsoft Excel spreadsheet (Excel
2010), to indirectly estimate hazard ratios (Tierney 2007).
Four trials including 1391 participants provided seizure data in
terms of the number of seizures recorded between each follow-up
visit rather than specific dates of seizures (Eun 2012; Lee 2011;
SANAD A 2007; Werhahn 2015). To enable the calculation of
time-to-event outcomes, we applied linear interpolation to ap-
proximate dates of seizures between follow-up visits. For example,
if the trial recorded four seizures between two visits that occurred
on 1 March 2010 and 1 May 2010 (interval of 61 days), then
the date of first seizure would be approximately 13 March 2010.
This allowed the computation of an estimate of the time to six-
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month remission, 12-month remission, 24-month remission and
first seizure.
We calculated time to six-month, 12-month and 24-month re-
mission from the date of randomisation to the date (or estimated
date) that the individual had first been free of seizures for six, 12
or 24 months, respectively. If the person had one or more seizures
during the trial, a six-month, 12-month or 24 month seizure-free
period could also occur between the estimated date of the last
seizure during the trial and a period of six, 12 or 24 months of
seizure freedom.
We calculated time to first seizure from the date of randomisation
to the date that we estimated their first seizure to have occurred. If
seizure data were missing for a particular visit, we censored these
outcomes at the previous visit. We also censored these outcomes if
the individual died or if follow-up ceased prior to the occurrence
of the event of interest. We used these methods in five trials in-
cluding 1383 participants (Brodie 1995 A; Brodie 1995 B; Brodie
1999;Nieto-Barrera 2001; Reunanen 1996), for whichwe directly
received outcome data (dates of seizures after randomisation).
For all trials we received data for date and reason of withdrawal
from the treatment or the date and reason for treatment failure.
Time to treatment failure was calculated as date of randomisation
to date of treatment failure. For the analysis of time-to-event, we
defined an ’event’ as treatment failure because of reasons related
to the treatment (i.e. lack of efficacy, adverse events, or both lack
of efficacy and adverse events, non-compliance with the treatment
regimen, withdrawal of consent from the trial, etc.). We censored
the outcome if treatment failure or withdrawal of treatment was
for reasons not related to the trial treatment: i.e. loss to follow-up,
death (not treatment or epilepsy-related), treatment withdrawn
due to remission, etc. We also censored individuals who were still
on allocated treatment at the date of the end of follow-up. We
considered documented reasons for treatment failure or treatment
withdrawal on a case-by-case basis for relation to treatment; two
authors (SJN andAGM) independently classified reasons for treat-
ment failure as events or censored and resolved any disagreements
by discussion. If reasons for treatment failure were classified differ-
ently as events or censored in the included trials to our definitions,
we conducted sensitivity analyses to account for differences in the
definition of a treatment failure ’event’ (see Sensitivity analysis).
For the analysis of ’Time to treatment failure due to adverse events,’
only treatment failures which were documented to be due to ad-
verse events (either as a sole reason or due to both a lack of efficacy
and adverse events) were classed as an ’event’ within time-to-event
analyses and all other reasons for treatment failure were censored.
Similarly, for the analysis of ’Time to treatment failure due to lack
of efficacy’ only treatment failures which were documented to be
due to lack of efficacy (i.e. continued seizures, either as a sole reason
or due to both a lack of efficacy and adverse events) were classed
as an ’event’ within time-to-event analyses and all other reasons
for treatment failure were censored.
Assessment of risk of bias in included studies
Two review authors (SJN and JW) independently assessed the
risk of bias for each trial using the Cochrane ’Risk of bias’ tool,
as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We rated each of the following six
domains as low, unclear or high risk of bias: method of generat-
ing random sequence, allocation concealment, blinding methods,
incomplete outcome data, selective outcome reporting and other
sources of bias. Any discrepancies in risk of bias judgements of the
two review authors were resolved by discussion. In the event of the
presence of high risk of bias in included trials (due to inadequate
allocation concealment or lack of blinding), we planned sensitivity
analyses excluding these trials.
Measures of treatment effect
We measured all outcomes in this review as time-to-event out-
comes with the hazard ratio (HR) and 95% confidence interval
(CI) used as the measure of treatment effect. We calculated out-
comes from IPD provided, where possible, or extracted from pub-
lished trials if possible.
Unit of analysis issues
The unit of allocation and analysis was the individual for all in-
cluded trials; and no trials included in meta-analyses were of a
repeated measures (longitudinal) nature or of a cross-over design.
One included trial allocated participants to three treatment arms,
100 mg/day lamotrigine, 200 mg/day lamotrigine or 600 mg/day
carbamazepine (Reunanen 1996). In the primary analysis for all
outcomes, we pooled the two lamotrigine arms and calculated
a hazard ratio of lamotrigine compared to carbamazepine using
the IPD provided. In sensitivity analysis, we calculated separate
hazard ratios for 100 mg/day lamotrigine versus carbamazepine
and 200mg/day lamotrigine versus carbamazepine to examine any
difference in the doses of lamotrigine compared to carbamazepine.
Dealing with missing data
For each trial that supplied IPD, we reproduced results from trial
results where possible and performed the following consistency
checks.
• We cross-checked trial details against any published report
of the trial and contacted original trial authors if we found
missing data, errors or inconsistencies. If trial authors could not
resolve inconsistencies between the IPD and the published data,
depending on the extent of the inconsistencies, we performed
sensitivity analysis or excluded the data from the meta-analysis.
• We reviewed the chronological randomisation sequence and
checked the balance of prognostic factors, taking account of
factors stratified for in the randomisation procedure.
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Assessment of heterogeneity
We assessed heterogeneity statistically using the Q test (P value
less than 0.10 for significance) and the I² statistic (Higgins 2003)
(greater than 50% indicating considerable heterogeneity), with
output produced using the generic inverse variance approach out-
lined in Data and analyses, and visually by inspecting forest plots.
Assessment of reporting biases
Two review authors (SJN and JW) undertook all full quality and
’Risk of bias’ assessments according to the methods outlined in
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011). In theory, a review using IPD should overcome
issues of reporting biases as unpublished data can be provided and
unpublished outcomes calculated. We requested trial protocols
with IPD for all trials. Any selective reporting bias detected could
be assessed with the Outcome Reporting Bias In Trials (ORBIT)
classification system (Kirkham 2010).
Data synthesis
We carried out our analysis on an intention-to-treat basis (that
is, we analysed participants in the group to which they were ran-
domised, irrespective of which treatment they actually received).
Therefore, for the time-to-event outcomes, ’time to six-month re-
mission’, ’time to 12-month remission’, ’time to 24 month remis-
sion’ and ’time to first seizure post randomisation’, we did not cen-
sor participants if treatment was withdrawn or if treatment failure
occurred but follow-up within the trial continued (e.g. if a partic-
ipant continued to be followed up on a different treatment).
An intention-to-treat analysis tends toward finding no difference
between treatments and we would have undertaken a secondary
’protocol correct’ analysis as a sensitivity analysis if the primary
analyses had suggested equivalence, in which case participants
would have been censored at the time of treatment failure for
seizure outcomes.
For all outcomes, we investigated the relationship between the
time-to-event and treatment effect of the AEDs. We used Cox
proportional hazards regressionmodels to obtain trial-specific esti-
mates of log (hazard ratio) or treatment effect and associated stan-
dard errors in Stata Statistical Software, version 14 (Stata 2015).
The model assumes that the ratio of hazards (risks) between the
two treatment groups is constant over time (i.e. hazards are pro-
portional). We tested this proportional hazards assumption of the
Cox regression model for each outcome of each trial by testing
the statistical significance of a time varying covariate in the model.
We evaluated overall pooled estimates of hazard ratios (with 95%
confidence intervals) using the generic inverse variance method.
We expressed results as a hazard ratio (HR) and a 95% confidence
interval (CI).
By convention, a HR greater than 1 indicates that an event is
more likely to occur earlier on lamotrigine than on carbamazepine.
Hence, for time to treatment failure or time to first seizure, a HR
greater than 1 indicates a clinical advantage for carbamazepine
(e.g. a HR of 1.2 would suggest a 20% increase in hazard of treat-
ment failure from lamotrigine compared with carbamazepine),
and for time to six-month, 12-month and 24-month remission a
HR greater than 1 indicates a clinical advantage for lamotrigine
(i.e. the seizure-free period occurs earlier on lamotrigine than car-
bamazepine).
Subgroup analysis and investigation of heterogeneity
There is a strong clinical belief that some AEDs are more ef-
fective in some seizure types than others (see Description of the
intervention and How the intervention might work), therefore
we stratified all analyses by seizure type (focal onset versus gener-
alised onset), according to the classification of main seizure type at
baseline. We classified focal seizures (simple or complex) and fo-
cal secondarily generalised seizures as focal epilepsy. We classified
primarily generalised seizures as generalised epilepsy.
We conducted a Chi² test of interaction between treatment and
epilepsy type. If we found significant statistical heterogeneity to be
present, we performedmeta-analysis with a random-effects model
in addition to a fixed-effect model, presenting the results of both
models and performing sensitivity analyses to investigate differ-
ences in trial characteristics. If heterogeneity is found to be present
in future updates and available data allow, we may investigate vari-
ables that may contribute to the variability (e.g. participant co-
variates, trial design) via regression models
Sensitivity analysis
We performed several sensitivity analyses to test the robustness of
our results to characteristics of the included trials, as follows.
• Definition of time to treatment failure: we classified reasons
for treatment failure that were related to the trial treatment as
’events’ and ’censored’ reasons not related to treatment in the
analysis of ’time to treatment failure’. If reasons for treatment
failure were classified differently as events or censored in
included trials to our definitions, we conducted sensitivity
analyses to account for differences in the definition of a
treatment failure ’event’.
One trial considered participants to have completed the trial and
hence withdrew treatment if they experienced a seizure after week
six (Reunanen 1996). This does not correspondwith the treatment
failure definition recommended by ILAE 1998, and used in this
review. We included treatment failure data for the participants
from this study, Reunanen 1996, in the primary analysis of time
to treatment failure and excluded them in sensitivity analysis to
examine any effect of the difference in definition of treatment
failure.
• Seizure dates: one trial did not include seizures that
occurred during the first four weeks of the trial in efficacy
analyses and dates of seizures before week four were not supplied
11Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
to us (Nieto-Barrera 2001). Therefore, we calculated seizure
outcomes as the time to first seizure and time to six-month
remission after week four rather than after randomisation. We
included seizure data from this study in the primary analysis of
time to first seizure and time to six-month remission and
excluded them in sensitivity analysis to examine any effect of the
difference in origin time of the seizure count.
• Aggregate data: time to treatment failure was presented as
summary statistics or graphically in four of the trials for which
IPD were not available (Gilad 2007; Rowan 2005; Saetre 2007;
Steinhoff 2005) and time to first seizure was presented
graphically in three of the trials for which IPD were not available
(Gilad 2007; Rowan 2005; Saetre 2007). In Saetre 2007, hazard
ratios and 95% confidence intervals were published for both
time-to-event outcomes. Due to the small number of events for
the outcomes in two studies (Gilad 2007; Steinhoff 2005), it was
possible to estimate individual treatment failure/seizure times
from the graphs and therefore calculate an estimated hazard ratio.
In Rowan 2005, we used indirect methods and approximate
numbers at risk at a range of time points throughout the trials
(described in Data extraction and management) to estimate the
hazard ratios for the outcomes. These estimated hazard ratios are
combined with the hazard ratios calculated from the trials
providing IPD in sensitivity analysis.
• Seizure freedom: all included trials were of at least 24 weeks’
(around six months’) duration. Those providing IPD that were
over six months’ duration contributed to the outcome ’time to
six-month remission of seizures’ (Brodie 1995 A; Brodie 1995 B;
Eun 2012; Lee 2011; Reunanen 1996; SANAD A 2007;
Werhahn 2015). Two trials were of 24 weeks’ duration (Brodie
1999; Nieto-Barrera 2001).
We conducted sensitivity analysis calculating a pooled risk ratio
of seizure freedom at six months and including the data from two
studies (Brodie 1999; Nieto-Barrera 2001), (assuming 24 weeks is
approximately equal to six months) and the trials for which IPD
were not available. We estimated seizure freedom at six months
from the graph of time to first seizure published in Saetre 2007.
We also conducted sensitivity analysis, calculating a pooled risk
ratio of seizure freedom throughout the whole trial combining
IPD and aggregated data from all included trials.
• Misclassification of seizure type is a recognised problem in
epilepsy, whereby some people with generalised seizures have
been mistakenly classed as having focal onset seizures and vice
versa. There is clinical evidence that individuals with generalised
onset seizures are unlikely to have an ’age of onset’ greater than
25 to 30 years (Malafosse 1994). Such misclassification impacted
upon the results of three reviews in our series of pair-wise reviews
for monotherapy in epilepsy comparing carbamazepine,
phenobarbitone, phenytoin and sodium valproate in which
around 30% to 50% of participants analysed may have had their
seizure type misclassified as generalised onset (Nolan 2016d;
Nolan 2016b; Nevitt 2017b). Given the potential biases
introduced into those reviews, we examined the distribution of
age at onset for individuals with generalised seizures in the trials
included in this review, to assess the potential impact of
misclassification of seizure type on the outcomes.
Two trials recruited only individuals with focal onset seizures (Eun
2012; Werhahn 2015), therefore there were no participants with
new onset generalised seizures over the age of 30 in these trials.
Two trials were designed to include participants with focal onset
seizures only, however three participants in Nieto-Barrera 2001,
and nine participants in SANADA 2007, were classified as having
generalised onset seizures. Further, seizure type was missing for 85
participants in SANADA 2007. We considered the individuals in
these two trials to have a misclassification of seizure type. Overall:
• in Brodie 1995 A, 20 out of the 54 participants (37%)
classified as having generalised onset seizures were over the age of
30 at entry into the trial (and all over the age of 29 at seizure
onset);
• in Brodie 1995 B, 23 out of the 62 participants (37%)
classified as having generalised onset seizures were over the age of
30 at entry into the trial (and all over the age of 29 at seizure
onset);
• in Brodie 1999, all 45 of the participants (100%) classified
as having generalised onset seizures were over the age of 30 at
entry into the trial (no age of onset data provided);
• in Lee 2011, 9 out of the 15 participants (60%) classified as
having generalised onset seizures were over the age of 30 at entry
into the trial (no age of onset data provided);
• in Reunanen 1996, 43 out of the 114 participants (38%)
classified as having generalised onset seizures were over the age of
30 at entry into the trial (and all over the age of 23 at seizure
onset).
In total, 152 out of 302 participants (50%) classified as having
generalised onset seizures may have been wrongly classified as hav-
ing new onset generalised seizures. To investigate misclassification
for each outcome, we undertook two sensitivity analyses:
• we reclassified the 152 individuals with generalised seizure
types and age at onset greater than 30 as having focal onset
seizures and repeated subgroup analysis;
• for SANAD A 2007, we reclassified the 152 individuals
with generalised seizure types and age at onset greater than 30,
and the 85 individuals with missing seizure type, into an
’uncertain seizure type’ group and repeated subgroup analysis
with three groups.
Summary of findings and quality of the evidence
(GRADE)
For the 2016 update, in a post hoc change from protocol, we have
added two ’Summary of findings’ tables to the review (outcomes
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in the tables decided before the update started based on clinical
relevance).
Summary of findings for themain comparison reports the primary
outcome of ’time to treatment failure’ in the subgroups of par-
ticipants with focal onset seizures, generalised onset seizures and
overall adjusted by epilepsy type.
Summary of findings 2 reports the secondary outcomes of ’time
to first seizure’ and ’time to 12-month remission’ in the subgroups
of participants with focal onset seizures, generalised onset seizures
and overall adjusted by epilepsy type. (Due to small numbers of
participants with generalised seizures contributing to the outcome
of time to 12-month remission, an overall treatment effect for all
participants is presented in Summary of findings 2.)
We determined the quality of the evidence using the GRADE ap-
proach, where we downgraded evidence in the presence of high
risk of bias in at least one trial, indirectness of the evidence, unex-
plained heterogeneity or inconsistency, imprecision of results and
high probability of publication bias. We downgraded evidence by
one level if the limitation was considered serious and two levels if
considered very serious, as judged by the review authors. Under
the GRADE approach, evidence may also be upgraded if a large
treatment effect is demonstrated with no obvious biases or if a
dose-response effect exists.
R E S U L T S
Description of studies
Results of the search
We included five trials in previous versions of this review (Brodie
1995 A; Brodie 1995 B; Brodie 1999; Nieto-Barrera 2001;
Reunanen 1996).
For the 2016 update of this review, we identified 148 records from
the databases and search strategies outlined in Electronic searches.
We removed 40 duplicate records and screened the titles and ab-
stracts of 108 records for inclusion in the review. We excluded
81 records based on the title and abstract and assessed 27 full-
text articles for inclusion in the review. We excluded 18 articles
from the review (see Excluded studies below), classified one ar-
ticle as awaiting assessment (Korean Lamotrigine Study Group
2008) and included eight additional trials (Eun 2012; Gilad 2007;
Lee 2011; Rowan 2005; Saetre 2007; SANAD A 2007; Steinhoff
2005; Werhahn 2015).
For the 2018 update of this review, we identified 52 records from
the databases and search strategies outlined in Electronic searches.
We removed 17 duplicate records and screened the titles and ab-
stracts of 35 records for inclusion in the review. All 35 records were
clearly irrelevant and were excluded. The one article which was
classified as awaiting in assessment in the 2016 update of the re-
view was now included (Korean Lamotrigine Study Group 2008).
Therefore, we included a total of 14 studies were included in the
review (see Included studies).
See Figure 1 for a PreferredReporting Items for SystematicReviews
and Meta-Analyses (PRISMA) study flow diagram.
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Figure 1. Study flow diagram.
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Included studies
We identified 13 published reports that met the inclusion criteria
for this review (Brodie 1995; Brodie 1999; Eun 2012; Gilad 2007;
Korean Lamotrigine Study Group 2008; Lee 2011; Nieto-Barrera
2001; Reunanen 1996; Rowan 2005; Saetre 2007; SANAD A
2007; Steinhoff 2005; Werhahn 2015). One of the published re-
ports (Brodie 1995), contained results on two separate randomised
controlled trials run on very similar protocols (Brodie 1995 A;
Brodie 1995 B). Although the two trials were reported within the
same publication we treated them as separate trials within this
Cochrane Review; therefore we included a total of 14 trials in the
review.
One trial recruited adults of all ages (Gilad 2007), and one trial
recruited adults over the age of 16 (Lee 2011). One trial recruited
children between the ages of 6 and 12 (Eun 2012). Two trials
recruited individuals over the age of 12 (Reunanen 1996; Steinhoff
2005), and two recruited individuals over the age of 13 (Brodie
1995 A; Brodie 1995 B). One trial recruited individuals over the
age of two (Nieto-Barrera 2001), and one recruited individuals
over the age of four (SANAD A 2007). Four trials recruited the
elderly; two trials recruited individuals over the age of 60 (Rowan
2005; Werhahn 2015), and two recruited individuals over the age
of 65 (Brodie 1999; Saetre 2007). The remaining trial did not
state the eligible age ranges recruited (Korean Lamotrigine Study
Group 2008).
Five trials were designed to recruit individuals with focal seizures
only (Eun 2012; Lee 2011; Nieto-Barrera 2001; SANADA 2007;
Werhahn 2015); however three of these trials did recruit some in-
dividuals with generalised onset seizures (Lee 2011; Nieto-Barrera
2001; SANAD A 2007). We examine this seizure classification in
sensitivity analysis. The remaining nine trials recruited individu-
als with focal or generalised tonic-clonic seizures with or without
other generalised seizure types.
Seven trials recruited individuals with new onset seizures (Brodie
1995 A; Brodie 1995 B; Brodie 1999; Eun 2012; Saetre 2007;
Steinhoff 2005; Werhahn 2015). Four trials recruited individuals
with new onset or untreated seizures (Korean Lamotrigine Study
Group 2008; Lee 2011; Nieto-Barrera 2001; Reunanen 1996),
one trial recruited individualswith newonset, untreated or seizures
treated to a “sub-therapeutic” level (Rowan 2005), one trial re-
cruited individuals with new onset, relapsed or recurrent seizures
(failure of an AED not randomised in the trial) (SANADA 2007),
and one trial recruited individuals with new onset seizures follow-
ing ischaemic stroke (Gilad 2007).
Four multicentre trials were conducted in the UK (Brodie 1995 A;
Brodie 1995 B; Brodie 1999; SANAD A 2007). Two multicentre
trials were conducted across Europe (Saetre 2007;Werhahn2015),
one multicentre trial across Europe and Mexico (Nieto-Barrera
2001), and one multicentre trial across Europe and Australia
(Reunanen 1996). One multicentre trial was conducted in Ger-
many (Steinhoff 2005), one multicentre trial in the USA (Rowan
2005), threemulticentre trials in theRepublic ofKorea (Eun 2012;
Korean Lamotrigine Study Group 2008; Lee 2011), and one sin-
gle-centre trial was conducted in Israel (Gilad 2007).
We did not obtain individual participant data (IPD) for five trials
including a total of 1215 participants. According to trial sponsor,
GlaxoSmithKline, data could not be located for two trials (Korean
Lamotrigine Study Group 2008; Saetre 2007), and data could not
be provided due to restrictions over the anonymisation of datasets
of trials conducted inGermany (Steinhoff 2005). For the other two
trials, we made contact with the authors/sponsors who expressed
interest in collaborating in this IPD meta-analysis but at the time
of writing, no data had been received (Gilad 2007; Rowan 2005).
If IPD are received from these trials, we will include the data in
future updates.
Individual participant data were available for the remaining nine
trials, which recruited a total of 2572 participants, representing
68% of 3787 individuals from all 14 identified eligible trials.
Data were available for the following participant characteristics
(percentage of 2572 participants with data available): drug ran-
domised (100%), sex (99%, data missing for 18 participants in
SANAD A 2007), seizure type (97%, data missing for 85 par-
ticipants in SANAD A 2007), age at randomisation (99%, data
missing for 18 participants in SANAD A 2007, one participant
in Nieto-Barrera 2001, and two participants in Reunanen 1996),
and number of seizures in the six months prior to randomisation
(99%, missing for 18 participants in SANADA 2007, one partic-
ipant in Reunanen 1996, and six participants in Werhahn 2015).
Time since first seizure to randomisation was provided for 691
participants out of 695 participants from four trials (Brodie 1995
A; Brodie 1995 B; Eun 2012 (data missing for one participant);
Reunanen 1996 (data missing for three participants)).
Seven trials provided the results of neurological examinations for
1693 out of 1711 participants (99%) (Brodie 1995 A; Brodie 1995
B; Brodie 1999; Eun 2012; Lee 2011; Reunanen 1996; SANAD
A 2007 (data for 18 participants missing)).
Six trials provided electroencephalographic (EEG) results for 710
out of 1044 participants (64%) (134 from Brodie 1995 A, 118
from Brodie 1995 B, 84 from Eun 2012, 110 from Lee 2011, 26
from Reunanen 1996, and 238 from Werhahn 2015).
Seven trials provided computerised tomography/magnetic reso-
nance imaging (CT/MRI) results for 788 out of 1194 participants
(66%) (94 from Brodie 1995 A, 92 fromBrodie 1995 B, 149 from
Brodie 1999, 84 from Eun 2012, 110 from Lee 2011, 21 from
Reunanen 1996, and 238 from Werhahn 2015).
See the Characteristics of included studies table, Table 1 and Table
2 for further details.
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Excluded studies
We excluded seven duplicate references (Eun 2008; Lee 2010;
Ramsay 2003; Saetre 2006; Saetre 2009; Saetre 2010; Steinhoff
2004), and retained the most relevant primary reference for the
trial in the review (Eun 2012; Lee 2011; Rowan 2005; Saetre
2007; Steinhoff 2005, respectively). We excluded five trials that
did not compare lamotrigine and carbamazepine (Czapinski 1997;
Gilliam 1998; Motte 1997; Steiner 1999; Stolarek 1994). We ex-
cluded three trials thatwere not of amonotherapy design (Carmant
2001; Fakhoury 2000; Jawad 1989). We excluded two trials that
were not randomised (Martinez 2000; Zeng 2010). We excluded
one trial that did not make a fully randomised comparison of
lamotrigine and carbamazepine (Baxter 1998); lamotrigine was
compared to the treating physician’s choice of carbamazepine or
sodium valproate. See Characteristics of excluded studies for fur-
ther details.
Risk of bias in included studies
For further details, see the Characteristics of included studies table
and Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
(1) Trials for which we received individual participant data
(information reported in published papers or provided with
IPD)
All nine trials used adequate methods of randomisation via com-
puter-generated random list and we judged them to be at low risk
of bias (Brodie 1995 A; Brodie 1995 B; Brodie 1999; Eun 2012;
Lee 2011; Nieto-Barrera 2001; Reunanen 1996; SANADA 2007;
Werhahn 2015); two trials reported that block randomisation was
used (Lee 2011; Werhahn 2015), and one trial reported that min-
imisation was used (SANAD A 2007).
Seven trials reported adequate methods of allocation concealment
and we judged them to be at low risk of bias; five concealed
treatment allocation with sealed, opaque envelopes (Brodie 1995
A; Brodie 1995 B; Brodie 1999; Nieto-Barrera 2001; Reunanen
1996); one trial used telephone randomisation to a central alloca-
tion service (SANAD A 2007), and one trial used pharmacy allo-
cation (Werhahn 2015). The remaining two trials did not report
how allocation was concealed and we judged them to be at unclear
risk of bias (Eun 2012; Lee 2011).
(2) Trials for which no individual participant data were
available (information reported in published papers only)
One of the trials reported that blocked randomisation via a com-
puter-generated list and telephone randomisation to a central al-
location service were used (Rowan 2005). We judged this trial to
be at low risk of selection bias for random sequence generation
and allocation concealment. The remaining four trials were de-
scribed as “randomised” but did not provide information about
the method of generation of the random list or allocation conceal-
ment so we judged them to be at unclear risk of bias (Gilad 2007;
Korean Lamotrigine Study Group 2008; Saetre 2007; Steinhoff
2005).
Blinding
(1) Trials for which we received individual participant data
(information reported in published papers or provided with
IPD)
Four trials were double-blind (participants and personnel) with
the blinding achieved by using tablets of identical appearance; we
judged these trials to be at low risk of performance bias (Brodie
1995 A; Brodie 1995 B; Brodie 1999; Werhahn 2015). In all four
of these trials, the trial investigator was blinded but no information
was provided as to whether other outcome assessors were blinded,
therefore we judged all four trials to be at unclear risk of detection
bias.
The remaining five trials were open-label and we judged them to
be at high risk of performance and detection bias (Eun 2012; Lee
2011; Nieto-Barrera 2001; Reunanen 1996; SANAD A 2007).
(2) Trials for which no individual participant data were
available (information reported in published papers only)
Two trials were double-blind (participants and personnel) with the
blinding achieved by using double dummy tablets; we judged these
trials to be at low risk of performance bias (Rowan 2005; Saetre
2007). However, for these two trials no information was provided
regarding blinding of outcome assessors therefore we judged the
two trials to be at unclear risk of detection bias.
The remaining three trials were open-label and we judged them
to be at high risk of performance and detection bias (Gilad 2007;
Korean Lamotrigine Study Group 2008; Steinhoff 2005).
Incomplete outcome data
(1) Trials for which we received individual participant data
(information reported in published papers or provided with
IPD)
In theory, a review using individual participant data should over-
come issues of attrition bias as unpublished data can be provided,
unpublished outcomes calculated and all randomised participants
can be analysed by an intention-to-treat approach. All nine tri-
als provided individual participant data for all randomised indi-
viduals and reported the extent of follow-up for each individual
(Brodie 1995A;Brodie 1995 B;Brodie 1999; Eun2012; Lee 2011;
Nieto-Barrera 2001; Reunanen 1996; SANAD A 2007; Werhahn
2015).We queried anymissing data with the original trial authors.
From the information provided by the authors, we deemed the
small amount of missing data present (see Included studies) to be
missing at random and not effecting our analysis.
(2) Trials for which no individual participant data were
available (information reported in published papers only)
Three trials reported attrition rates and analysed all randomised
participants using an intention-to-treat approach and we judged
them to be at low risk of attrition bias (Gilad 2007; Rowan 2005;
Saetre 2007). The remaining two trials did not analyse data for all
randomised participants (Korean Lamotrigine Study Group 2008;
Steinhoff 2005) and one of the trials did not state to which drug
those excluded from analysis were randomised (Steinhoff 2005).
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This is not an intention-to-treat analysis therefore we judged these
trials to be at high risk of attrition bias.
Selective reporting
(1) Trials for which we received individual participant data
(information reported in published papers or provided with
IPD)
In theory, a review using individual participant data should over-
come issues of reporting biases as unpublished data can be pro-
vided and unpublished outcomes calculated. We sought trial pro-
tocols in all individual participant data requests and seven proto-
cols were provided (Brodie 1995 A; Brodie 1995 B; Brodie 1999;
Nieto-Barrera 2001; Reunanen 1996; SANAD A 2007; Werhahn
2015). We received sufficient individual participant data to calcu-
late all outcomes for all nine trials (depending on trial duration;
e.g. time to 12-month remission could not be calculated for a trial
of 24 weeks etc.)
(2) Trials for which no individual participant data were
available (information reported in published papers only)
Protocols were not available for any of the four trials, however
a clinical summary report was provided for two trials from the
sponsor (Saetre 2007; Steinhoff 2005), and case report forms of
data collected were provided for one trial by the sponsor (Rowan
2005). All trials reported seizure and adverse event outcomes well,
therefore we judged all five trials to be at low risk of selective
reporting bias (Gilad 2007; Korean Lamotrigine Study Group
2008; Rowan 2005; Saetre 2007; Steinhoff 2005).
Other potential sources of bias
We identified no other sources of bias for 13 of the 14 included
trials (Brodie 1995 A; Brodie 1995 B; Brodie 1999; Eun 2012;
Korean Lamotrigine Study Group 2008; Lee 2011; Nieto-Barrera
2001; Reunanen 1996; Rowan 2005; Saetre 2007; SANAD A
2007; Steinhoff 2005;Werhahn 2015). In one trial, it was unclear
if all participants were receivingAEDmonotherapy treatment (’to-
tal number of AEDs’ described in Table 1 of the publication), so
we judged this trial to be at unclear risk of bias (Gilad 2007).
Effects of interventions
See: Summary of findings for themain comparison Summary of
findings: lamotrigine compared with carbamazepine for epilepsy
(primary outcomes); Summary of findings 2 Summary of
findings: lamotrigine compared with carbamazepine for epilepsy
(secondary outcomes)
See Table 3 for details regarding the number of individuals (with
individual participant data (IPD)) contributing to each analysis,
Summary of findings for the main comparison for a summary
of the results for the primary outcome ’time to treatment failure’
(stratified by epilepsy type), and Summary of findings 2 for a sum-
mary of results for the secondary outcomes ’time to first seizure’
and ’time to 12-month remission’.
For survival curve plots (cumulative incidence), see Figure 3;
Figure 4; Figure 5; Figure 6; Figure 7; Figure 8; Figure 9; Figure 10;
Figure 11; Figure 12 and Figure 13. We produced all cumulative
incidence plots in Stata software version 14 (Stata 2015), using
data from all trials providing IPD combined. We note that partici-
pants with event times of zero (i.e. those who withdrew from treat-
ment or experienced seizure recurrence on the day of randomi-
sation) are not included in the ’Numbers at risk’ on the graphs
and that data is not stratified by trial within these survival curve
plots. All figures are intended to provide a visual representation
of outcomes, extent of follow-up and visual differences between
seizure types. These graphs are not intended to show statistical
significance and numerical values may vary compared to the text
due to differences in methodology.
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Figure 3. Time to treatment failure for any reason related to treatment (CBZ: Carbamazepine; LTG:
Lamotrigine)
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Figure 4. Time to treatment failure due to adverse effects (CBZ: Carbamazepine; LTG: Lamotrigine)
21Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 5. Time to treatment failure due to lack of efficacy (CBZ: Carbamazepine; LTG: Lamotrigine)
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Figure 6. Time to treatment failure for any reason related to treatment - by seizure type (CBZ:
Carbamazepine; LTG: Lamotrigine)
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Figure 7. Time to treatment failure for due to adverse events - by seizure type (CBZ: Carbamazepine; LTG:
Lamotrigine)
24Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 8. Time to first seizure (CBZ: Carbamazepine; LTG: Lamotrigine)
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Figure 9. Time to first seizure - by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)
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Figure 10. Time to six-month remission (CBZ: Carbamazepine; LTG: Lamotrigine)
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Figure 11. Time to six-month remission - by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)
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Figure 12. Time to 12-month remission (CBZ: Carbamazepine; LTG: Lamotrigine)
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Figure 13. Time to 24-month remission (CBZ: Carbamazepine; LTG: Lamotrigine)
We calculated all hazard ratios (HRs) presented below by generic
inverse variance fixed-effect meta-analysis unless otherwise stated.
All analyses met the assumption of proportional hazards (addition
of time-varying covariate into the model non-significant) unless
stated below.
Primary outcome
Time to treatment failure
For this outcome, a HR of less than 1 indicates a clinical advantage
for lamotrigine.
See Table 4 for reasons for premature termination for 3768 par-
ticipants in all 14 included trials (missing data for 19 participants
from one trial (Korean Lamotrigine Study Group 2008)), and
how we classified these reasons in analysis of IPD. In one study,
one participant randomised to lamotrigine had missing date and
reason for treatment failure (Nieto-Barrera 2001), and in another
study two participants had missing dates of treatment failure (one
withdrew from lamotrigine due to remission of seizures and one
withdrew from carbamazepine due to ’other’ reasons not related
to the allocated drug) (SANAD A 2007).
Times to treatment failure and reasons for treatment withdrawal
or treatment failure were available for 2569 participants from the
nine trials providing IPD (99.9% of 2572 participants with IPD
available included in this analysis, see Table 3) (Brodie 1995 A;
Brodie 1995 B; Brodie 1999; Eun 2012; Lee 2011; Nieto-Barrera
2001; Reunanen 1996; SANAD A 2007; Werhahn 2015).
Out of 3768 participants for whom we had reasons for treat-
ment failure or withdrawal, 1416 participants prematurely with-
drew from treatment (38%): 697 out of 2144 (33%) participants
randomised to lamotrigine and 719 out of 1624 (44%) partic-
ipants randomised to carbamazepine. We deemed 1224 partici-
pants (86% of total treatment failures) to have withdrawn for rea-
sons related to the allocated drug: 602 (86% of treatment failures)
on lamotrigine and 622 (87% of treatment failures) on carba-
mazepine and we classified these reasons as ’events’ in the analysis.
The most common treatment-related reason for treatment failure
was adverse events: 624 withdrawals (44% of total treatment fail-
ures), 251 (36% of total treatment failures) on lamotrigine and
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373 (52% of total treatment failures) on carbamazepine.
We classed the other 192 reasons (95 on lamotrigine and 97 on
carbamazepine) to be not related to the allocated drug and cen-
sored these participants in the analysis, in addition to the 2352 par-
ticipants (1447 on lamotrigine and 905 on carbamazepine) who
completed the trial without withdrawing or failing treatment.
Considering time to treatment failure for any reason related to the
treatment, the overall pooledHR (for 2569 participants providing
IPD from nine trials) was 0.73 (95% confidence interval (CI) 0.64
to 0.82, P < 0.00001, moderate-quality evidence) indicating a
statistically significant advantage with lamotrigine; in other words,
treatment failure occurred significantly earlier on carbamazepine
compared to lamotrigine in the nine included trials (Analysis 1.1).
No important heterogeneity was present between trials (I2= 13%).
Considering time to treatment failure due to adverse events (all
other reasons for treatment failure or treatment withdrawal cen-
sored in analysis), the overall pooled HR (for 2569 participants
providing IPD from nine trials) was 0.54 (95% CI 0.45 to 0.65,
P < 0.00001, moderate-quality evidence) indicating a statistically
significant advantage with lamotrigine; in other words, treatment
failure due to adverse events occurred significantly earlier on car-
bamazepine compared to lamotrigine in the nine included trials
(Analysis 1.2). No heterogeneity was present between trials (I2=
0%).
Considering time to treatment failure due to lack of efficacy (all
other reasons for treatment failure or treatment withdrawal cen-
sored in analysis), 1874 participants provided IPD from five trials;
, no participants withdrew from one or both of the drugs due to
lack of efficacy in four trials (Brodie 1999; Eun 2012; Lee 2011;
Reunanen 1996; see Table 4). The overall pooled HR was 1.03
(95% CI 0.75 to 1.41, P =0.86, moderate-quality evidence) in-
dicating no statistically significant difference between lamotrigine
and carbamazepine (Analysis 1.3). No heterogeneity was present
between trials (I2= 0%).
Subgroup analyses: seizure type (focal versus generalised
onset)
Seizure type wasmissing for 85 participants fromSANAD A2007,
and nine participants were classified as having generalised onset
seizures, even though the trial was designed to include only partic-
ipants with focal onset seizures. Similarly, in Nieto-Barrera 2001,
including participants with focal onset seizures, three participants
were classified as having generalised onset seizures. The latter three
participants were excluded from the subgroup analyses (all com-
pleted the trial).
Considering time to treatment failure for any reason related to
the treatment,for participants with generalised onset seizures (299
participants providing IPD from six trials), the pooled HR was
0.51 (95% CI 0.33 to 0.78, P = 0.002, I² = 18%, low-quality
evidence) and for participants with focal onset seizures (2182 par-
ticipants providing IPD from nine trials) the pooled HR was 0.74
(95% CI 0.64 to 0.86, P = 0.0001, I² = 0%, moderate-quality
evidence) (Analysis 1.4), indicating a statistically significant ad-
vantage for lamotrigine over carbamazepine for both participants
with focal onset and generalised onset seizures. Excluding the nine
participants from SANADA 2007 with generalised onset seizures
produced similar results and did not change the conclusions.
The test for subgroup differences between focal and generalised
onset seizures was not statistically significant (P = 0.10, I² = 63.4%
for variability due to subgroup differences).
The overall pooled HR (adjusted for epilepsy type for 2481 par-
ticipants from nine trials) was HR 0.71 (95% CI 0.62 to 0.82, P <
0.00001, moderate-quality evidence). No important heterogene-
ity was present between trials overall (I2 =3%).
Considering time to treatment failure due to adverse events, for
participants with generalised onset seizures (284 participants pro-
viding IPD from five trials), the pooled HR was 0.49 (95% CI
0.27 to 0.88, P = 0.002, I² = 52%, low-quality evidence) and for
participants with focal onset seizures (2182 participants providing
IPD from nine trials) the pooled HR was 0.56 (95% CI 0.45 to
0.68, P<0.00001, I² = 0%, moderate-quality evidence) (Analysis
1.5), indicating a statistically significant advantage for lamotrig-
ine over carbamazepine for both participants with focal onset and
generalised onset seizures. Excluding the nine participants from
SANAD A 2007 with generalised onset seizures produced similar
results and did not change the conclusions.
The test for subgroup differences between focal and generalised
onset seizures was not statistically significant (P = 0.70, I² =0%
for variability due to subgroup differences).
The overall pooled HR (adjusted for epilepsy type for 2466 par-
ticipants from nine trials) was HR 0.55 (95% CI 0.45 to 0.66,
P < 0.00001, moderate-quality evidence). No heterogeneity was
present between trials overall (I² =0%).
Due to small numbers of participants withdrawing from treatment
due to lack of efficacy (see Table 4), and even smaller numbers
within each seizure type subgroup, subgroup analysis by seizure
type was not conducted for time to treatment failure due to lack
of efficacy was not conducted.
Sensitivity analyses
One study, Reunanen 1996, considered participants to have com-
pleted the trial and hence withdrew treatment if they experi-
enced a seizure after week six. This does not correspond with the
treatment failure definition recommended by the Commission on
Antiepileptic Drugs of the International League Against Epilepsy
(ILAE 1998); therefore we performed sensitivity analysis exclud-
ing this trial from Analysis 1.1 and Analysis 1.4. This sensitivity
analysis produced similar results and did not change the conclu-
sions.
One included trial allocated participants to three treatment arms:
100 mg/day lamotrigine (LTG100), 200 mg/day lamotrigine
(LTG 200) or 600 mg/day carbamazepine (CBZ) (Reunanen
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1996). See Table 5 for a sensitivity analysis comparing the primary
analysis (LTG arms pooled versus CBZ), LTG 100 with the other
arms in the trial, LTG 200 with the other arms in the trial, LTG
200 versus CBZ and LTG 100 versus CBZ.When including these
alternative estimates in meta-analysis, the pooled result is numer-
ically similar and the conclusions unchanged.
From four out of the five trials without IPD available, we indi-
rectly estimated aggregate hazard ratios of time to treatment fail-
ure due to adverse events (Gilad 2007), time to early termination
(Rowan 2005), and retention time (Steinhoff 2005), and we ex-
tracted a published hazard ratio for time to all-cause withdrawal
(Saetre 2007). We were unable to estimate or extract an estimate
from Korean Lamotrigine Study Group 2008. We note that these
definitions do not directly correspond to our definition of treat-
ment failure (i.e. all withdrawals and treatment failures are classed
as events rather than only treatment-related failures, see Table 4).
Combining IPD and aggregate data, the pooled HR for 3391 par-
ticipants from 13 included trials was 0.709 (95% CI 0.63 to 0.78,
P < 0.00001, I² = 27%) (Analysis 1.6). This indicates that the ad-
vantage to lamotrigine over carbamazepine remains and is robust
to the inclusion of treatment failure data of variable definitions.
Given the subjective nature of the outcome of time to treatment
failure, an outcome which can be influenced by the participant
and personnel, we conducted a further subgroup analysis separat-
ing the trials that were of a double-blind design (Brodie 1995 A;
Brodie 1995 B; Brodie 1999; Rowan 2005; Saetre 2007;Werhahn
2015, 1231 participants included in analyses) and those which
were an open-label design (Eun 2012; Gilad 2007; Lee 2011;
Nieto-Barrera 2001; Reunanen 1996; Steinhoff 2005; SANAD
A 2007, 2160 participants included in analyses). Including treat-
ment failure data from 13 trials (aggregate data from four trials),
we found the following results.
• In the double-blind trials, 242 out of 644 (38%)
randomised participants withdrew from lamotrigine and 313 out
of 587 (53%) withdrew from carbamazepine (in total 45% of
participants withdrew from the randomised drug for any reason).
• In the open-label trials, 368 out of 1248 (29%) randomised
participants withdrew from lamotrigine and 369 out of 915
(40%) withdrew from carbamazepine (in total 34% of
participants withdrew from the randomised drug for any reason).
• The advantage for lamotrigine over carbamazepine was
slightly larger in the double-blind trials (HR 0.65, 95% CI 0.56
to 0.75, P<0.00001, I² = 24%) than in the open-label trials (HR
0.76, 95% CI 0.65 to 0.90, P=0.001, I² = 21%) (Analysis 1.7).
• When including only the nine trials for which IPD were
provided (double-blind: Brodie 1995 A; Brodie 1995 B; Brodie
1999; Werhahn 2015; open-label: Eun 2012; Lee 2011;
Nieto-Barrera 2001; Reunanen 1996; SANAD A 2007), the
advantage for lamotrigine over carbamazepine was still slightly
larger in the double-blind trials (HR 0.68, 95% CI 0.57 to 0.81,
P<0.0001, I² = 36%) than the open-label trials (HR 0.77, 95%
CI 0.65 to 0.92, P=0.003, I² = 0%)
These results suggest that the design of a trial (i.e. whether or
not a participant and their clinician is aware of the treatment a
participant is taking) may influence the withdrawal rates of the
trial, with participants significantly more likely to withdraw from
a double-blind trial than an open-label trial (45% versus 34%:
risk ratio (RR) 1.32 (95% CI 1.22 to 1.44, P < 0.00001)), and
in turn this may influence the perceived effectiveness of the two
drugs under comparison.
Following reclassification of 152 individuals from seven trials with
potentially misclassified generalised onset seizures (Brodie 1995
A; Brodie 1995 B; Brodie 1999; Lee 2011; Nieto-Barrera 2001;
Reunanen 1996; SANAD A 2007), and 85 individuals with miss-
ing seizure type from one trial (SANAD A 2007), the results of
the two sensitivity analyses are shown in Table 6. In summary,
the results overall by seizure type and for individuals with focal
onset seizures are very similar. Also, following reclassification, the
advantage for lamotrigine over carbamazepine in those with gen-
eralised onset seizures is reduced and the test of difference between
subgroups is no longer significant. There is a statistically signifi-
cant advantage for lamotrigine over carbamazepine in those with
uncertain seizure type.
Secondary outcomes
Time to first seizure post randomisation
For this outcome, a HR of less than 1 indicates a clinical advantage
for lamotrigine.
Times to first seizure were available for 2564 participants from the
nine trials providing IPD (99% of 2572 participants with IPD
available included in this analysis, see Table 3) (Brodie 1995 A;
Brodie 1995 B; Brodie 1999; Eun 2012; Lee 2011; Nieto-Barrera
2001; Reunanen 1996; SANAD A 2007; Werhahn 2015).
Seizure recurrence was experienced by 1330 out of 2564 partici-
pants (52%), 805 out of 1476 (55%) on lamotrigine and 525 out
of 1088 (48%) on carbamazepine. The overall pooled HR (for
2564 participants) was 1.22 (95% CI 1.09 to 1.37, P = 0.0004)
indicating a statistically significant advantage to carbamazepine;
in other words, participants experienced first seizure recurrence
earlier on lamotrigine than carbamazepine in the nine included
trials (Analysis 1.8). No heterogeneity was present between trials
(I2= 0%).
Subgroup analyses: seizure type (focal versus generalised
onset)
Seizure type wasmissing for 85 participants fromSANAD A2007,
and nine participants were classified as having generalised onset
seizures, even though the trial was designed to include only partic-
ipants with focal onset seizures. Similarly, in Nieto-Barrera 2001,
including participants with focal onset seizures, three participants
were classified as having generalised onset seizures. The latter three
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participants were excluded from the subgroup analyses (all com-
pleted the trial).
For participants with generalised onset seizures (299 participants
providing IPD from six trials), the pooled HR was 0.98 (95% CI
0.65 to 1.48, P = 0.94, moderate-quality evidence), indicating no
difference between the two drugs and for participants with focal
onset seizures (2177 participants providing IPD from nine trials)
the pooled HR was 1.29 (95% CI 1.14 to 1.45, P < 0.0001, high-
quality evidence) (Analysis 1.9), indicating a statistically signif-
icant advantage for carbamazepine. There was no evidence of a
difference between the subgroups (test for subgroup differences P
= 0.22). Excluding the nine participants from SANAD A 2007
with generalised onset seizures produced similar results and did
not change the conclusions.
The overall pooled HR (adjusted for epilepsy type for 2476 par-
ticipants from nine trials) was 1.26 (95% CI 1.12 to 1.41, P <
0.0001, high-quality evidence). No heterogeneity was present be-
tween trials overall or by subgroups (I2 =0%).
Sensitivity analyses
Data from one trial could not be included for this outcome as
the dates of seizures that occurred during the first four weeks of
the trial were not supplied (Nieto-Barrera 2001). A total of 216
participants (lamotrigine: 160, carbamazepine: 56) (35% of the
number in the trial) experienced at least one seizure during the
first four weeks, however dates of these seizures were not supplied.
Therefore, for Nieto-Barrera 2001, this outcome is calculated as
’time to first seizure after four weeks of treatment’ rather than
’time to first seizure after randomisation’. Excluding this trial in
sensitivity analysis produces very similar numerical results and the
conclusions are unchanged.
One included trial allocated participants to three treatment arms:
100 mg/day lamotrigine (LTG100), 200 mg/day lamotrigine
(LTG 200) or 600 mg/day carbamazepine (CBZ) (Reunanen
1996). See Table 5 for sensitivity analysis comparing the primary
analysis (LTG arms pooled versus CBZ), LTG 100 with the other
arms in the trial, LTG 200 with the other arms in the trial, LTG
200 versus CBZ and LTG 100 versus CBZ.When including these
alternative estimates in meta-analysis, the pooled result is numer-
ically similar and the conclusions unchanged.
From three out of the five trials without IPD available, we indi-
rectly estimated aggregate hazard ratios of time to first seizure from
published graphs in two trials (Gilad 2007; Rowan 2005), and
extracted a published hazard ratio of time to first seizure (Saetre
2007). We were unable to estimate or extract an estimate from
Steinhoff 2005 or Korean Lamotrigine Study Group 2008. Com-
bining IPD and aggregate data, the pooled HR for 3216 partici-
pants from the 12 included trials was 1.24 (95% CI 1.12 to 1.37,
P < 0.00001, I2=15%) (Analysis 1.10). This again shows an ad-
vantage to carbamazepine over lamotrigine.
Wewere able to calculate or extract seizure freedom throughout the
whole trial for all trials included in this review (in Rowan 2005, it
was not statedwhether any participantswhowithdrew experienced
seizure recurrence, therefore we have conducted an intention-to-
treat analysis of seizure freedom rather than seizure recurrence). For
consistency with the primary analysis of the outcome, in Analysis
1.11 we have swapped event and non-event so that a RR less than
1 indicates a clinical advantage for lamotrigine.
The pooled RR of seizure freedom (for 3760 participants from 14
trials) is 1.11 (95%CI 1.04 to 1.18, P = 0.0006, I2=53%), indicat-
ing a statistically significant advantage to carbamazepine. There-
fore, following the inclusion of seizure freedom/recurrence data
from all included trials, the advantage to carbamazepine remains.
There is now a large amount of heterogeneity present between the
trials, which was not present in the IPD meta-analysis (I2 =53%,
Analysis 1.11). This may reflect the variable follow-up lengths of
the trials (from 24 weeks to over six years), or may reflect the way
the aggregate data are presented in some of the trials; for example
in Rowan 2005, seizure freedom rates are presented only for those
who have completed the trial.
Following reclassification of 152 individuals from seven trials with
potentially misclassified generalised onset seizures (Brodie 1995
A; Brodie 1995 B; Brodie 1999; Lee 2011; Nieto-Barrera 2001;
Reunanen 1996; SANAD A 2007), and 85 individuals with miss-
ing seizure type from one trial (SANAD A 2007), the results of
the two sensitivity analyses are shown in Table 6. In summary, the
results overall by seizure type and for individuals with focal onset
seizures are very similar. Following reclassification, there is a slight
advantage to carbamazepine, which is not statistically significant,
for those with generalised onset seizures. For those with uncertain
seizure type, there is a slight advantage to lamotrigine that is not
statistically significant.
Time to achieve six-month remission
For this outcome, a HR of less than 1 indicates a clinical advantage
for carbamazepine.
Times to six-month remission were available for 1793 participants
from the seven trials providing IPD (70% of 2572 participants
with IPD available included in this analysis, see Table 3) (Brodie
1995 A; Brodie 1995 B; Eun 2012; Lee 2011; Reunanen 1996;
SANAD A 2007; Werhahn 2015). The remaining two trials were
of 24 weeks duration so were not included in the analysis of time
to six-month remission but are included in the sensitivity analysis
of seizure freedom (Brodie 1999; Nieto-Barrera 2001).
Six-month remission was achieved by 1113 out of 1793 partici-
pants (62%), 572 out of 955 (60%) on lamotrigine and 541 out of
838 (65%) on carbamazepine. The overall pooled HR (for 1793
participants) was 0.84 (95% CI 0.74 to 0.94, P = 0.003) indi-
cating a statistically significant advantage to carbamazepine; in
other words, participants experienced six-month remission earlier
on lamotrigine than carbamazepine in the seven included trials
(Analysis 1.12). No heterogeneity was present between trials (I2=
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0%).
Subgroup analyses: seizure type (focal versus generalised
onset)
Seizure type was missing for 85 participants from SANAD A
2007, and nine participants were classified as having generalised
onset seizures, even though the trial was designed to include only
participants with focal onset seizures.
For participants with generalised onset seizures (254 participants
providing IPD from five trials), the pooled HR was 0.78 (95%
CI 0.55 to 1.11, P = 0.16, I2 =0%), indicating an advantage to
carbamazepine that is not statistically significant, and for partici-
pants with focal onset seizures (1454 participants providing IPD
from seven trials) the pooled HR was 0.87 (95% CI 0.77 to 1.00,
P = 0.04, I2 =25%) (Analysis 1.13), indicating a statistically sig-
nificant advantage for carbamazepine. There was no evidence of
a difference between the subgroups (test for subgroup differences
P = 0.54). Excluding the nine participants from SANAD A 2007
with generalised onset seizures produced similar results and did
not change the conclusions.
The overall pooled HR (adjusted for epilepsy type for 1708 par-
ticipants from seven trials) was 0.86 (95% CI 0.76 to 0.97, P =
0.02) (Analysis 1.13) .No heterogeneity was present between trials
overall (I2= 0%).
Sensitivity analyses
One included trial allocated participants to three treatment arms,
100 mg/day lamotrigine (LTG 100), 200 mg/day lamotrigine
(LTG 200) or 600 mg/day carbamazepine (CBZ) (Reunanen
1996). See Table 5 for a sensitivity analysis comparing the primary
analysis (LTG arms pooled versus CBZ), LTG 100 with the other
arms in the trial, LTG 200 with the other arms in the trial, LTG
200 versus CBZ and LTG 100 versus CBZ.When including these
alternative estimates in meta-analysis, the pooled result is numer-
ically similar and the conclusions unchanged.
We were able to calculate or extract seizure freedom at six months
for all trials included in this review (estimated from the graph
published in Saetre 2007). A RR less than 1 indicates a clinical
advantage for carbamazepine.
The pooled RR of seizure freedom at six months (for 3760 partic-
ipants from 14 trials) is RR 0.96 (95% CI 0.89 to 1.03, P = 0.25, I
2 =21%) (Analysis 1.14), indicating no statistically significant ad-
vantage to either drug. As above, we note that the way the aggre-
gate data are presented in some trials may influence the results; for
example in Rowan 2005, seizure freedom rates are presented only
for those who have completed the trial.
Following reclassification of 152 individuals from seven trials with
potentially misclassified generalised onset seizures (Brodie 1995 A;
Brodie 1995 B; Lee 2011; Reunanen 1996; SANADA 2007), and
85 individuals with missing seizure type from one trial (SANADA
2007), the results of the two sensitivity analyses are shown in Table
6. In summary, the results overall by seizure type are very similar
to the subgroup analysis described above and the conclusions are
unchanged. For those with uncertain seizure type, there is a slight
advantage to carbamazepine that is not statistically significant.
In Lee 2011, analysis adjusted for epilepsy type, there was some
evidence that the proportional hazards assumption of the Cox
model may have been violated; the P value of the time-varying
covariate was 0.051. However, the time varying covariate is not
significant in the analysis without adjustment for seizure type (P
= 0.146).
Following visual inspection of a cumulative incidence plot (not
shown but available from the authors), the curves appear to cross
around 200 days, when less than 20% of randomised participants
remain at risk in the trial. Therefore, we conclude that the crossing
of the curves is likely to be due to small numbers of participants
with generalised seizure types and small numbers remaining in
the trial leading to changes and events being magnified at this
time. The proportional hazards assumption of the Cox model was
satisfied for all other trials included in analysis.
Time to achieve 12-month (one-year) remission
For this outcome, a HR of less than 1 indicates a clinical advantage
for carbamazepine.
Times to 12-month remission were available for 988 participants
from the two trials providing IPD of sufficient duration (70% of
2572 participants with IPD available included in this analysis, see
Table 3) (SANAD A 2007; Werhahn 2015).
Twelve-month remission was achieved by 564 out of 998 partici-
pants (57%), 276 out of 474 (58%) on lamotrigine and 288 out
of 474 (61%) on carbamazepine. The overall pooled HR (for 998
participants) was HR 0.91 (95% CI 0.77 to 1.07, P = 0.26, high-
quality evidence), indicating an advantage to carbamazepine that
was not statistically significant (Analysis 1.15). No heterogeneity
was present between trials (I2= 0%).
Subgroup analysis and sensitivity analysis
All participants had focal onset seizures in Werhahn 2015; and in
SANAD A 2007, the design was to include only those with focal
onset seizures. However, seizure type was missing for 85 partici-
pants, and nine participants were classified as having generalised
onset seizures. Given the small numbers in the generalised onset
group (which are likely to have been misclassified), we did not
perform a sensitivity analysis by seizure type.
Instead we performed a subgroup analysis of those with focal
seizures specified at baseline (all participants in Werhahn 2015,
and 661 participants in SANAD A 2007) and those with uncer-
tain seizure type (85 with missing seizure type and nine with gen-
eralised onset seizures in SANAD A 2007).
For those with uncertain seizure type (94 participants provid-
ing IPD from one trial), the HR was 0.81 (95% CI 0.47 to
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1.37, P = 0.43) (Analysis 1.16), indicating an advantage to carba-
mazepine that is not statistically significant. For those with focal
onset seizures (894 participants providing IPD from two trials),
the pooled HR was 0.91 (95% CI 0.77 to 1.09, P = 0.31, I2=
0%), also indicating an advantage to carbamazepine that is not
statistically significant (Analysis 1.16). There was no evidence of
a difference between the subgroups (test for subgroup differences
P = 0.66).
Time to achieve 24-month (two-year) remission
For this outcome, a HR of less than 1 indicates a clinical advantage
for carbamazepine.
Times to 24-month remission were available for 755 participants
from one trial providing IPD of sufficient duration (29% of 2572
participants with IPD available included in this analysis, see Table
3) (SANAD A 2007).
Twenty-four month remission was achieved by 296 out of 755
participants (39%), 149 out of 377 (40%) on lamotrigine and 147
out of 378 (39%) on carbamazepine. The overall HR (for 755
participants from one trial) was 1.00 (95% CI 0.80 to 1.25, P =
0.99), indicating no statistically significant difference between the
drugs (Analysis 1.17).
Subgroup analysis and sensitivity analysis
Seizure type was missing for 85 participants from SANAD A
2007, and nine participants were classified as having generalised
onset seizures, even though the trial was designed to include only
participants with focal onset seizures.
Given the small numbers in the generalised onset group (which are
likely to have been misclassified), we did not perform a sensitivity
analysis by seizure type.
Instead we performed a subgroup analysis of those with focal
seizures specified at baseline (661 participants) and those with un-
certain seizure type (85 with missing seizure type and nine with
generalised onset seizures). For those with uncertain seizure type
(94 participants providing IPD from one trial), the HR was 0.86
(95% CI 0.44 to 1.67, P = 0.65) (Analysis 1.18), indicating an
advantage to carbamazepine that is not statistically significant. For
those with focal onset seizures (661 participants providing IPD
from two trials), the pooled HR was 1.06 (95% CI 0.83 to 1.35,
P = 0.66), indicating an slight advantage to lamotrigine that is not
statistically significant (Analysis 1.18). There was no evidence of
a difference between the subgroups (test for subgroup differences
P = 0.57).
In SANAD A 2007 (analyses with and without adjustment for
epilepsy type), there was evidence that the proportional hazards
assumption of the Cox model may have been violated; the P value
of the time-varying covariate was 0.025.
Following visual inspection of a cumulative incidence plot (Figure
13), the curves appear to cross around 1200 days. Considering
the distribution of events, all 24-month remission events occurred
before 1200 days; none of the 164 participants (82 in each treat-
ment group) experienced remission after 1200 days. This obser-
vation would explain the apparent change in treatment effect over
time (i.e. a difference in censoring times). The proportional haz-
ards assumption of the Cox model was satisfied for all other trials
included in analysis.
Incidence of adverse events
We were provided with individual participant data for adverse
events experienced during the trial for nine trials (Brodie 1995 A;
Brodie 1995 B; Brodie 1999; Eun 2012; Lee 2011; Nieto-Barrera
2001; Reunanen 1996; SANAD A 2007; Werhahn 2015), and
we extracted information relating to adverse events from the re-
maining five publications (Gilad 2007; Korean Lamotrigine Study
Group 2008; Rowan 2005; Saetre 2007; Steinhoff 2005). Due to
the wide range of events reported in the trials and the different
methods of recording adverse events, we have not analysed adverse
event data in meta-analysis and provide a narrative report.
Seven trials provided very detailed information regarding all ad-
verse events experienced by all participants during the trials
(Brodie 1995 A; Brodie 1995 B; Brodie 1999;Nieto-Barrera 2001;
Reunanen 1996; SANAD A 2007; Werhahn 2015). This infor-
mation is summarised in Table 7, Table 8 and Table 9.
The most common adverse events, reported 10 or more times in
at least one of the seven trials are: accidental injury/fracture, ag-
gression, anorexia/weight loss, anxiety/depression, aphasia, ataxia,
chest infection/bronchitis, cold/influenza, concentration, confu-
sion, cough/wheeze, dental, dizzy/faint, drowsy/fatigued, gastroin-
testinal disturbances, hair loss, headache/migraine, impotence,
increased/worsened seizures, kidney/urinary problems, memory
problems, menstrual problems, mood/behavioural change, nau-
sea/vomiting, pain, pins and needles/tingling, rash/skin problems,
sleep problems/dreams, throat/tonsil infection, tremor/twitch, vi-
sual disturbance/nystagmus, weight gain.
The five most commonly reported adverse events on both drugs
were: dizzy/faint, drowsy/fatigued, gastrointestinal disturbances,
headache/migraine, and rash/skin problems. Across all the trials,
the rates of these common adverse events were similar for the two
drugs. We did not statistically analyse adverse event data.
A summary for the other seven trials is as follows.
In Eun 2012, five events related to treatment were reported in
three participants taking lamotrigine (all skin rashes). Eight events
related to treatment were reported in six participants taking car-
bamazepine (six with tiredness/lethargy, two with skin rashes). All
adverse events were described as non-serious.
In Gilad 2007, two participants taking lamotrigine had adverse
events: somnolence and dizziness, respectively. Twelve participants
in the carbamazepine group had adverse events: three with nausea
and vomiting, three with skin eruptions, two with confusion and
one with overdose symptoms who was hospitalised
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InKorean Lamotrigine StudyGroup2008, adverse events reported
were rash (12.8% of participants on lamotrigine and 8.6% of par-
ticipants on carbamazepine), dizziness (6.8% of participants on
lamotrigine and 10.1% of participants on carbamazepine), dysp-
noea (0.4% of participants on lamotrigine and 7.0% of partici-
pants on carbamazepine), somnolence (0 of participants on lam-
otrigine and 4.7% of participants on carbamazepine), headache
(5.3% of participants on lamotrigine and 0% of participants on
carbamazepine), acne (1.1% of participants on lamotrigine and
0% of participants on carbamazepine), asthenia (0.8% of partici-
pants on lamotrigine and 1.6% of participants on carbamazepine),
oesophageal ulceration (0.4% of participants on lamotrigine and
1.6% of participants on carbamazepine), abnormal liver function
(0% of participants on lamotrigine and 1.6% of participants on
carbamazepine). Non-fatal serious adverse events were reported in
4 participants on lamotrigine; three with rash and one with post-
ictal psychosis. All serious adverse events were deemed to be re-
lated to treatment.
In Lee 2011, four participants taking lamotrigine reported skin
rash (related to treatment), five participants taking carbamazepine
reported skin rash (related to treatment) and one participant on
carbamazepine reported mitral stenosis (unrelated to treatment).
In Rowan 2005, systemic and neurologic toxicities experienced
were weight gain or weight loss (87.4% of participants on lam-
otrigine and 80.1% of carbamazepine), gastrointestinal problems
(33.9% on lamotrigine and 32.2% on carbamazepine), hypersen-
sitivity/severe hypersensitivity (3.3% on lamotrigine and 13.4%
on carbamazepine), water retention (10.4% on lamotrigine and
8.8% on carbamazepine), hyponatraemia (6.6% on lamotrigine
and 11.1% on carbamazepine), impotence (4.4% on lamotrigine
and 7.6% on carbamazepine), and renal or liver disease (1.6% on
lamotrigine and 4.1% on carbamazepine).
In Saetre 2007, for lamotrigine, 82 participants reported 378
events: 36 participants reported 53 gastrointestinal events, 20 par-
ticipants reported 26 infections, 19 participants reported 36 mus-
culoskeletal events, 44 participants reported 111 events of the ner-
vous system, 13 participants reported 23 psychiatric events, 12
participants reported 20 skin problems, 11 participants reported
11 vascular disorders and two participants reported two events of
the immune system and 24 participants reported 37 other events.
For carbamazepine, 79 participants reported 310 events: 29 par-
ticipants reported 46 gastrointestinal events, 13 participants re-
ported 23 infections, 18 participants reported 29 musculoskeletal
events, 45 participants reported 76 events of the nervous system,
12 participants reported 16 psychiatric events, 21 participants re-
ported 25 skin problems, five participants reported six vascular
disorders and 11 participants reported 14 events of the immune
system and 27 participants reported 41 other events. For both
treatments around half of the events were thought to be related to
treatment, particularly dizziness, rash, headache, somnolence and
gastrointestinal symptoms.
In Steinhoff 2005, the most frequent adverse events for lamot-
rigine were fatigue (14.8% of participants), rash, headache and
nausea (5.7%), nervousness, sleep disorders, pruritus, alopecia and
dizziness (4.5%). Three severe adverse events were reported, all
possibly related to treatment (nausea and diarrhoea, leucopenia
and fatigue). Most frequent adverse events for carbamazepine were
fatigue (43.2%), amnesia and pruritus (10.2%), rash (9.1%), ab-
normal thoughts and abnormal gait (8%). Seven severe adverse
events were reported - four were almost certainly related to treat-
ment (rash, dermatitis, abnormal gait and fatigue), two were prob-
ably related to treatment (rash and hyponatraemia) and one was
unrelated (astrocytoma).
Serious adverse events or adverse events requiring hospitalisation
were reported in the seven trials providing detailed IPD (we note
that some events were reported multiple times by participants), as
follows.
In Brodie 1995 A, 16 serious adverse events were reported in seven
participants. On lamotrigine, there were 13 events in five partic-
ipants: suicidal ideation (unknown if related to treatment), knee
arthroscopy (not related to treatment), recurrent seizures (related
to treatment), aggression (unknown if related to treatment) and
headache, diplopia, vertigo, photophobia and vomiting (in a single
participant, all related to treatment) and on carbamazepine there
were three events in two participants (meningioma not related to
treatment and pain possibly related to treatment).
In Brodie 1995 B, seven serious adverse events were reported in
six participants. On lamotrigine, there were five events in four
participants: haematemesis and stomach ulcer (both related to
treatment), appendicitis and tumour in two participants (none
related to treatment). On carbamazepine, there were, two events
in two participants: meningioma and tumour (neither related to
treatment).
In Brodie 1999, 69 serious adverse events were reported in 36
participants. On lamotrigine, there were 36 events in 21 partic-
ipants: six events in four participants were thought to be related
to treatment (sickness, abdominal pain and vomiting in one par-
ticipant, fracture, seizure recurrence and paranoia) and 30 events
in 17 participants were not thought to be related to treatment
(asthma, stroke in four participants, glaucoma and vomiting in
one participant, urinary retention in one participant, chest infec-
tion and vomiting blood in one participant, fracture in two par-
ticipants, seizure recurrence, vomiting, myalgia and chest pain in
one participant, bronchospasm, atrial fibrillation and cardiac fail-
ure in one participant, tachycardia in one participant, myocardial
infarction and pancreatitis in one participant).On carbamazepine,
there were 33 events in 15 participants: eight events in four par-
ticipants were thought to be related to treatment (rashes in three
participants and diarrhoea and vomiting in one participant) and
25 events in 11 participants were not thought to be related to
treatment (cerebrovascular accident and upper respiratory tract in-
fection in two participants, leg cramps, myocardial infarction and
collapse in one participant, stroke and bronchopneumonia in one
participant, dizziness and syncope in one participant, high tem-
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perature, chest infection and vomiting in one participant, hyper-
glycaemic coma, pneumonia and septicaemia in one participant,
angina and atrial fibrillation in one participant, falls and vagueness
in one participant, ventricular failure and intestinal obstruction in
one participant, and seizure recurrence in two participants).
In Nieto-Barrera 2001, 40 serious adverse events were reported in
32 participants. On lamotrigine, there were 27 events in 23 par-
ticipants: six events in five participants were thought to be related
to treatment (rash, raised intracranial pressure, increased seizures,
allergic reaction and vertigo) and 23 events in 18 participants were
not thought to be related to treatment (change in seizure type,
gastric infection, two participants with back pain, broken clavi-
cle, febrile convulsions, tonic-clonic seizures and related injury,
intracranial bleeding, haematoma, low pressure of shunt system,
complex seizure, traffic accident, pneumonia, gingivostomatitis,
fractured elbow, infection, two sudden deaths and cerebral tu-
mour). On carbamazepine, there were 13 events in nine partici-
pants: five events in three participants were thought to be related
to treatment (diarrhoea and difficulty walking, allergic reaction
and atrial fibrillation and hydrothorax) and eight events in six par-
ticipants were not thought to be related to treatment (tumour,
pneumonia, infection, febrile convulsions, embolisation, hepatitis
B and cardiac arrest).
In Reunanen 1996, 12 serious adverse events were reported in
seven participants (none related to treatment). On lamotrigine,
there were 10 events in five participants: haematemesis and cere-
bral infarct, uterine bleeding and hysterectomy, cerebral and reti-
nal emboli, pain and postoperative infection, and stroke. Three
life-threatening events were reported in three participants on lam-
otrigine (none related to treatment): carbon monoxide poisoning
(fatal), myocardial infarction (fatal) and brain tumour. On carba-
mazepine, there were two events in two participants: pulmonary
oedema and angioma.
In SANAD A 2007, 177 events resulting in hospitalisation were
reported for 99 participants (it is not stated if the events were
related to treatment). On lamotrigine, there were 86 events in
53 participants: worsening of seizures in 13 participants, seizure-
related injury in seven participants, cardiovascular events in five
participants, stomach ulcer in two participants, infection in two
participants, attempted suicide in one participant, rectal bleeding
in one participant, pneumonia in one participant; swollen ear in
one participant, enlarged prostate in one participant, bowel in-
fection in one participant, malignancy in one participant, legion-
naires disease in one participant, haemorrhage in one participant,
stroke in one participant, meningioma in one participant, vomit-
ing in one participant, hepatitis in one participant, constipation
in one participant, allergic rash in one participant, aneurysm in
one participant, vertigo in one participant, carcinoma in one par-
ticipant, occipital arteriovenous malformations in one participant,
Bell’s palsy in one participant, allergic rash in one participant, lym-
phadenopathy in one participant, fractured clavicle in one partici-
pant, childbirth in one participant, miscarriage in one participant
and toxicity in one participant. On carbamazepine, there were
91 events in 46 participants: worsening of seizures in 12 partici-
pants, cardiovascular events in five participants, attempted suicide
in three participants, seizure-related injury in three participants,
allergic rash in two participants, antiphospholipid syndrome in
one participant, arthritis in one participant, stomach cancer in
one participant, urinary tract infection in one participant, disori-
entation in one participant, psychotic illness in one participant,
exacerbation of chronic obstructive pulmonary disease in one par-
ticipant, hysterectomy in one participant, torsion of testis in one
participant, myringotomy in one participant, infection in one par-
ticipant, worsening of seizures and visual disturbance in one par-
ticipant, constipation in one participant, low serum in one partic-
ipant, breast cancer in one participant, abdominal pain in one par-
ticipant, ataxia in one participant, child birth in one participant,
pneumonia in two participant and headache in one participant.
In Werhahn 2015, 120 serious adverse events were reported in 70
participants. On lamotrigine, there were 58 events in 34 partici-
pants: two events in two participants were thought to be related
or possibly related to treatment (psychiatric disorder and halluci-
nation) and 56 events in 33 participants were not thought to be
related to treatment (worsening seizures in eight participants, gas-
troenteritis in one participant, transient ischaemic attack in two
participants, myocardial infarction in two participants, alcohol
poisoning in one participant, prostatic hyperplasia in one partici-
pant, sudden hearing loss in one participant, sudden death in one
participant, cerebral infarction in one participant, astrocytoma in
one participant, brain neoplasm in one participant, radius fracture
in one participant, bursitis in one participant, head injury in one
participant, osteoarthritis in one participant, pneumonia in one
participant, urinary tract infection in one participant, herpes in
one participant, angina in one participant, asthma in one partici-
pant, memory impairment in one participant, intestinal obstruc-
tion in one participant, vertebral fracture in one participant, sui-
cidal ideation in one participant, meningioma in one participant
and hernia in one participant). On carbamazepine, there were 62
events in 36 participants: four events in three participants were
thought to be related to treatment (hepatic enzyme increased, liver
disorder and allergic rash), 13 events in four participants were
thought to be probably related to treatment (diarrhoea in one par-
ticipant, headache andhyponatraemia in one participant, dizziness
and nausea in two participants), eight events in five were thought
to be possibly related to treatment (purpura in one participant,
gastroenteritis in two participants, confusion in one participant,
lupus erythematosus in one participant), and 28 events in 25 par-
ticipants were not thought to be related to treatment (worsening
seizures in six participants, pneumonia in two participants, sleep
apnoea in one participant, cholecystitis in one participant, abdom-
inal pain and nausea in one participant, pain in one participant,
spine fusion surgery in one participant, acute coronary syndrome
in one participant, gastrointestinal haemorrhage in one partici-
pant, death in one participant, hypertension in one participant,
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device occlusion in one participant, carcinoma in one participant,
intestinal obstruction in one participant, melanoma in one par-
ticipant, dementia in one participant, infectious peritonitis in one
participant, pulmonary embolism in one participant, renal cancer
in one participant and constipation in one participant).
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Lamotrigine compared with carbamazepine for epilepsy
Patient or population: adults and children with focal onset or generalised onset seizures (generalised tonic-clonic with or without other generalised seizure types)
Settings: outpat ients
Intervention: lamotrigine
Comparison: carbamazepine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)1
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Carbamazepine Lamotrigine
Time to first seizure
All participants
Range of follow-up: 0 to
2420 days
The median t ime to f irst
seizure was 232 days
in the carbamazepine
group
The median t ime to f irst
seizure was 134 days
(98 days shorter) in the
lamotrigine group
HR 1.26 (1.12 to 1.41)a 2476 (9 trials) ⊕⊕⊕⊕
highb
HR of less than 1 indi-
cates an advantage for
lamotrigine
Time to first seizure
Subgroup: focal onset
seizures
Range of follow-up: 0 to
2420 days
The median t ime to f irst
seizure was 208 days
in the carbamazepine
group
The median t ime to f irst
seizure was 96 days
(112 days shorter) in
the lamotrigine group
HR 1.29 (1.14 to 1.45) 2177 (9 trials) ⊕⊕⊕⊕
highb
HR of less than 1 indi-
cates an advantage for
lamotrigine
Time to first seizure
Subgroup: generalised on-
set seizures
Range of follow-up: 0 to
853 days
The median t ime to f irst
seizure was 853 days
in the carbamazepine
group
The median t ime to f irst
seizure was 337 days
(516 days longer) in the
lamotrigine group
HR 0.98 (0.65 to 1.48) 277 (6 trials) ⊕⊕©©
lowb,c
HR of less than 1 indi-
cates an advantage for
lamotrigine
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Time to 12-month re-
mission
All participants
Range of follow-up: 0 to
2420 days
The median t ime to 12-
month remission was
452 days in the carba-
mazepine group
The median t ime to 12-
month remission was
538 days (86 days
longer) in the lamotrig-
ine group
HR 0.91 (0.77 to 1.07) 988 (2 trials) ⊕⊕⊕⊕
highb
HR of less than 1 indi-
cates an advantage for
carbamazepine
Time to 12-month re-
m ission not presented
by seizure type due
to small numbers of
part icipants with gener-
alised onset seizures in
the two trials
* Illustrat ive risks in the carbamazepine and lamotrigine groups are calculated at the median t ime to f irst seizure or t ime to 12-month remission (i.e. the t ime to 50% of
part icipants experiencing a f irst seizure or 12-months of remission) within each group across all t rials. The relat ive ef fect (pooled hazard rat io) shows the comparison of ’t ime
to f irst seizure’ or ’t ime to 12-month remission’ between the treatment groups
Abbreviations: 95% CI: 95% conf idence interval; HR: hazard rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a. Pooled hazard rat io for all part icipants adjusted for seizure type.
b. High risk of bias due to the open-label design in some of the included trials, however outcomes are object ive and unlikely
to be inf luenced by knowledge of drug allocat ion. No downgrade made.
c. Downgraded once due to potent ial m isclassif icat ion of generalised onset seizures in up to 50% of part icipants in the trials.
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D I S C U S S I O N
Summary of main results
The results of this review provide statistically significant, but mod-
erate- to low-quality evidence of an advantage for lamotrigine over
carbamazepine for our primary global effectiveness outcome, time
to treatment failure. Considering time to treatment failure for any
reason related to treatment, for 2569 participants providing indi-
vidual participant data (IPD) from nine trials, the pooled hazard
ratio (HR) was 0.73 (95% confidence interval (CI) 0.64 to 0.82,
P < 0.00001, moderate-quality evidence). This advantage was also
present in the 2182 participants with focal onset seizures (pooled
HR 0.74, 95% CI 0.64 to 0.86, P = 0.0001, moderate-quality
evidence) and the 299 participants with generalised onset seizures
(pooled HR 0.51, 95% CI 0.33 to 0.78, P = 0.002, low-quality
evidence) from the nine trials providing IPD.
The advantage also remained when incorporating aggregate data
from four trials for which IPD were not available, allowing for
alternative definitions of treatment failure from the definition used
in this review (ILAE 1998), and allowing for blinded trial design.
There was also an advantage for lamotrigine over carbamazepine
when considering time to treatment failure due to adverse events
in all 2569 participants (pooled HR 0.54 (95% CI 0.45 to 0.65,
P < 0.00001, moderate-quality evidence)), the 2182 participants
with focal onset seizures (pooled HR 0.56 (95% CI 0.45 to 0.68,
P<0.00001, moderate-quality evidence) and the 299 participants
with generalised onset seizures (pooled HR 0.49 (95% CI 0.27
to 0.88, P = 0.002, low-quality evidence) but no difference be-
tween lamotrigine and carbamazepine when considering time to
treatment failure due to lack of efficacy in 1874 participants in
five trials where at least one participant on each treatment failed
treatment due to lack of efficacy (pooled HR 1.03 (95% CI 0.75
to 1.41, P =0.86), moderate-quality evidence).
The results of this review provide statistically significant and high-
quality evidence of an advantage for carbamazepine over lamot-
rigine for our secondary efficacy outcomes, time to first seizure
(pooled HR for 2564 participants: 1.22, 95% CI 1.09 to 1.37, P
= 0.0004, high-quality evidence) and time to six-month remission
(pooled HR for 1793 participants: 0.84, 95% CI 0.74 to 0.94,
P = 0.003, high-quality evidence). As above, this advantage was
present in the subgroup of participants with focal onset seizures
(high-quality evidence), but in the smaller subgroup of partici-
pants with generalised onset seizures we found no significant dif-
ference between the drugs (moderate-quality evidence).
We found no statistically significant difference between the drugs
for the longer-term outcomes of time to 12-month remission
and time to 24-month remission (high-quality evidence); however
fewer data were available for inclusion in analyses at these time
points due to the short duration of most included trials.
The most commonly reported adverse events for both of the drugs
across all of the included trials were dizziness, fatigue, gastroin-
testinal disturbances, headache and skin problems. The rate of ad-
verse events and serious adverse events was similar across the two
drugs.
Overall completeness and applicability of
evidence
We have gratefully received individual participant data (IPD) for
2572 individuals (68% of 3787 individuals from all eligible tri-
als) from the authors or sponsors of nine trials (Brodie 1995 A;
Brodie 1995 B; Brodie 1999; Eun 2012; Lee 2011; Nieto-Barrera
2001; Reunanen 1996; SANAD A 2007; Werhahn 2015), which
included a comparison of lamotrigine with carbamazepine for the
treatment of epilepsy.
At the time of review, we have not been able to obtain IPD for the
remaining five included trials with a total of 1215 participants.
For three trials including 753 individuals (Korean Lamotrigine
StudyGroup 2008; Saetre 2007; Steinhoff 2005), the trial sponsor
confirmed that data could not bemade available. For the other two
trials, we made contact with the authors/sponsors who expressed
interest in collaborating in this IPD meta-analysis but at the time
of writing, no data had been received (Gilad 2007; Rowan 2005).
If IPD are received from these trials, we will include the data in
future updates. We were able to extract aggregate data from four
out of the five trial publications to include in meta-analysis for
our primary outcome of ’time to treatment failure,’ resulting in a
similar pooled estimate to that from IPD only. Therefore, we do
not believe that our failure to obtain IPD from 32% of eligible
participants from the five trials has had a large impact on the ap-
plicability of the results of the review. We do, however, encour-
age caution when interpreting the numerical results of the review,
particularly longer-term remission outcomes for which only two
trials were of sufficient duration. Given the results of this meta-
analysis it could be that, compared to carbamazepine, the initial
doses of lamotrigine chosen were too low. Hence lamotrigine fared
better for treatment failure as the dose chosen caused compara-
tively fewer side effects but was less effective at preventing seizures.
This highlights the importance of measuring longer-term seizure
outcomes such as time to one- or two-year remission from seizures,
which would be much less affected by initial drug titration and
initial target doses.
We have good evidence from previous reviews conducted by the
Cochrane Epilepsy Group that misclassification of seizure type,
particularly generalised seizure types, is an important issue in
epilepsy trials (Nevitt 2017b; Nolan 2016b; Nolan 2016d). It is
also likely in this review that a large proportion of individuals who
were classified as experiencing generalised onset seizures at baseline
had their seizure type wrongly classified, meaning that the results
of the original trials and therefore the results of this review may
have been confounded by classification bias. Following sensitivity
analyses to account for this potential misclassification, the overall
conclusions for our primary and secondary outcomes were not
changed (see Summary of main results). However, due to the small
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proportion of total participants included experiencing generalised
onset seizures (302 out of 2572, 12% of total participants) and up
to 50% of those participants with potentially misclassified seizure
type, the results of this review are primarily applicable to partici-
pants with focal onset seizures.
Quality of the evidence
The nine trials for which IPD were made available (as well as ad-
ditional trial design information from trial authors/sponsors) were
of generally good quality. Less information was available for trials
without IPD available where risk of bias assessments were made
only based on published information. Six trials were of a double-
blind design (Brodie 1995 A; Brodie 1995 B; Brodie 1999; Rowan
2005; Saetre 2007; Werhahn 2015), and eight trials were of an
open-label design (Eun 2012; Gilad 2007; Korean Lamotrigine
Study Group 2008; Lee 2011; Nieto-Barrera 2001; Reunanen
1996; Steinhoff 2005; SANAD A 2007). The results of this re-
view suggest that the design of a trial (double-blind versus open-
label) may influence the withdrawal and treatment failure rates of
the trial, an outcome that is subjective and can be influenced by
the participant or clinician. It is argued that an open-label design
is more pragmatic and reflective of ’real world’ treatment for a
trial of a chronic condition such as epilepsy where treatments are
likely to be taken long-term by participants (SANAD A 2007),
and it is shown in this review that a significantly higher proportion
of participants failed treatment in the trials with a double-blind
design compared to the open-label trials (45% versus 34%, P <
0.0001, see Effects of interventions). However, in a trial of a ’new’
compared to a ’standard’ intervention, knowledge of the treatment
allocation may influence the choice of the participant or clinician
to continue taking the treatment, which may then influence the
perceived effectiveness of the two drugs under comparison. There-
fore, we have considered an open-label design to potentially intro-
duce bias into the results for the subjective outcomes of time to
treatment failure, but not for the objective secondary outcomes of
time to first seizure and remission.
Due to this potential risk of bias from an open-label design, we
have rated the evidence provided in this review according to Grad-
ing of Recommendations Assessment, Development and Evalua-
tion (GRADE) criteria for our primary outcome of ’time to treat-
ment failure’ as ’moderate’ for all participants and the subgroup of
participants with focal onset seizures. Due to the limited number
of participants with generalised onset seizures (and potential mis-
classification of seizure type), we have rated this evidence as low
quality for the primary outcome (see Summary of findings for the
main comparison).
For our secondary (objective) outcomes of time to first seizure and
remission, we have rated the evidence as high-quality (moderate-
quality in the subgroup of generalised onset seizures for the reasons
stated above) (see Summary of findings 2).
Potential biases in the review process
Wewere able to include individual participant data (IPD) for 2572
out of 3787 eligible participants (68%) from nine out of 14 tri-
als in this review and we were able to analyse all outcomes using
IPD. Such an approach has many advantages, such as allowing
the standardisation of definitions of outcomes across trials, and
attrition and reporting biases are reduced as we can perform ad-
ditional analyses and calculate additional outcomes from unpub-
lished data. For the outcomes we used in this review that are of
a time-to-event nature, an IPD approach is considered to be the
’gold standard’ approach to analysis (Parmar 1998).
For reasons outside of our control, we were unable to obtain IPD
for 1215 participants from five trials for inclusion in this review.
However, following sensitivity analyses using aggregate data, we
do not believe that the exclusion of 32% of eligible participants
is likely to have impacted on the conclusions of this review (see
Overall completeness and applicability of evidence).
Finally, we made some assumptions in the statistical methodology
used in this review. Firstly, when we received only follow-up dates
and seizure frequencies, we used linear interpolation to estimate.
We are aware that an individual’s seizure patterns may be non-
linear; therefore, we recommend caution when interpreting the
numerical results of the seizure-related outcomes.
We also made an assumption that treatment effect for each out-
come did not change over time (proportional hazards assumption,
see Data synthesis). We are aware that in trials of long duration
(e.g. SANAD A 2007, and Werhahn 2015, of over one year dura-
tion), the assumption of treatment effect remaining constant over
time may not be appropriate; for example, there is likely to be a
difference between participants who achieve immediate remission
compared with participants who achieve later remission, and we
encourage that results should be interpreted with this limitation
in mind.
Agreements and disagreements with other
studies or reviews
To our knowledge, together with previous versions of this review,
this is the only systematic review and meta-analysis that com-
pares lamotrigine and carbamazepine monotherapy for focal on-
set seizures and generalised onset tonic-clonic seizures. A network
meta-analysis has been published (Nevitt 2017a), comparing all
direct and indirect evidence from lamotrigine, carbamazepine and
other standard and new antiepileptic drugs licensed formonother-
apy. The results of this review generally agree with the results of
the network meta-analysis.
A U T H O R S ’ C O N C L U S I O N S
41Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Implications for practice
Current UK guidelines recommend carbamazepine or lamotrigine
as first-line treatment for adults and children with new onset focal
seizures and sodium valproate for adults and children with new
onset generalised seizures (NICE 2012).
For individuals with new onset focal seizures, the moderate-qual-
ity evidence provided by this review suggests that lamotrigine is
likely to be a more effective drug than carbamazepine in terms
of treatment retention (treatment failure for any reason related to
treatment or due to adverse events). However, high-quality evi-
dence provided by this review suggests that individuals are likely
to achieve earlier remission and later seizure recurrence when tak-
ing carbamazepine compared to lamotrigine. Therefore a choice
between these two first-line treatments for individuals with new
onset focal seizures must be carefully considered, taking the per-
sonal circumstances of an individual into account.
For individuals with new onset generalised seizures, the evidence
in the review is limited and of moderate to low quality due to
small numbers of participantswith certain generalised seizure types
recruited into the included trials. There is evidence that carba-
mazepine may exacerbate some generalised seizure types so should
be used with caution in individuals with this seizure type (Liporace
1994; Shields 1983; Snead 1985). Lamotrigine may be an effec-
tive treatment option for new onset generalised seizures, but more
evidence is required to confirm this.
Implications for research
This review highlights the need for the design of future antiepilep-
tic drug monotherapy trials that recruit individuals with specific
epilepsy syndromes to be powered to detect a difference between
particular antiepileptic drugs. An approach likely to reflect and in-
form clinical practice, as well as being statistically powerful, would
be to recruit heterogeneous populations for whom epilepsy syn-
dromes have been adequately defined, with testing for interaction
between treatment and epilepsy syndrome. In view of potential
problems of misclassification, syndromes will have to be well de-
fined, with adequate checking mechanisms to ensure that classi-
fications are accurate and a system to recognise uncertainty sur-
rounding epilepsy syndromes in individuals within trials. It is also
important that future trials are of a sufficient duration to measure
long-term effectiveness of antiepileptic drugs (treatments that will
be life-long for many individuals with epilepsy), as well as psy-
chosocial, quality-of-life and health economic outcomes.
Consideration is also required in the design of a trial regarding
whether to blind participants and outcome assessors to treatment
allocation. While an open-label design is a more pragmatic and
practical approach for large, long-term trials, when trials involve a
new intervention compared to an established ’standard’ interven-
tion, masking of treatment may be important to avoid preconcep-
tions over the relative effectiveness of the drugs.
The choice of outcomes at the design stage of a trial and the pre-
sentation of the results of outcomes, particularly of a time-to-event
nature, require very careful consideration. While the majority of
trials of a monotherapy design record an outcome measuring effi-
cacy (seizure control) and an outcome measuring tolerability (ad-
verse events), there is little uniformity between the definition of the
outcomes and the reporting of the summary statistics related to the
outcomes (Nolan 2013a), making an aggregate data approach to
meta-analysis in reviews of monotherapy trials impossible. Where
trial authors cannot or will not make individual participant data
available for analysis, we are left with no choice but to exclude a
proportion of relevant evidence from the review, which may im-
pact upon the interpretation of the results of the review and the
applicability of the evidence and conclusions. The International
League Against Epilepsy recommends that trials of a monother-
apy design should adopt a primary effectiveness outcome of time
to treatment failure (i.e. retention time) and should be of a du-
ration of at least 48 weeks to allow for assessment of longer-term
outcomes, such as remission (ILAE 1998; ILAE 2006). If trials
followed these recommendations, an aggregate data approach to
meta-analysis may be feasible, reducing the resources and time re-
quired from an individual participant data approach.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brodie 1995 A
Methods Randomised, double-blind, parallel-group trial conducted in 8 centres in the UK
2 treatment arms: LTG and CBZ
Participants Adults and children over the age of 13 with newly diagnosed epilepsy
Number randomised: LTG = 70, CBZ = 66;
56 males (41%)
82 with focal seizures (60%)
None had received previous AED treatment
Mean age (range): 34 (13 to 71) years
Interventions Monotherapy with LTG or CBZ for 48 weeks
4-week escalation phase leading to LTG = 150 mg/day, CBZ = 600 mg/day
Range of follow-up: 0 to 398 days
Outcomes Time to first seizure after 6 weeks of treatment
Time to treatment withdrawal
Proportion of randomised patients remaining seizure-free during the last 40 and 24
weeks of trial
Percentages of patients who reported adverse events
Notes IPD provided by trial sponsor GlaxoSmithKline for time to treatment failure, time to
first seizure and time to 6-month remission
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated random sequence (in-
formation provided by drug manufacturer)
. Stratification by seizure type
Allocation concealment (selection bias) Low risk Allocation concealed by individual sealed
opaque envelopes (information provided
by drug manufacturer)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind achieved using LTG tablets
formulated to be identical in appearance to
CBZ tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trial investigator blinded, not stated if
other outcome assessors were blinded
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Brodie 1995 A (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported; all randomised
participants analysed from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk None identified
Brodie 1995 B
Methods Randomised, double-blind, parallel-group trial conducted in 8 centres in the UK
2 treatment arms: LTG and CBZ
Participants Adults and children over the age of 13 with newly diagnosed epilepsy
Number randomised: LTG = 61, CBZ = 63
56 males (45%)
62 with focal seizures (50%)
None had received previous AED treatment
Mean age (range): 30 (14 to 86) years
Interventions Monotherapy with LTG or CBZ for 48 weeks
4-week escalation phase leading to LTG = 150 mg/day, CBZ = 600 mg/day
Range of follow-up: 0 to 398 days
Outcomes Time to first seizure after 6 weeks of treatment
Time to treatment withdrawal
Proportion of randomised patients remaining seizure-free during the last 40 and 24
weeks of trial
Percentages of patients who reported adverse events
Notes IPD provided by trial sponsor GlaxoSmithKline for time to treatment failure, time to
first seizure and time to 6-month remission
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated random sequence (in-
formation provided by drug manufacturer)
. Stratification by seizure type
Allocation concealment (selection bias) Low risk Allocation concealed by individual sealed
opaque envelopes (information provided
by drug manufacturer)
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Brodie 1995 B (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind achieved using LTG tablets
formulated to be identical in appearance to
CBZ tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trial investigator blinded, not stated if
other outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported; all randomised
participants analysed from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk None identified
Brodie 1999
Methods Randomised, multicentre, double-blind, parallel-group trial conducted in the UK
2 treatment arms: LTG and CBZ randomised in a 2:1 ratio
Participants Adults over the age of 65 with newly diagnosed epilepsy with 2 or more seizures in the
previous year with at least 1 seizure in the last 6 months
Number randomised: LTG = 102, CBZ = 48
83 males (55%)
105 with focal seizures (70%)
Not stated if any participants had received previous AED treatment
Mean age (range): 77 (65 to 94) years
Interventions Monotherapy with LTG or CBZ for 24 weeks
4-week escalation phase leading to LTG = 100 mg/day, CBZ = 400 mg/day
Range of follow-up = 0 to 280 days
Outcomes Time to first seizure after 6 weeks of treatment
Time to treatment withdrawal
Percentage of patients reporting an adverse event
Proportion of patients who were both seizure-free in the last 16 weeks of the trial and
did not discontinue treatment
Notes IPD provided by trial sponsor GlaxoSmithKline for time to treatment failure and time
to first seizure (plus seizure freedom rates at 24 weeks)
Risk of bias
Bias Authors’ judgement Support for judgement
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Brodie 1999 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
(information provided by drug manufac-
turer). Participants randomised in a 2:1 ra-
tio (LTG:CBZ)
Allocation concealment (selection bias) Low risk Allocation concealed with pharmacy-dis-
pensed treatment packs labelled with par-
ticipant’s trial number
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind achieved using LTG tablets
formulated to be identical in appearance to
CBZ tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trial investigator blinded, not stated if
other outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported; all randomised
participants analysed from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk None identified
Eun 2012
Methods Randomised, multicentre, open-label, parallel-group trial conducted in 7 hospitals in
the Republic of Korea
2 treatment arms: LTG and CBZ
Participants Children between the ages of 6 and 12 with a new diagnosis of focal epilepsy and at least
2 seizures in the last 6 months
Number randomised: LTG = 43, CBZ = 41
48 males (57%)
100% focal epilepsy
Not stated if any participants had received previous AED treatment
Mean age (range): 9 (5 to 13) years
Interventions Monotherapy with LTG or CBZ for 32 weeks
8-week escalation phase leading to LTG = 3 to 6 mg/kg/day, CBZ = 10 to 20 mg/kg/day
Range of follow-up: 12 to 788 days
Outcomes Seizure-free rate over 6 months (maintenance period) by treatment group
Change in cognition (neuropsychological), behaviour and quality of life from screening
to the end of the maintenance phase by treatment group
Incidence of adverse events
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Eun 2012 (Continued)
Notes IPD provided by trial author for time to treatment failure, time to first seizure and time
to 6-month remission
No source of funding stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Each centre received a separate and inde-
pendent computer-generated random code
list
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported; all randomised
participants analysed from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk None identified
Gilad 2007
Methods Randomised single-centre, open-label, parallel-group trial conducted at Tel Aviv Uni-
versity and Medical Centre, Israel
2 treatment arms: LTG and CBZ
Participants Adults admitted to the neurological department with a first seizure event after an is-
chaemic stroke
Number randomised: LTG = 32, CBZ = 32
46 males (72%)
100% focal seizures
Unclear if any participants had received previous AED treatment
Mean age (range): 67.5 (38 to 90) years
Interventions Monotherapy with LTG or CBZ for 12 months
Dose escalation phase (length not stated) leading to LTG 100 mg/day, CBZ 300 mg/
day
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Gilad 2007 (Continued)
Range of follow-up: not stated
Outcomes The appearance of a second seizure under treatment or by finishing the 12-month follow-
up without seizures
Tolerability: incidence of adverse events
Treatment withdrawals due to adverse events
Notes Contact made with trial author who was willing to provide IPD but data never received.
Aggregate data extracted from graphs in the publication. Stated in the title of the paper
that LTG and CBZ were monotherapy treatments but Table 1 of the paper refers to total
no. AED; unclear if all participants were receiving monotherapy treatment. No source
of funding stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised in a 1:1 ratio, no further in-
formation provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rate reported; all randomised par-
ticipants included in analysis
Selective reporting (reporting bias) Low risk No protocol available. Seizure outcomes
and adverse events well reported
Other bias Unclear risk Unclear if all participants were receiving
monotherapy treatment
Korean Lamotrigine Study Group 2008
Methods Phase IV, open label, randomised, multicentre trial conducted in 21 Centres in Korea
Two treatment arms: CBZ and LTG
Participants Participants were untreated epileptics who had at least 2 unprovoked seizures (focal or
generalised tonic clonic) during the last 24 weeks before the study start, more than 24
hours apart
Number randomised: CBZ=129, LTG=264 (ITT population)
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Korean Lamotrigine Study Group 2008 (Continued)
154 male participants (39%);
288 participants (73%) with focal epilepsy
Mean age (SD): CBZ=37.6 (15.8), LTG=34.2 (16.3) years
Interventions Monotherapy with CBZ or LTG
Permitted doses LTG: 100mg/day - 500mg/day for LTG , CBZ: 400mg/day - 1200mg/
day
Outcomes Retention Rate at Study End
Terminal 24 week seizure free rate and time interval from the end of dose titration phase
to the first seizure
Notes Full text of the trial published in Korean. Abstract and clinical trial summary available
in English
IPD requested from trial sponsor Glaxo Smith Kline but data could not be located
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Trial described as randomised, no further
information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rate reported, not all participants
included in analysis, which is not an ITT
approach
Selective reporting (reporting bias) Low risk Results for all outcomes summarised for all
listed outcomes
Other bias Unclear risk None identified
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Lee 2011
Methods Randomised, multicentre, open-label, parallel-group trial conducted in the Republic of
Korea
2 treatment arms: LTG and CBZ
Participants Adults over the age of 16 with newly diagnosed focal epilepsy or untreated focal epilepsy
for at least 1 year
Number randomised: LTG = 57, CBZ = 53
57 males (52%)
95 focal seizures (86%)
Not stated how many participants had received previous AED treatment
Mean age (range): 36 (16 to 60) years
Interventions Monotherapy with LTG or CBZ for 48 weeks
8-week escalation phase leading to LTG = 200 mg/day, CBZ = 600 mg/day
Range of follow-up: 14 to 337 days
Outcomes Change of neuropsychological and cognitive scores from baseline: general intellectual
ability, learning and memory, attention and executive function (group-by-time interac-
tion)
Frequency of psychological and health-related quality of life symptoms
Proportion with seizure freedom during the maintenance period
Notes IPD provided by trial author for time to treatment failure, time to first seizure and time
to 6-month remission
This trial was supported by a grant from GlaxoSmithKline Korea. No other funding
sources stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation (block size 4) via a
computer randomisation program (infor-
mation provided by trial author)
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported; all randomised
participants analysed from IPD provided
(see footnote 2)
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Lee 2011 (Continued)
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk None identified
Nieto-Barrera 2001
Methods Randomised,multicentre, open-label, parallel-group trial conducted in Europe andMex-
ico
2 treatment arms: LTG and CBZ randomised in a 2:1 ratio
Participants Adults and children over the age of 2 with newly diagnosed or currently untreated focal
epilepsy with 2 or more seizures in the previous 6 months and with at least 1 seizure in
the last 3 months
Number randomised: LTG = 420, CBZ = 202
329 males (53%)
619 with focal seizures (99.5%)
Not stated how many participants had received previous AED treatment
Mean age (range): 27 (2 to 84) years
Interventions Monotherapy with LTG or CBZ for 24 weeks
6-week escalation phase leading to minimum of LTG 2 mg/kg/day age range 2 to 12
years, 200 mg/day age range 13 to 64 years and 100 mg/day age > 65 years. CBZ aged
2 to 12 years 5 to 40 mg/kg, age > 12 years 100 to 1500 mg/day
Range of follow-up: 0 to 245 days
Outcomes Proportion of patients seizure-free during the last 16 weeks of treatment
Efficacy success: proportion of patients who did not withdraw before the end of week
18 and were seizure-free in the last 16 weeks of the trial
Time to withdrawal from the trial (proportion of patients completing the trial)
Proportion of patients experiencing adverse events
Treatment withdrawals due to adverse events
Notes IPD provided by trial sponsor GlaxoSmithKline for time to treatment failure and time
to first seizure (plus seizure freedom rates at 24 weeks)
Dates of seizures during the first 4 weeks not provided with individual participant data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence.
Participants randomised in a 2:1 ratio
(LTG:CBZ), stratified by age group and
country
Allocation concealment (selection bias) Low risk Allocation concealed by individual sealed,
opaque envelopes
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Nieto-Barrera 2001 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported; all randomised
participants analysed from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk Protocol provided. All outcomes reported
or calculated with IPD provided (see foot-
note 2)
Other bias Low risk None identified
Reunanen 1996
Methods Randomised, double-blind, parallel-group trial conducted in 56 centres in Europe and
Australia
3 treatment arms: LTG (200 mg/day), LTG (100 mg/day) and CBZ
Participants Adults and children over the age of 12 with newly diagnosed, currently untreated or
recurrent epilepsy with 2 or more seizures in the previous 6 months and with at least 1
seizure in the last 3 months. Participants must not have taken antiepileptic medication
in the previous 6 months
Number randomised: LTG (200 mg) = 115, LTG (100 mg) = 116, CBZ = 121
188 males (54%)
237 with focal seizures (68%)
Not stated how many participants had received previous AED treatment
Mean age (range): 32 (12 to 71) years
Interventions Monotherapy with LTG or CBZ for 30 weeks
4-week escalation phase leading to LTG = 100 mg/day, LTG = 200 mg/day, CBZ = 600
mg/day
Range of follow-up: 0 to 378 days
Outcomes Proportion seizure-free after the first 6 weeks of treatment
Time to first seizure
Time to treatment withdrawal
Frequency of adverse events with at least 5% incidence in any treatment group
Notes IPD provided by trial sponsor GlaxoSmithKline for time to treatment failure, time to
first seizure and time to 6-month remission
Participants considered to complete the trial if they experienced a seizure after the first
6 weeks
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Reunanen 1996 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
(information provided by drug manufac-
turer)
Allocation concealment (selection bias) Low risk Allocation concealed by individual sealed,
opaque envelopes (information provided
by drug manufacturer)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported; all randomised
participants analysed from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided (see footnote 2)
Other bias Low risk None identified
Rowan 2005
Methods Randomised, double-blind, parallel-group trial conducted in 18Veterans AffairsMedical
Centres in the United States
3 treatment arms: LTG, CBZ and gabapentin (GBP)
Participants Adults over the age of 60 with newly diagnosed seizures, untreated or treated with sub-
therapeutic AED levels, with at least 1 seizure in the previous 3 months
Number randomised: LTG = 200, CBZ = 198
378 males (95%)
299 with focal seizures (75%)
Not stated how many participants had received previous AED treatment
Mean age: 72 years, range not stated
Interventions Monotherapy with LTG or CBZ for 12 months
6-week escalation phase leading to LTG = 150 mg/day, CBZ = 600 mg/day
Range of follow-up: not stated
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Rowan 2005 (Continued)
Outcomes Retention in the trial for 12 months
Seizure freedom at 12 months
Time to 1st, 2nd, 5th and 10th seizure (time to seizures)
Drug toxicity (incidence of systemic and neurologic toxicities)
Serum drug levels and compliance
Seizure-free retention rates
Notes IPD requested from trial sponsor, the Department of Veterans Affairs, USA. At the time
of review, IPD have not been received. Aggregate data extracted from graphs in the
publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation (varying sizes) per-
formedby site via a computer-generated list
Allocation concealment (selection bias) Low risk Telephone randomisation used and phar-
macy dispensed a prescription of the allo-
cated drug (part of a blinded drug kit) to
participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinding achieved with double
dummy tablets; doses of both increased and
decreased simultaneously
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specifically stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. Most of the ran-
domised participants included in analysis;
3 excluded due to site closure (not related
to treatment)
Selective reporting (reporting bias) Low risk No protocol available but case report forms
of data collected provided by the sponsor.
Seizure outcomes and adverse events well
reported
Other bias Low risk None identified
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Saetre 2007
Methods Randomised, double-blind, parallel-group trial conducted in 29 centres across Croatia,
Finland, France, Finland and Norway. 2 treatment arms: LTG, CBZ
Participants Adults over the age of 65 with newly diagnosed seizures, with a history of at least 2
seizures and at least 1 seizure in the previous 6 months. Participants must not have taken
antiepileptic medication for more than 2 weeks in the previous 6 months and never
taken CBZ or LTG
Number randomised: LTG = 94, CBZ = 92
102 males (54%)
Proportion with focal seizures not stated
Not stated how many participants had received previous AED treatment
Mean age: 74 (65 to 91) years
Interventions Monotherapy with LTG or CBZ for 40 weeks
4-week escalation phase leading to LTG = 100 mg/day, CBZ = 400 mg/day
Range of follow-up: not stated
Outcomes Retention in the trial (time to treatment withdrawal for any cause)
Seizure freedom after week 4
Seizure freedom after week 20
Time to first seizure
Adverse event reports
Tolerability according to the Liverpool Adverse Event profile (AEP)
Notes IPD requested from trial sponsor Glaxo Smith Kline but data could not be located
Aggregate summary data extracted from the publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, no other infor-
mation provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinding achieved with double
dummy tablets, packaged together
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specifically stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported; all participants
who received trial treatment were included
in an intention-to-treat analysis
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Saetre 2007 (Continued)
Selective reporting (reporting bias) Low risk Noprotocol available but clinical trial sum-
mary provided by the sponsor. Seizure out-
comes and adverse events well reported
Other bias Low risk None identified
SANAD A 2007
Methods Randomised, multicentre, open-label, parallel-group trial conducted in the UK
5 treatment arms: LTG, CBZ, GBP, topiramate (TPM) and oxcarbazepine (OXC)
Participants Adults and children over the age of 4 years with newly diagnosed focal epilepsy, relapsed
focal epilepsy or failed treatment with a previous drug not used in this trial
Number randomised: LTG = 378, CBZ = 378
409 males (54%)
662 focal epilepsy (88%)
139 had received previous AED treatment (18%)
Mean age (range): 38 (5 to 83) years
Interventions Monotherapy for LTG or CBZ (no fixed trial duration)
Titration doses and maintenance doses decided by treating clinician
Range of follow-up: 17 to 2420 days
Outcomes Time to treatment failure
Time to 1-year (12-month) remission
Time to 2-year remission
Time to first seizure
Health-related quality of life via the NEWQOL (Newly Diagnosed Epilepsy Quality of
Life Battery)
Health economic assessment and cost-effectiveness of the drugs (cost per QALY gained
and cost per seizure avoided)
Frequency of clinically important adverse events
Notes IPD provided for time to treatment failure, time to first seizure, time to 6-month, time
to 12-month and time to 24-month remission (trial conducted at our site and sponsored
by the Health Technology Assessment programme of the National Institute of Health
Research)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerminimisationprogram stratified
by centre, sex and treatment history
Allocation concealment (selection bias) Low risk Telephone randomisation to a central ran-
domisation allocation service
61Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
SANAD A 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported; all randomised
participants analysed from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk Protocol provided. All outcomes reported
or calculated with IPD provided (see foot-
note 2)
Other bias Low risk None identified
Steinhoff 2005
Methods Randomised, open-label, parallel-group trial conducted in 24 centres across Germany
4 treatment arms: LTG (2 arms), CBZ and sodium valproate (SV)
Participants with focal and generalised epilepsy randomised separately to LTG or CBZ
and LTG or SV respectively
Participants Adults and children over the age of 12 with newly diagnosed epilepsy; at least 1 seizure
and electroencephalographic imaging suggesting epilepsy
Number randomised not stated; number included in analysis: LTG = 88, CBZ = 88
106 males (64%)
100% focal seizures
Not stated how many participants had received previous AED treatment
Mean age: 47.5 years, range not stated
Interventions Monotherapy with LTG or CBZ for 22 to 26 weeks
4-week escalation phase leading to LTG = 100 to 200 mg/day, CBZ = 600 to 1200 mg/
day in adults and 600 to 1000 mg/day in children aged 11 to 15
Range of follow-up: not stated
Outcomes Number of seizure-free patients during trial weeks 17 to 24
“Leaving the study” (retention rates)
Adverse event rates
Notes IPD requested from trial sponsor GlaxoSmithKline but data could not be provided due
to restrictions over the de-identification of datasets from trials conducted in Germany
Aggregate data extracted from graphs in the publication
Data from participants with focal seizures only included as this is the randomised com-
parison of LTG and CBZ
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Steinhoff 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, no other infor-
mation provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of participants randomised to
each group not reported (254 randomised
and 239 analysed in the 4 arms of the trial)
. Reasons for exclusion stated but not to
which drug these participants were ran-
domised
Selective reporting (reporting bias) Low risk Noprotocol available but clinical trial sum-
mary provided by the sponsor. Seizure out-
comes and adverse events well reported
Other bias Low risk None identified
Werhahn 2015
Methods Randomised, double-blind, parallel-group trial conducted in 47 centres across Germany,
Austria and Switzerland
3 treatment arms: LTG, CBZ and levetiracetam (LEV)
Participants Adults over the age of 60 with newly diagnosed focal seizures, with a history of at least
2 seizures and at least 1 seizure in the previous 6 months. Participants must not have
taken antiepileptic medication for more than 4 weeks
Number randomised: LTG = 118, CBZ = 121
135 males (56%)
100% focal epilepsy
Not stated how many participants had received previous AED treatment
Mean age (range): 71 (60 to 89) years
Interventions Monotherapy with LTG or CBZ for 58 weeks
6-week escalation phase leading to LTG = 100 mg/day, CBZ = 400 mg/day
Range of follow-up: 0 to 1508 days
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Werhahn 2015 (Continued)
Outcomes Retention rate at week 58
Time to discontinuation from randomisation
Seizure freedom rates at week 30 and week 58
Time to first seizure from randomisation
Time to first drug-related adverse event
Adverse events (by severity)
Notes IPD provided by trial author for time to treatment failure, time to first seizure, time to
6-month and time to 12-month remission
Trial was sponsored by UCB
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation list for each centre (ran-
dom permuted blocks) was prepared by the
Interdisciplinary Centre for Clinical Trials
(IZKS), Mainz, Germany
Allocation concealment (selection bias) Low risk The pharmacy of the University Hospi-
tal Mainz encapsulated the trial drugs and
labelled the blinded medication including
the randomisation number
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and trial investigator blinded
by the use of matching capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trial investigator blinded; not stated if
other outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported; all randomised
participants analysed from IPD provided
(see footnote 2)
Selective reporting (reporting bias) Low risk Protocol provided. All outcomes reported
or calculated with IPD provided (see foot-
note 2)
Other bias Low risk None identified
1Abbreviations
AED: antiepileptic drug
CBZ: carbamazepine
IPD: individual participant data
ITT: intention-to-treat
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LTG: lamotrigine
QALY: quality-adjusted life year
2For trials for which IPD were provided attrition and reporting bias are reduced as attrition rates and unpublished outcome data are
requested (Brodie 1995 A; Brodie 1995 B; Brodie 1999 Nieto-Barrera 2001; Reunanen 1996).
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baxter 1998 Participants randomised to lamotrigine and physician’s choice of carbamazepine or valproate. No fully randomised
comparison between lamotrigine and carbamazepine
Carmant 2001 Not monotherapy
Czapinski 1997 Wrong drug comparison
Eun 2008 Conference abstract for full publication Eun 2012
Fakhoury 2000 Withdrawn to monotherapy. Design excluded.
Gilliam 1998 Wrong drug comparison
Jawad 1989 Not monotherapy
Lee 2010 Conference abstract for full publication Lee 2011
Martinez 2000 Not randomised
Motte 1997 Wrong drug comparison
Ramsay 2003 Abstract of full publication Rowan 2005
Saetre 2006 Conference abstract for full publication Saetre 2007
Saetre 2009 Subset of Saetre 2007
Saetre 2010 Subset of Saetre 2010
Steiner 1999 Wrong drug comparison
Steinhoff 2004 Abstract of full publication Steinhoff 2005
Stolarek 1994 Wrong drug comparison
Zeng 2010 Not randomised
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D A T A A N D A N A L Y S E S
Comparison 1. Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to treatment failure (any
reason related to the treatment)
9 2569 Hazard Ratio (Fixed, 95% CI) 0.73 [0.64, 0.82]
2 Time to treatment failure due to
adverse events
9 2569 Hazard Ratio (Fixed, 95% CI) 0.54 [0.45, 0.65]
3 Time to treatment failure due to
lack of efficacy
5 1874 Hazard Ratio (Fixed, 95% CI) 1.03 [0.75, 1.41]
4 Time to treatment failure (any
reason related to the treatment)
- by seizure type
9 2481 Hazard Ratio (Fixed, 95% CI) 0.71 [0.62, 0.82]
4.1 Focal 9 2182 Hazard Ratio (Fixed, 95% CI) 0.74 [0.64, 0.86]
4.2 Generalised 6 299 Hazard Ratio (Fixed, 95% CI) 0.51 [0.33, 0.78]
5 Time to treatment failure due to
adverse events - by seizure type
9 2466 Hazard Ratio (Fixed, 95% CI) 0.55 [0.45, 0.66]
5.1 Focal 9 2182 Hazard Ratio (Fixed, 95% CI) 0.56 [0.45, 0.68]
5.2 Generalised 5 284 Hazard Ratio (Fixed, 95% CI) 0.49 [0.27, 0.88]
6 Time to treatment failure (any
reason related to the treatment,
with aggregate data)
13 3391 Hazard Ratio (Fixed, 95% CI) 0.70 [0.63, 0.78]
7 Time to treatment failure (any
reason related to the treatment)
- subgroup analysis (blinding)
13 3391 Hazard Ratio (Fixed, 95% CI) 0.70 [0.63, 0.78]
7.1 Double-blind 6 1231 Hazard Ratio (Fixed, 95% CI) 0.65 [0.56, 0.75]
7.2 Open-label 7 2160 Hazard Ratio (Fixed, 95% CI) 0.76 [0.65, 0.90]
8 Time to first seizure 9 2564 Hazard Ratio (Fixed, 95% CI) 1.22 [1.09, 1.37]
9 Time to first seizure by seizure
type
9 2476 Hazard Ratio (Fixed, 95% CI) 1.26 [1.12, 1.41]
9.1 Focal 9 2177 Hazard Ratio (Fixed, 95% CI) 1.29 [1.14, 1.45]
9.2 Generalised 6 299 Hazard Ratio (Fixed, 95% CI) 0.98 [0.65, 1.48]
10 Time to first seizure (with
aggregate data)
12 3216 Hazard Ratio (Fixed, 95% CI) 1.24 [1.12, 1.37]
11 Seizure freedom (whole study) 14 3760 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [1.04, 1.18]
12 Time to 6-month remission 7 1793 Hazard Ratio (Fixed, 95% CI) 0.84 [0.74, 0.94]
13 Time to 6-month remission by
seizure type
7 1708 Hazard Ratio (Fixed, 95% CI) 0.86 [0.76, 0.97]
13.1 Focal 7 1454 Hazard Ratio (Fixed, 95% CI) 0.87 [0.77, 1.00]
13.2 Generalised 5 254 Hazard Ratio (Fixed, 95% CI) 0.78 [0.55, 1.11]
14 Seizure freedom at 6 months 14 3760 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.89, 1.03]
15 Time to 12-month remission 2 988 Hazard Ratio (Fixed, 95% CI) 0.91 [0.77, 1.07]
16 Time to 12-month remission
by seizure type
2 988 Hazard Ratio (Fixed, 95% CI) 0.90 [0.76, 1.07]
16.1 Focal 2 894 Hazard Ratio (Fixed, 95% CI) 0.91 [0.77, 1.09]
16.2 Uncertain 1 94 Hazard Ratio (Fixed, 95% CI) 0.81 [0.47, 1.37]
17 Time to 24-month remission 1 755 Hazard Ratio (Fixed, 95% CI) 1.00 [0.80, 1.25]
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18 Time to 24-month remission
by seizure type
1 755 Hazard Ratio (Fixed, 95% CI) 1.03 [0.82, 1.30]
18.1 Focal 1 661 Hazard Ratio (Fixed, 95% CI) 1.06 [0.83, 1.35]
18.2 Uncertain 1 94 Hazard Ratio (Fixed, 95% CI) 0.86 [0.44, 1.67]
Analysis 1.1. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 1 Time to
treatment failure (any reason related to the treatment).
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 1 Time to treatment failure (any reason related to the treatment)
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Brodie 1995 A 70 66 -0.3841084 (0.2689244) 5.4 % 0.68 [ 0.40, 1.15 ]
Brodie 1995 B 61 63 -0.5816703 (0.3097266) 4.1 % 0.56 [ 0.30, 1.03 ]
Brodie 1999 102 48 -0.8881041 (0.2706493) 5.4 % 0.41 [ 0.24, 0.70 ]
Eun 2012 43 41 0.1635266 (0.6708601) 0.9 % 1.18 [ 0.32, 4.39 ]
Lee 2011 57 53 0.2539776 (0.3819136) 2.7 % 1.29 [ 0.61, 2.73 ]
Nieto-Barrera 2001 419 202 -0.3245885 (0.1954537) 10.3 % 0.72 [ 0.49, 1.06 ]
Reunanen 1996 230 121 -0.5267081 (0.2614281) 5.8 % 0.59 [ 0.35, 0.99 ]
SANAD A 2007 377 377 -0.2445736 (0.10813) 33.7 % 0.78 [ 0.63, 0.97 ]
Werhahn 2015 118 121 -0.2827565 (0.1112988) 31.8 % 0.75 [ 0.61, 0.94 ]
Total (95% CI) 1477 1092 100.0 % 0.73 [ 0.64, 0.82 ]
Heterogeneity: Chi2 = 9.18, df = 8 (P = 0.33); I2 =13%
Test for overall effect: Z = 5.10 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours LTG Favours CBZ
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Analysis 1.2. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 2 Time to
treatment failure due to adverse events.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 2 Time to treatment failure due to adverse events
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Brodie 1995 A 70 66 -0.3599679 (0.3179593) 9.0 % 0.70 [ 0.37, 1.30 ]
Brodie 1995 B 61 63 -1.250439 (0.4340584) 4.8 % 0.29 [ 0.12, 0.67 ]
Brodie 1999 102 48 -1.006539 (0.3258141) 8.5 % 0.37 [ 0.19, 0.69 ]
Eun 2012 43 41 -0.0552479 (0.8165342) 1.4 % 0.95 [ 0.19, 4.69 ]
Lee 2011 57 53 -0.5948531 (0.626858) 2.3 % 0.55 [ 0.16, 1.88 ]
Nieto-Barrera 2001 419 202 -0.4967546 (0.2605566) 13.4 % 0.61 [ 0.37, 1.01 ]
Reunanen 1996 230 121 -0.8848151 (0.4282505) 4.9 % 0.41 [ 0.18, 0.96 ]
SANAD A 2007 377 377 -0.6624554 (0.1505037) 40.0 % 0.52 [ 0.38, 0.69 ]
Werhahn 2015 118 121 -0.2947725 (0.2407681) 15.6 % 0.74 [ 0.46, 1.19 ]
Total (95% CI) 1477 1092 100.0 % 0.54 [ 0.45, 0.65 ]
Heterogeneity: Chi2 = 7.17, df = 8 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 6.45 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 3 Time to
treatment failure due to lack of efficacy.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 3 Time to treatment failure due to lack of efficacy
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Brodie 1995 A 70 66 0.1764452 (0.9129594) 3.1 % 1.19 [ 0.20, 7.14 ]
Brodie 1995 B 61 63 0.9287065 (1.154834) 1.9 % 2.53 [ 0.26, 24.34 ]
Nieto-Barrera 2001 419 202 0.3184965 (0.5774057) 7.8 % 1.38 [ 0.44, 4.26 ]
SANAD A 2007 377 377 -0.0046645 (0.1752766) 84.1 % 1.00 [ 0.71, 1.40 ]
Werhahn 2015 118 121 -0.4816807 (0.9136511) 3.1 % 0.62 [ 0.10, 3.70 ]
Total (95% CI) 1045 829 100.0 % 1.03 [ 0.75, 1.41 ]
Heterogeneity: Chi2 = 1.23, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 4 Time to
treatment failure (any reason related to the treatment) - by seizure type.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 4 Time to treatment failure (any reason related to the treatment) - by seizure type
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal
Brodie 1995 A 44 38 -0.4903434 (0.3499528) 4.3 % 0.61 [ 0.31, 1.22 ]
Brodie 1995 B 27 35 -0.4780626 (0.4379546) 2.8 % 0.62 [ 0.26, 1.46 ]
Brodie 1999 72 33 -0.6166394 (0.3324762) 4.8 % 0.54 [ 0.28, 1.04 ]
Eun 2012 43 41 0.1635266 (0.6708601) 1.2 % 1.18 [ 0.32, 4.39 ]
Lee 2011 51 44 0.5280987 (0.4378595) 2.8 % 1.70 [ 0.72, 4.00 ]
Nieto-Barrera 2001 417 201 -0.3202355 (0.1954507) 13.9 % 0.73 [ 0.49, 1.06 ]
Reunanen 1996 150 87 -0.4195474 (0.3213621) 5.1 % 0.66 [ 0.35, 1.23 ]
SANAD A 2007 328 332 -0.2792206 (0.1171957) 38.6 % 0.76 [ 0.60, 0.95 ]
Werhahn 2015 118 121 -0.2827565 (0.1861855) 15.3 % 0.75 [ 0.52, 1.09 ]
Subtotal (95% CI) 1250 932 88.7 % 0.74 [ 0.64, 0.86 ]
Heterogeneity: Chi2 = 5.61, df = 8 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 3.86 (P = 0.00012)
2 Generalised
Brodie 1995 A 26 28 -0.2344441 (0.4208695) 3.0 % 0.79 [ 0.35, 1.80 ]
Brodie 1995 B 34 28 -0.6660747 (0.4411548) 2.7 % 0.51 [ 0.22, 1.22 ]
Brodie 1999 30 15 -1.440732 (0.4909836) 2.2 % 0.24 [ 0.09, 0.62 ]
Lee 2011 6 9 -1.052829 (1.118916) 0.4 % 0.35 [ 0.04, 3.13 ]
Reunanen 1996 80 34 -0.7645662 (0.4495981) 2.6 % 0.47 [ 0.19, 1.12 ]
SANAD A 2007 5 4 1.122911 (1.15833) 0.4 % 3.07 [ 0.32, 29.76 ]
Subtotal (95% CI) 181 118 11.3 % 0.51 [ 0.33, 0.78 ]
Heterogeneity: Chi2 = 6.09, df = 5 (P = 0.30); I2 =18%
Test for overall effect: Z = 3.13 (P = 0.0017)
Total (95% CI) 1431 1050 100.0 % 0.71 [ 0.62, 0.82 ]
Heterogeneity: Chi2 = 14.43, df = 14 (P = 0.42); I2 =3%
Test for overall effect: Z = 4.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.73, df = 1 (P = 0.10), I2 =63%
0.005 0.1 1 10 200
Favours LTG Favours CBZ
70Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 5 Time to
treatment failure due to adverse events - by seizure type.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 5 Time to treatment failure due to adverse events - by seizure type
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal
Brodie 1995 A 44 38 -0.7301503 (0.4276836) 5.2 % 0.48 [ 0.21, 1.11 ]
Brodie 1995 B 27 35 -1.099853 (0.567083) 3.0 % 0.33 [ 0.11, 1.01 ]
Brodie 1999 72 33 -0.6358123 (0.4036616) 5.9 % 0.53 [ 0.24, 1.17 ]
Eun 2012 43 41 -0.0552479 (0.8165342) 1.4 % 0.95 [ 0.19, 4.69 ]
Lee 2011 51 44 -0.1092987 (0.7072286) 1.9 % 0.90 [ 0.22, 3.59 ]
Nieto-Barrera 2001 417 201 -0.4926564 (0.2605535) 14.1 % 0.61 [ 0.37, 1.02 ]
Reunanen 1996 150 87 -0.8369717 (0.5040289) 3.8 % 0.43 [ 0.16, 1.16 ]
SANAD A 2007 328 332 -0.7034758 (0.1600991) 37.4 % 0.49 [ 0.36, 0.68 ]
Werhahn 2015 118 121 -0.2947725 (0.2407681) 16.5 % 0.74 [ 0.46, 1.19 ]
Subtotal (95% CI) 1250 932 89.2 % 0.56 [ 0.45, 0.68 ]
Heterogeneity: Chi2 = 4.20, df = 8 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 5.67 (P < 0.00001)
2 Generalised
Brodie 1995 A 26 28 0.1368005 (0.4862035) 4.1 % 1.15 [ 0.44, 2.97 ]
Brodie 1995 B 34 28 -1.333781 (0.6772766) 2.1 % 0.26 [ 0.07, 0.99 ]
Brodie 1999 30 15 -1.733886 (0.6051581) 2.6 % 0.18 [ 0.05, 0.58 ]
Reunanen 1996 80 34 -0.9568174 (0.8168725) 1.4 % 0.38 [ 0.08, 1.90 ]
SANAD A 2007 5 4 0.7218652 (1.230733) 0.6 % 2.06 [ 0.18, 22.97 ]
Subtotal (95% CI) 175 109 10.8 % 0.49 [ 0.27, 0.88 ]
Heterogeneity: Chi2 = 8.19, df = 4 (P = 0.08); I2 =51%
Test for overall effect: Z = 2.39 (P = 0.017)
Total (95% CI) 1425 1041 100.0 % 0.55 [ 0.45, 0.66 ]
Heterogeneity: Chi2 = 12.54, df = 13 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 6.14 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
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Analysis 1.6. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 6 Time to
treatment failure (any reason related to the treatment, with aggregate data).
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 6 Time to treatment failure (any reason related to the treatment, with aggregate data)
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Brodie 1995 A 70 66 -0.3841084 (0.2689244) 4.2 % 0.68 [ 0.40, 1.15 ]
Brodie 1995 B 61 63 -0.5816703 (0.3097266) 3.1 % 0.56 [ 0.30, 1.03 ]
Brodie 1999 102 48 -0.8881041 (0.2706493) 4.1 % 0.41 [ 0.24, 0.70 ]
Eun 2012 43 41 0.1635266 (0.6708601) 0.7 % 1.18 [ 0.32, 4.39 ]
Gilad 2007 32 32 -2.424 (1.0493) 0.3 % 0.09 [ 0.01, 0.69 ]
Lee 2011 57 53 0.2539776 (0.3819136) 2.1 % 1.29 [ 0.61, 2.73 ]
Nieto-Barrera 2001 419 202 -0.3245885 (0.1954537) 7.9 % 0.72 [ 0.49, 1.06 ]
Reunanen 1996 230 121 -0.5267081 (0.2614281) 4.4 % 0.59 [ 0.35, 0.99 ]
Rowan 2005 200 198 -0.59 (0.14) 15.3 % 0.55 [ 0.42, 0.73 ]
Saetre 2007 93 91 -0.26 (0.27) 4.1 % 0.77 [ 0.45, 1.31 ]
SANAD A 2007 377 377 -0.2445736 (0.10813) 25.7 % 0.78 [ 0.63, 0.97 ]
Steinhoff 2005 88 88 -0.222 (0.276) 3.9 % 0.80 [ 0.47, 1.38 ]
Werhahn 2015 118 121 -0.2827565 (0.1112988) 24.3 % 0.75 [ 0.61, 0.94 ]
Total (95% CI) 1890 1501 100.0 % 0.70 [ 0.63, 0.78 ]
Heterogeneity: Chi2 = 16.54, df = 12 (P = 0.17); I2 =27%
Test for overall effect: Z = 6.58 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 7 Time to
treatment failure (any reason related to the treatment) - subgroup analysis (blinding).
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 7 Time to treatment failure (any reason related to the treatment) - subgroup analysis (blinding)
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Double-blind
Brodie 1995 A 70 66 -0.3841084 (0.2689244) 4.2 % 0.68 [ 0.40, 1.15 ]
Brodie 1995 B 61 63 -0.5816703 (0.3097266) 3.1 % 0.56 [ 0.30, 1.03 ]
Brodie 1999 102 48 -0.8881041 (0.2706493) 4.1 % 0.41 [ 0.24, 0.70 ]
Rowan 2005 200 198 -0.59 (0.14) 15.3 % 0.55 [ 0.42, 0.73 ]
Saetre 2007 93 91 -0.26 (0.27) 4.1 % 0.77 [ 0.45, 1.31 ]
Werhahn 2015 118 121 -0.2827565 (0.1112988) 24.3 % 0.75 [ 0.61, 0.94 ]
Subtotal (95% CI) 644 587 55.1 % 0.65 [ 0.56, 0.75 ]
Heterogeneity: Chi2 = 6.58, df = 5 (P = 0.25); I2 =24%
Test for overall effect: Z = 5.91 (P < 0.00001)
2 Open-label
Eun 2012 43 41 0.1635266 (0.6708601) 0.7 % 1.18 [ 0.32, 4.39 ]
Gilad 2007 32 32 -2.424 (1.0493) 0.3 % 0.09 [ 0.01, 0.69 ]
Lee 2011 57 53 0.2539776 (0.3819136) 2.1 % 1.29 [ 0.61, 2.73 ]
Nieto-Barrera 2001 419 202 -0.3245885 (0.1954537) 7.9 % 0.72 [ 0.49, 1.06 ]
Reunanen 1996 230 121 -0.5267081 (0.2614281) 4.4 % 0.59 [ 0.35, 0.99 ]
SANAD A 2007 377 377 -0.2445736 (0.10813) 25.7 % 0.78 [ 0.63, 0.97 ]
Steinhoff 2005 88 88 -0.222 (0.276) 3.9 % 0.80 [ 0.47, 1.38 ]
Subtotal (95% CI) 1246 914 44.9 % 0.76 [ 0.65, 0.90 ]
Heterogeneity: Chi2 = 7.64, df = 6 (P = 0.27); I2 =21%
Test for overall effect: Z = 3.28 (P = 0.0010)
Total (95% CI) 1890 1501 100.0 % 0.70 [ 0.63, 0.78 ]
Heterogeneity: Chi2 = 16.54, df = 12 (P = 0.17); I2 =27%
Test for overall effect: Z = 6.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.32, df = 1 (P = 0.13), I2 =57%
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Analysis 1.8. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 8 Time to first
seizure.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 8 Time to first seizure
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Brodie 1995 A 70 66 0.36048 (0.24798) 5.3 % 1.43 [ 0.88, 2.33 ]
Brodie 1995 B 61 63 0.12822 (0.23634) 5.9 % 1.14 [ 0.72, 1.81 ]
Brodie 1999 102 48 -0.15608 (0.23751) 5.8 % 0.86 [ 0.54, 1.36 ]
Eun 2012 43 41 -0.26785 (0.36609) 2.4 % 0.77 [ 0.37, 1.57 ]
Lee 2011 57 53 0.1156 (0.35958) 2.5 % 1.12 [ 0.55, 2.27 ]
Nieto-Barrera 2001 419 202 0.29979 (0.12767) 20.1 % 1.35 [ 1.05, 1.73 ]
Reunanen 1996 230 121 0.21504 (0.18849) 9.2 % 1.24 [ 0.86, 1.79 ]
SANAD A 2007 377 378 0.20983 (0.08648) 43.7 % 1.23 [ 1.04, 1.46 ]
Werhahn 2015 117 116 0.334 (0.25469) 5.0 % 1.40 [ 0.85, 2.30 ]
Total (95% CI) 1476 1088 100.0 % 1.22 [ 1.09, 1.37 ]
Heterogeneity: Chi2 = 5.35, df = 8 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.54 (P = 0.00040)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 9 Time to first
seizure by seizure type.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 9 Time to first seizure by seizure type
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal
Brodie 1995 A 44 38 0.53643 (0.2991) 3.8 % 1.71 [ 0.95, 3.07 ]
Brodie 1995 B 27 35 0.25662 (0.31735) 3.4 % 1.29 [ 0.69, 2.41 ]
Brodie 1999 72 33 0.04267 (0.269) 4.8 % 1.04 [ 0.62, 1.77 ]
Eun 2012 43 41 -0.26785 (0.36609) 2.6 % 0.77 [ 0.37, 1.57 ]
Lee 2011 51 44 0.2468 (0.38907) 2.3 % 1.28 [ 0.60, 2.74 ]
Nieto-Barrera 2001 417 201 0.30024 (0.12774) 21.1 % 1.35 [ 1.05, 1.73 ]
Reunanen 1996 150 87 0.27389 (0.21388) 7.5 % 1.32 [ 0.86, 2.00 ]
SANAD A 2007 328 333 0.2404 (0.09128) 41.3 % 1.27 [ 1.06, 1.52 ]
Werhahn 2015 117 116 0.334 (0.25469) 5.3 % 1.40 [ 0.85, 2.30 ]
Subtotal (95% CI) 1249 928 92.0 % 1.29 [ 1.14, 1.45 ]
Heterogeneity: Chi2 = 3.80, df = 8 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 4.11 (P = 0.000040)
2 Generalised
Brodie 1995 A 26 28 -0.08293 (0.4607) 1.6 % 0.92 [ 0.37, 2.27 ]
Brodie 1995 B 34 28 0.13928 (0.36114) 2.6 % 1.15 [ 0.57, 2.33 ]
Brodie 1999 30 15 -0.99643 (0.54129) 1.2 % 0.37 [ 0.13, 1.07 ]
Lee 2011 6 9 -17.8823 (6501) 0.0 % 0.00 [ 0.0, ]
Reunanen 1996 80 34 0.25181 (0.40443) 2.1 % 1.29 [ 0.58, 2.84 ]
SANAD A 2007 5 4 0.61633 (0.8761) 0.4 % 1.85 [ 0.33, 10.31 ]
Subtotal (95% CI) 181 118 8.0 % 0.98 [ 0.65, 1.48 ]
Heterogeneity: Chi2 = 4.45, df = 5 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Total (95% CI) 1430 1046 100.0 % 1.26 [ 1.12, 1.41 ]
Heterogeneity: Chi2 = 9.77, df = 14 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.92 (P = 0.000090)
Test for subgroup differences: Chi2 = 1.53, df = 1 (P = 0.22), I2 =35%
0.1 0.2 0.5 1 2 5 10
Favours LTG Favours CBZ
75Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.10. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 10 Time to first
seizure (with aggregate data).
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 10 Time to first seizure (with aggregate data)
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Brodie 1995 A 70 66 0.36048 (0.24798) 4.4 % 1.43 [ 0.88, 2.33 ]
Brodie 1995 B 61 63 0.12822 (0.23634) 4.8 % 1.14 [ 0.72, 1.81 ]
Brodie 1999 102 48 -0.15608 (0.23751) 4.8 % 0.86 [ 0.54, 1.36 ]
Eun 2012 43 41 -0.26785 (0.36609) 2.0 % 0.77 [ 0.37, 1.57 ]
Gilad 2007 32 32 -0.7856 (0.4129) 1.6 % 0.46 [ 0.20, 1.02 ]
Lee 2011 57 53 0.1156 (0.35958) 2.1 % 1.12 [ 0.55, 2.27 ]
Nieto-Barrera 2001 419 202 0.29979 (0.12767) 16.5 % 1.35 [ 1.05, 1.73 ]
Reunanen 1996 230 121 0.21504 (0.18849) 7.6 % 1.24 [ 0.86, 1.79 ]
Rowan 2005 200 198 0.37 (0.15) 12.0 % 1.45 [ 1.08, 1.94 ]
Saetre 2007 93 91 0.41 (0.26) 4.0 % 1.51 [ 0.91, 2.51 ]
SANAD A 2007 377 378 0.20983 (0.08648) 36.1 % 1.23 [ 1.04, 1.46 ]
Werhahn 2015 118 121 0.334 (0.25469) 4.2 % 1.40 [ 0.85, 2.30 ]
Total (95% CI) 1802 1414 100.0 % 1.24 [ 1.12, 1.37 ]
Heterogeneity: Chi2 = 12.90, df = 11 (P = 0.30); I2 =15%
Test for overall effect: Z = 4.15 (P = 0.000034)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 11 Seizure
freedom (whole study).
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 11 Seizure freedom (whole study)
Study or subgroup LTG CBZ
Risk
Ratio(Non-
event) Weight
Risk
Ratio(Non-
event)
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brodie 1995 A 31/70 38/66 3.2 % 1.31 [ 0.93, 1.86 ]
Brodie 1995 B 23/61 29/63 3.7 % 1.15 [ 0.85, 1.56 ]
Brodie 1999 49/102 21/48 4.1 % 0.92 [ 0.68, 1.26 ]
Eun 2012 27/43 25/41 1.8 % 0.95 [ 0.55, 1.64 ]
Gilad 2007 23/32 15/32 1.9 % 0.53 [ 0.28, 1.01 ]
Korean Lamotrigine Study Group 2008 96/252 45/122 11.5 % 0.98 [ 0.83, 1.16 ]
Lee 2011 41/57 38/53 1.7 % 0.99 [ 0.55, 1.80 ]
Nieto-Barrera 2001 191/419 118/202 12.6 % 1.31 [ 1.09, 1.58 ]
Reunanen 1996 135/230 81/121 5.8 % 1.25 [ 0.93, 1.68 ]
Rowan 2005 57/200 45/198 17.1 % 0.93 [ 0.82, 1.04 ]
Saetre 2007 50/93 60/91 3.5 % 1.36 [ 0.95, 1.95 ]
SANAD A 2007 95/377 123/378 28.3 % 1.11 [ 1.01, 1.21 ]
Steinhoff 2005 62/88 72/88 1.8 % 1.63 [ 0.94, 2.81 ]
Werhahn 2015 79/117 90/116 2.9 % 1.45 [ 0.94, 2.22 ]
Total (95% CI) 2141 1619 100.0 % 1.11 [ 1.04, 1.18 ]
Total events: 959 (LTG), 800 (CBZ)
Heterogeneity: Chi2 = 27.55, df = 13 (P = 0.01); I2 =53%
Test for overall effect: Z = 3.42 (P = 0.00064)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LTG Favours CBZ
77Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.12. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 12 Time to 6-
month remission.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 12 Time to 6-month remission
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Brodie 1995 A 70 66 -0.29789 (0.27574) 4.8 % 0.74 [ 0.43, 1.27 ]
Brodie 1995 B 61 63 -0.45437 (0.26847) 5.1 % 0.63 [ 0.38, 1.07 ]
Eun 2012 43 41 0.02671 (0.28928) 4.4 % 1.03 [ 0.58, 1.81 ]
Lee 2011 57 53 0.05511 (0.23827) 6.5 % 1.06 [ 0.66, 1.69 ]
Reunanen 1996 230 121 -0.14772 (0.15401) 15.5 % 0.86 [ 0.64, 1.17 ]
SANAD A 2007 377 378 -0.1919 (0.08292) 53.5 % 0.83 [ 0.70, 0.97 ]
Werhahn 2015 117 116 -0.19551 (0.18937) 10.2 % 0.82 [ 0.57, 1.19 ]
Total (95% CI) 955 838 100.0 % 0.84 [ 0.74, 0.94 ]
Heterogeneity: Chi2 = 2.78, df = 6 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 13 Time to 6-
month remission by seizure type.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 13 Time to 6-month remission by seizure type
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal
Brodie 1995 A 44 38 0.40112 (0.37028) 2.9 % 1.49 [ 0.72, 3.09 ]
Brodie 1995 B 27 35 -0.8553 (0.42023) 2.2 % 0.43 [ 0.19, 0.97 ]
Eun 2012 43 41 0.02671 (0.28928) 4.7 % 1.03 [ 0.58, 1.81 ]
Lee 2011 51 44 0.2466 (0.26055) 5.8 % 1.28 [ 0.77, 2.13 ]
Reunanen 1996 150 87 -0.09697 (0.18806) 11.1 % 0.91 [ 0.63, 1.31 ]
SANAD A 2007 328 333 -0.18685 (0.08831) 50.3 % 0.83 [ 0.70, 0.99 ]
Werhahn 2015 117 116 -0.19551 (0.18937) 10.9 % 0.82 [ 0.57, 1.19 ]
Subtotal (95% CI) 760 694 87.9 % 0.87 [ 0.77, 1.00 ]
Heterogeneity: Chi2 = 7.98, df = 6 (P = 0.24); I2 =25%
Test for overall effect: Z = 2.01 (P = 0.044)
2 Generalised
Brodie 1995 A 26 28 -0.06409 (0.41807) 2.2 % 0.94 [ 0.41, 2.13 ]
Brodie 1995 B 34 28 -0.20324 (0.36452) 3.0 % 0.82 [ 0.40, 1.67 ]
Lee 2011 6 9 -0.84161 (0.69791) 0.8 % 0.43 [ 0.11, 1.69 ]
Reunanen 1996 80 34 -0.25098 (0.27001) 5.4 % 0.78 [ 0.46, 1.32 ]
SANAD A 2007 5 4 -0.38853 (0.76944) 0.7 % 0.68 [ 0.15, 3.06 ]
Subtotal (95% CI) 151 103 12.1 % 0.78 [ 0.55, 1.11 ]
Heterogeneity: Chi2 = 0.97, df = 4 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Total (95% CI) 911 797 100.0 % 0.86 [ 0.76, 0.97 ]
Heterogeneity: Chi2 = 9.31, df = 11 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.54), I2 =0.0%
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Analysis 1.14. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 14 Seizure
freedom at 6 months.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 14 Seizure freedom at 6 months
Study or subgroup LTG CBZ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brodie 1995 A 20/70 21/66 2.7 % 0.90 [ 0.54, 1.50 ]
Brodie 1995 B 19/61 17/63 2.1 % 1.15 [ 0.66, 2.00 ]
Brodie 1999 36/102 8/48 1.4 % 2.12 [ 1.07, 4.20 ]
Eun 2012 23/43 22/41 2.8 % 1.00 [ 0.67, 1.48 ]
Gilad 2007 23/32 16/32 2.0 % 1.44 [ 0.96, 2.16 ]
Korean Lamotrigine Study Group 2008 156/252 77/122 13.0 % 0.98 [ 0.83, 1.16 ]
Lee 2011 30/57 30/53 3.9 % 0.93 [ 0.66, 1.31 ]
Nieto-Barrera 2001 124/419 67/202 11.3 % 0.89 [ 0.70, 1.14 ]
Reunanen 1996 108/230 58/121 9.5 % 0.98 [ 0.78, 1.23 ]
Rowan 2005 75/200 71/198 8.9 % 1.05 [ 0.81, 1.35 ]
Saetre 2007 53/93 62/91 7.8 % 0.84 [ 0.67, 1.05 ]
SANAD A 2007 132/377 158/378 19.7 % 0.84 [ 0.70, 1.00 ]
Steinhoff 2005 62/88 72/88 9.0 % 0.86 [ 0.73, 1.02 ]
Werhahn 2015 52/117 46/116 5.8 % 1.12 [ 0.83, 1.52 ]
Total (95% CI) 2141 1619 100.0 % 0.96 [ 0.89, 1.03 ]
Total events: 913 (LTG), 725 (CBZ)
Heterogeneity: Chi2 = 16.48, df = 13 (P = 0.22); I2 =21%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 15 Time to 12-
month remission.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 15 Time to 12-month remission
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
SANAD A 2007 377 378 -0.10204 (0.0923) 83.5 % 0.90 [ 0.75, 1.08 ]
Werhahn 2015 117 116 -0.05938 (0.20772) 16.5 % 0.94 [ 0.63, 1.42 ]
Total (95% CI) 494 494 100.0 % 0.91 [ 0.77, 1.07 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 16 Time to 12-
month remission by seizure type.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 16 Time to 12-month remission by seizure type
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal
SANAD A 2007 328 333 -0.09769 (0.0987) 73.6 % 0.91 [ 0.75, 1.10 ]
Werhahn 2015 117 116 -0.05938 (0.20772) 16.6 % 0.94 [ 0.63, 1.42 ]
Subtotal (95% CI) 445 449 90.2 % 0.91 [ 0.77, 1.09 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
2 Uncertain
SANAD A 2007 49 45 -0.21512 (0.27024) 9.8 % 0.81 [ 0.47, 1.37 ]
Subtotal (95% CI) 49 45 9.8 % 0.81 [ 0.47, 1.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
Total (95% CI) 494 494 100.0 % 0.90 [ 0.76, 1.07 ]
Heterogeneity: Chi2 = 0.22, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.22)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.66), I2 =0.0%
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Analysis 1.17. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 17 Time to 24-
month remission.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 17 Time to 24-month remission
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
SANAD A 2007 377 378 -0.00098 (0.11628) 100.0 % 1.00 [ 0.80, 1.25 ]
Total (95% CI) 377 378 100.0 % 1.00 [ 0.80, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 18 Time to 24-
month remission by seizure type.
Review: Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
Comparison: 1 Lamotrigine (LTG) versus carbamazepine (CBZ)
Outcome: 18 Time to 24-month remission by seizure type
Study or subgroup LTG CBZ log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal
SANAD A 2007 328 333 0.05553 (0.1249) 88.0 % 1.06 [ 0.83, 1.35 ]
Subtotal (95% CI) 328 333 88.0 % 1.06 [ 0.83, 1.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
2 Uncertain
SANAD A 2007 49 45 -0.15202 (0.33844) 12.0 % 0.86 [ 0.44, 1.67 ]
Subtotal (95% CI) 49 45 12.0 % 0.86 [ 0.44, 1.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 377 378 100.0 % 1.03 [ 0.82, 1.30 ]
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.57), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Demographic characteristics of trial participants (trials providing individual participant data)
Focal seizures: n
(%)
Male gender: n
(%)
Age at entry
(years):
Mean (SD), range
Aged
> 30 and gener-
alised seizures: n
(%)
Epilepsy duration
(years):
Mean (SD), range
Number of
seizures in prior
6months:median
(range)
LTG
CBZ Miss-
ing
LTG
CBZ Miss-
ing
LTG
CBZ Miss-
ing
LTG
CBZ Miss-
ing
LTG
CBZ Miss-
ing
LTG
CBZ Miss-
ing
Brodie
1995
A
44
(63%)
38
(58%)
0 28
(40%)
28
(42%)
0 35.3
(17.
1)
, 15
32.5
(14.
4)
, 13
0 11 9 0 2.
2 (3.
3), 0
to
1.
8 (2.
3)
, 0.
0 4
(1 to
490)
3
(1 to
960)
0
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Table 1. Demographic characteristics of trial participants (trials providing individual participant data) (Continued)
to
71
to
69
17.9 3 to
11.0
Brodie
1995
B
27
(44%)
35
(56%)
0 26
(43%)
30
(48%)
0 30.9
(14.
5)
, 14
to
86
29.1
(13.
9)
, 14
to
81
0 12 11 0 1.
4 (3.
2), 0
to
19.4
1.
2 (1.
8), 0
to 7.
1
0 3 (1
to
1020)
3
(2 to
122)
0
Brodie
1999
72
(71%)
33
(69%)
0 55
(54%)
28
(58%)
0 77.
3 (6.
1)
, 65
to
94
76.
2 (5.
9)
, 66
to
88
0 30 15 0 NA NA 150 3
(1 to
163)
4.5
(1 to
108)
0
Eun
2012
43
(100%)
41
(100%)
0 24
(56%)
24
(59%)
0 9.
2 (2.
0), 6
to
13
8.
3 (2.
1), 5
to
12
0 0 0 0 0.
6 (0.
9), 0
to 4.
5
0.
5 (0.
3), 0
to 1.
4
1 3
(2 to
11)
3
(2 to
11)
0
Lee
2011
51
(89%)
44
(83%)
0 24
(42%)
33
(62%)
0 33.6
(12.
6)
, 16
to
60
38.3
(11.
5)
, 16
to
60
0 2 7 0 NA NA 110 2
(0 to
60)
2
(0 to
200)
0
Ni-
eto-
Bar-
rera
2001
418
(99.
5%)
201
(99.
5%)
0 222
(53%)
107
(53%)
0 27.1
(21.
7), 2
to
84
27.5
(21.
0), 2
to
77
1 1 1 0 NA NA 622 4 (1
to
9000)
3 (1
to
3600)
0
Re-
una-
nen
1996
150
(65%)
87
(72%)
0 127
(55%)
61
(50%)
0 31.8
(14.
0)
, 12
to
71
32.7
(14.
6)
, 13
to
71
2 31 12 0 2.
2 (3.
2), 0
to
17.1
2.
2 (3.
7),
0.26
to 8
3 3
(1 to
133)
3
(1 to
145)
1
SANAD
A
2007
329
(99%)
333
(99%)
85 205
(55%)
204
(55%)
18 36.8
(18.
4), 6
to
83
39.3
(18.
4), 5
to
82
18 46 42 0 NA NA 727 2(0
to
1185)
4
(0 to
466)
19
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Table 1. Demographic characteristics of trial participants (trials providing individual participant data) (Continued)
Wer-
hahn
2015
118
(100%)
121
(100%)
0 69
(59%)
65
(54%)
0 70.
8 (7.
5)
, 60
to
88
71.
8 (6.
7)
, 60
to
89
0 0 0 0 NA NA 239 2
(1 to
20)
2
(1 to
90)
6
CBZ = carbamazepine, LTG = lamotrigine; n = number of participants; NA = not applicable; SD = standard deviation
Table 2. Baseline neurologic characteristics of participants (trials providing individual participant data)
EEG normal: n (%) CT scan normal: n (%) Neurological exam
normal: n (%)
LTG CBZ Missing LTG CBZ Missing LTG CBZ Missing
Brodie
1995 A
32 (46%) 30 (46%) 2 38 (84%) 44 (90%) 42 62 (89%) 61 (92%) 0
Brodie
1995 B
42 (73%) 34 (56%) 6 34 (77%) 38 (79%) 32 56 (92%) 52 (83%) 0
Brodie
1999
NA NA 150 39 (39%) 23 (48%) 1 59 (58%) 31 (65%) 0
Eun 2012 3 (7%) 3 (7%) 0 38 (88%) 37(90%) 0 43 (100%) 40 (98%) 0
Lee 2011 31 (54%) 27 (51%) 0 36 (63%) 38 (72%) 0 57 (100%) 53 (100%) 0
Nieto-
Barrera
2001
NA NA 622 NA NA 622 NA NA 622
Reunanen
1996
9 (53%) 4 (44%) 325 11 (73%) 5 (83%) 330 202 (89%) 103 (85%) 0
SANAD A
2007
NA NA 756 NA NA 756 277 (75%) 281 (76%) 18
Werhahn
2015
45 (38%) 37 (31%) 1 26 (22%) 26 (21%) 1 NA NA 239
CBZ = carbamazepine; CT = computerised tomography; EEG = electroencephalogram; LTG = lamotrigine; n = number of participants;
NA = not applicable
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Table 3. Number of participants included in analyses (trials providing individual participant data)
Number
randomised
Time to treatment
failure
Time to first
seizure
Time to 6-
month remission1
Time to 12-
month remission
Time to 24-
month remission
LTG
CBZ
To-
tal
LTG
CBZ
To-
tal
LTG
CBZ
To-
tal
LTG
CBZ
To-
tal
LTG
CBZ
To-
tal
LTG
CBZ
To-
tal
Brodie
1995
A
70 66 136 70 66 136 70 66 136 70 66 136 NA NA NA NA NA NA
Brodie
1995
B
61 63 124 61 63 124 61 63 124 61 63 124 NA NA NA NA NA NA
Brodie
1999
1
102 48 150 102 48 150 102 48 150 102 48 150 NA NA NA NA NA NA
Eun
2012
43 41 84 43 41 84 43 41 84 43 41 84 NA NA NA NA NA NA
Lee
2011
57 53 110 57 53 110 57 53 110 57 53 110 NA NA NA NA NA NA
Ni-
eto-
Bar-
rera
2001
1,2
420 202 622 419 202 621 419 202 621 419 202 621 NA NA NA NA NA NA
Re-
una-
nen
1996
230 121 351 230 121 351 230 121 351 230 121 351 NA NA NA NA NA NA
SANAD
A
2007
3
378 378 756 377 377 754 377 378 755 377 378 755 377 378 755 377 378 755
Wer-
hahn
118 121 239 118 121 239 117 116 233 117 116 233 117 116 233 NA NA NA
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Table 3. Number of participants included in analyses (trials providing individual participant data) (Continued)
2015
4
To-
tal 1479 1093 2572 1477 1092 2569 1476 1088 2564 1476 1088 2564
494 494 988 377 378 755
CBZ = carbamazepine; LTG = lamotrigine; NA: not applicable (trial duration not sufficient to measure the outcome).
1. Brodie 1999, and Nieto-Barrera 2001, are of 24 weeks duration (approximately six months). The two trials are not included in the
analyses of time to six-month remission but are included in sensitivity analysis of seizure freedom at six months.
2. Follow-up data are missing for one participant in Nieto-Barrera 2001.
3. Treatment failure time missing for two participants and seizure data after follow-up missing for one participant in SANAD A 2007.
4. Seizure data after follow-up missing for six participants in Werhahn 2015.
Table 4. Reasons for premature discontinuation (treatment failure)
Reason for
early
termination1
Classification in time-to-event analyses: Event Classification in time-to-event analyses:
Censored
Total
Ad-
verse
events
Inade-
quate
re-
sponse/
seizure
recur-
rence
Both
adverse
events
and in-
ade-
quate
re-
sponse
Proto-
col vio-
lation/
non-
com-
pliance
With-
drew
con-
sent/
partici-
pant
choice
3
Other
(treat-
ment-
re-
lated)4
Ill-
ness or
death
(not
treat-
ment-
re-
lated)
Remis-
sion of
seizures
Lost to
follow-
up
Other
(not
treat-
ment-
re-
lated)5
Com-
pleted
trial
Brodie
1995 A
LTG 18 3 0 3 1 0 1 0 1 0 43 70
CBZ 22 2 0 6 1 0 0 0 2 0 33 66
Brodie
1995 B
LTG 7 3 0 5 2 0 0 0 1 0 43 61
CBZ 23 1 0 3 1 0 0 0 1 0 34 63
Brodie
1999
LTG 18 0 0 7 3 0 1 0 2 0 71 102
CBZ 20 0 0 3 2 2 0 0 1 0 20 48
Eun
2012
LTG 3 2 0 0 0 0 0 0 4 0 34 43
CBZ 3 0 0 0 1 0 0 0 2 0 35 41
Gilad
20072
LTG 1 0 0 0 0 0 0 0 0 0 31 32
CBZ 10 0 0 0 0 0 1 0 0 0 21 32
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Table 4. Reasons for premature discontinuation (treatment failure) (Continued)
Korean
Lam-
otrig-
ine
Study
Group
20082
LTG 24 11 0 0 0 52 0 0 0 0 165 252
CBZ 13 2 0 0 0 22 0 0 0 0 85 122
Lee
2011
LTG 4 3 0 2 7 0 0 0 2 0 39 57
CBZ 7 0 0 3 2 0 0 0 7 0 34 53
Nieto-
Barrera
20017
LTG 34 12 0 6 16 0 0 0 13 0 339 420
CBZ 26 4 0 11 2 0 0 0 3 0 156 202
Reuna-
nen
1996
LTG 10 1 0 17 3 3 4 0 0 0 192 230
CBZ 12 0 0 11 6 0 2 0 0 0 90 121
Rowan
20052
LTG 20 7 0 15 24 0 7 0 10 5 112 200
CBZ 54 3 0 14 28 0 14 0 4 10 71 198
Saetre
20072
LTG 13 0 0 2 0 10 0 0 0 0 68 93
CBZ 23 0 0 1 0 6 0 0 0 0 61 91
SANAD
A 2007
8
LTG 61 60 11 1 4 16 7 23 0 14 181 378
CBZ 104 43 20 2 1 7 10 25 0 15 151 378
Stein-
hoff
20052
LTG 7 1 0 0 13 3 0 0 0 0 64 88
CBZ 17 0 0 0 7 5 0 0 0 0 59 88
Wer-
hahn
2015
LTG 31 2 0 6 13 1 0 0 0 0 65 118
CBZ 39 3 0 4 20 0 0 0 0 0 55 121
Total LTG 251 105 11 64 86 85 20 23 33 19 1447 2144
Total CBZ 373 58 20 58 71 42 27 25 20 25 905 1624
Total (all) 624 163 31 122 157 127 47 48 53 44 2352 3768
1. Primary reason for discontinuation specified - participants may have withdrawn from allocated treatment for a combination of
reasons.
2. Reasons for treatment failure extracted from trial publications for Gilad 2007, Korean Lamotrigine Study Group 2008; Rowan 2005,
Saetre 2007, and Steinhoff 2005. Individual participant data for reasons for treatment failure provided for other trials.
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3. Withdrawal of consent/participant choice classified as an event in this review but censored in included trial (SANAD A 2007).
Sensitivity analysis classifying withdrawal of consent as a censored observation did not change the conclusions (results available on
request).
4. Other treatment-related reasons: investigator choice (Werhahn 2015), drug-related death, pregnancy or perceived remission (SANAD
A 2007). Specified only as ’other reason’ for Brodie 1999; Reunanen 1996; Korean Lamotrigine Study Group 2008; Saetre 2007 and
Steinhoff 2005.
5. Other reasons (not treatment-related): epilepsy diagnosis changed (SANAD A 2007). Specified only as ’other reason’ for Rowan
2005, and for seven participants in SANAD A 2007.
6. No information on whether participants withdrew from treatment or completed the study available for 19 participants
7. One participant (randomised to LTG) with date and reason for treatment failure missing.
8. Two participants with date of treatment failure missing so not included in analysis of time to treatment failure but with reasons
for treatment failure provided (both censored: one withdrew from LTG due to remission of seizures, one withdrew from CBZ due to
’other’ non-treatment-related reason).
Table 5. Sensitivity analysis - Reunanen 1996
Treat-
ment
N Com-
parator
N Total Time to treatment
failure
Time to first seizure Time to 6-month remission
HR (95%
CI)
P value HR (95%
CI)
P value HR (95% CI) P value
Lamot-
rig-
ine (both
arms)
230 Carba-
mazepine
121 351 0.59 (0.35
to 0.99)
0.04 1.24 (0.86 to
1.79)
0.25 0.84 (0.36 to 1.
95)
0.68
Lamot-
rigine
200 mg
115 Lamot-
rigine 100
mg + car-
ba-
mazepine
236 351 0.47 (0.25
to 0.86)
0.02 0.96 (0.67 to
1.36)
0.8 0.62 (0.24 to 1.
58)
0.32
Lamot-
rigine
100 mg
115 Lamot-
rigine 200
mg + car-
ba-
mazepine
236 351 1.05 (0.63
to 1.75)
0.85 1.29 (0.91 to
1.83)
0.15 1.33 (0.56 to 3.
17)
0.52
Lamot-
rigine
200 mg
115 Carba-
mazepine
121 236 0.41 (0.21
to 0.78)
0.007 1.12 (0.73 to
1.72)
0.59 0.63 (0.22 to 1.
78)
0.39
Lamot-
rigine
100 mg
115 Carba-
mazepine
121 236 0.73 (0.43
to 1.26)
0.26 1.37 (0.90 to
2.07)
0.14 1.10 (0.41 to 2.
92)
0.86
mg= milligrams per day; HR = hazard ratio; 95% CI = 95% confidence interval
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Table 6. Sensitivity analysis - misclassification of seizure type
Time to treatment failure Time to first seizure Time to 6-month remission
Original analysis F: HR 0.74, 95% CI (0.64 to
0.86)
G: HR 0.51, 95% CI (0.33 to
0.78)
O: HR 0.71, 95% CI (0.62 to
0.82)
F: HR 1.29, 95% CI (1.14 to
1.45)
G: HR 0.98, 95% CI (0.65 to
1.48)
O: HR 1.26, 95% CI (1.12 to
1.41)
F: HR 0.87, 95% CI (0.77 to
1.00)
G: HR 0.78, 95% CI (0.55 to
1.11)
O: HR 0.86, 95% CI (0.76 to
0.97)
Test of subgroup differences Chi² = 2.73, df = 1 (P = 0.10),
I² = 63.4%
Chi² = 1.53, df = 1 (P = 0.22),
I² = 34.5%
Chi² = 0.37, df = 1 (P = 0.54),
I² = 0%
Generalised onset and age at on-
set > 30 reclassified
as focal onset
F: HR 0.72, 95% CI (0.62 to
0.83)
G: HR 0.58, 95% CI (0.32 to
1.06)
O: HR 0.71, 95% CI (0.62 to
0.82)
F: HR 1.25, 95% CI (1.11 to
1.41)
G: HR 1.17, 95% CI (0.67 to
2.04)
O: HR 1.25, 95% CI (1.11 to
1.40)
F: HR 0.85, 95% CI (0.75 to
0.97)
G: HR 0.69, 95% CI (0.44 to
1.08)
O: HR 0.84, 95% CI (0.74 to
0.95)
Test of subgroup differences Chi² = 0.45, df = 1 (P = 0.50),
I² = 0%
Chi² = 0.06, df = 1 (P = 0.81),
I² = 0%
Chi² = 0.80, df = 1 (P = 0.37),
I² = 0%
Generalised onset and age at on-
set > 30 reclassified
as uncertain seizure type
F: HR 0.74, 95% CI (0.64 to
0.86)
G: HR 0.58, 95% CI (0.32 to
1.06)
U: HR 0.62, 95% CI (0.39 to
0.97)
O: HR 0.72, 95% CI (0.63 to
0.83)
F: HR 1.29, 95% CI (1.14 to
1.45)
G: HR 1.17, 95% CI (0.67 to
2.04)
U: HR 0.88, 95% CI (0.58 to
1.33)
O: HR 1.24, 95% CI (1.11 to
1.39)
F: HR 0.87, 95% CI (0.77 to
1.00)
G: HR 0.69, 95% CI (0.44 to
1.08)
U: HR 0.89, 95% CI (0.60 to
1.31)
O: HR 0.86, 95% CI (0.76 to
0.97)
Test of subgroup differences Chi² = 1.15, df = 2 (P = 0.56),
I² = 0%
Chi² = 3.03, df = 2 (P = 0.22),
I² = 33.9%
Chi² = 1.02, df = 2 (P = 0.60),
I² = 0%
CI = confidence interval; F = focal onset seizures; G = generalised onset seizures; HR = hazard ratio; O = overall pooled result adjusted
by seizure type; U = uncertain seizure type.
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Table 7. Summary of adverse events experienced (seven trials providing detailed individual participant data)
Trial Number
experiencing
adverse events
Number of
adverse events
Number of
adverse
events
per person
(range)
Number of drug-
related
adverse events1
Number of adverse
events requiring
action/
treatment change
Number of
patients
needing a treat-
ment
change/dose
change
LTG CBZ To-
tal
LTG CBZ To-
tal
LTG CBZ LTG CBZ To-
tal
LTG CBZ To-
tal
LTG CBZ To-
tal
Brodie
1995
A
62 58 120 388 322 710 1 to
30
1 to
17
94 124 218 167 111 278 22 32 54
Brodie
1995
B
54 58 112 285 291 576 1 to
14
1 to
18
81 125 206 98 81 179 20 40 60
Brodie
1999
91 41 132 338 173 511 1 to
12
1 to
10
109 73 182 92 66 158 39 27 66
Eun
2012
3 6 9 5 8 13 1 to
30
1 to
2
NA NA NA NA NA NA NA NA NA
Lee
2011
4 6 10 NA NA NA NA NA 4 5 9 NA NA NA NA NA NA
Ni-
eto-
Bar-
rera
2001
218 120 338 524 277 801 1 to
10
1 to
11
238 152 390 116 82 198 70 54 124
Re-
una-
nen
1996
124 77 201 451 243 694 1 to
14
1 to
8
138 169 307 156 52 208 23 36 59
SANAD
A
2007
229 260 489
1038 1339 2377
1 to
25
1 to
37
NA NA NA 447 665
1112
120 173 293
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Table 7. Summary of adverse events experienced (seven trials providing detailed individual participant data) (Continued)
Wer-
hahn
2015
120 110 230 779 770
1549
1 to
53
1 to
30
291 382 673 147 159 306 64 65 129
CBZ = carbamazepine; LTG = lamotrigine; NA = information not available.
1. In Brodie 1995 A, Brodie 1995 B and Reunanen 1996 adverse events that are “definitely related”, in Brodie 1999 and Nieto-Barrera
2001 “a reasonable possibility” that adverse events are treatment-related and in Werhahn 2015 adverse events are “related, probably
related or possibility related”.
Table 8. Most commonly occurring adverse events (trials providing detailed individual participant data)
Most
com-
monly
oc-
cur-
ring
ad-
verse
events
Brodie 1995 A Brodie 1995 B Brodie 1999 Nieto-Barrera 2001
LTG CBZ LTG CBZ LTG CBZ LTG CBZ
Events
Ppts
Events
Ppts
Events
Ppts
Events
Ppts
Events
Ppts
Events
Ppts
Events
Ppts
Events
Ppts
Acci-
den-
tal
in-
jury/
frac-
ture
2 2 1 1 3 3 2 2 19 12 4 3 7 7 1 1
Ag-
gres-
sion
8 6 2 2 0 0 0 0 2 2 0 0 3 3 2 2
Anorexia/
weight
loss
2 2 0 0 6 4 0 0 2 2 1 1 6 5 0 0
Anx-
iety/
de-
pres-
sion
12 5 7 5 6 3 10 7 3 3 0 0 8 8 2 2
Apha-
sia
0 0 3 3 0 0 0 0 1 1 2 2 1 1 0 0
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Table 8. Most commonly occurring adverse events (trials providing detailed individual participant data) (Continued)
Ataxia
2 2 6 5 0 0 0 0 0 0 0 0 2 2 3 3
Chest
in-
fec-
tion/
bron-
chitis
11 6 12 8 3 3 1 1 16 12 4 4 18 15 8 8
Cold/
in-
fluenza
17 15 4 4 8 8 10 9 7 7 1 1 25 19 11 11
Con-
cen-
tra-
tion
0 0 1 1 0 0 1 1 0 0 0 0 4 4 1 1
Con-
fu-
sion
1 1 0 0 0 0 0 0 2 2 1 1 0 0 0 0
Cough/
wheeze
5 5 5 5 2 2 1 1 6 5 1 1 6 5 6 5
Den-
tal
3 3 2 2 1 1 1 1 1 1 1 1 6 6 3 3
Dizzy/
faint
16 9 16 11 12 9 22 14 26 18 16 14 43 34 16 15
Drowsy/
fa-
tigued
32 21 52 31 34 20 49 36 25 17 21 15 36 34 45 40
Gas-
troin-
testi-
nal
dis-
tur-
bances
14 7 10 8 6 6 7 5 29 22 14 11 36 28 17 17
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Table 8. Most commonly occurring adverse events (trials providing detailed individual participant data) (Continued)
Hair
loss
0 0 0 0 1 1 1 1 0 0 0 0 0 0 1 1
Headache/
mi-
graine
77 27 31 17 48 24 52 22 14 10 8 8 56 46 16 14
Im-
po-
tence
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
In-
creased/
wors-
ened
seizures
1 1 2 2 1 1 0 0 4 4 2 2 14 12 4 4
Kid-
ney/
uri-
nary
prob-
lems
3 2 2 2 4 4 1 1 12 10 4 4 4 4 1 1
Mem-
ory
prob-
lems
7 5 2 2 5 3 3 2 4 4 0 0 2 2 1 1
Men-
strual
prob-
lems
3 3 16 12 0 0 4 4 0 0 1 1 0 0 0 0
Mood/
be-
havioural
change
9 5 6 5 1 1 6 6 5 4 0 0 7 7 4 4
Nau-
sea/
vom-
iting
17 13 15 11 26 18 21 9 21 17 8 6 26 23 13 11
Pain 19 13 9 6 23 13 7 5 20 17 7 7 13 8 4 2
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Table 8. Most commonly occurring adverse events (trials providing detailed individual participant data) (Continued)
Pins
and
nee-
dles/
tin-
gling
2 1 3 2 3 3 0 0 1 1 0 0 1 1 0 0
Rash/
skin
prob-
lems
25 21 20 13 32 15 32 23 31 19 30 14 49 46 32 30
Sleep
prob-
lems/
dreams
4 3 4 4 8 5 12 5 9 8 0 0 19 19 1 1
Throat/
tonsil
in-
fec-
tion
11 7 7 6 6 5 3 3 1 1 0 0 15 14 7 7
Tremor/
twitch
1 1 2 1 0 0 0 0 1 1 0 0 0 0 2 2
Vi-
sual
dis-
tur-
bance/
nys-
tag-
mus
8 4 6 5 2 2 9 6 1 1 4 3 7 7 3 2
Weight
gain
3 3 1 1 2 1 0 0 0 0 0 0 3 3 3 3
Table of most commonly occurring adverse events split into two for formatting reasons.
Events = number of adverse events reported; Ppts = number of participants reporting the adverse event (a participant could report the
same type of adverse event multiple times).
LTG = lamotrigine; CBZ = carbamazepine
Most common adverse events are defined as events reported 10 or more times in at least one of the seven trials (Brodie 1995 A; Brodie
1995 B; Brodie 1999; Nieto-Barrera 2001; Reunanen 1996; SANADA 2007; Werhahn 2015). Less commonly reported adverse events
are not summarised in this table but details are available on request from the review authors. General terminology for the type of adverse
events was defined by the review authors based on the individual participant data provided.
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Table 9. Most commonly occurring adverse events continued (trials providing detailed individual participant data)
Most
com-
monly
oc-
cur-
ring
ad-
verse
events
Reunanen 1996 SANAD A 2007 Werhahn 2015 Total (across seven studies)
LTG CBZ LTG CBZ LTG CBZ LTG CBZ
Events
Ppts
Events
Ppts
Events
Ppts
Events
Ppts
Events
Ppts
Events
Ppts
Events
Ppts
Events
Ppts
Acci-
den-
tal
in-
jury/
frac-
ture
2 2 0 0 29 19 10 10 16 15 14 7 78 60 32 24
Ag-
gres-
sion
1 1 0 0 25 18 41 21 1 1 1 1 40 31 46 26
Anorexia/
weight
loss
3 2 0 0 12 11 16 13 1 1 0 0 32 27 17 14
Anx-
iety/
de-
pres-
sion
4 4 2 2 48 34 46 34 17 14 17 10 98 71 84 60
Apha-
sia
1 1 0 0 7 4 11 8 1 1 7 5 11 8 23 18
Ataxia
0 0 3 3 38 20 30 22 1 1 0 0 43 25 42 33
Chest
in-
fec-
tion/
bron-
chitis
3 3 1 1 2 1 6 5 8 8 3 3 61 48 35 30
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Table 9. Most commonly occurring adverse events continued (trials providing detailed individual participant data) (Contin-
ued)
Cold/
in-
fluenza
9 8 2 2 1 1 3 3 11 9 20 15 78 67 51 45
Con-
cen-
tra-
tion
3 3 4 3 8 7 11 11 5 5 3 3 20 19 21 20
Con-
fu-
sion
0 0 0 0 30 19 33 22 4 4 5 5 37 26 39 28
Cough/
wheeze
3 3 0 0 4 4 1 1 14 11 13 11 40 35 27 24
Den-
tal
6 5 0 0 7 7 16 11 3 2 2 2 27 25 25 20
Dizzy/
faint
17 13 20 13 55 32 64 37 74 46 62 41 243 161 216 145
Drowsy/
fa-
tigued
56 40 77 47 125 72 267 123 30 24 51 46 338 228 562 338
Gas-
troin-
testi-
nal
dis-
tur-
bances
21 17 10 8 48 31 49 35 45 34 65 42 199 145 172 126
Hair
loss
0 0 0 0 6 4 15 6 3 3 3 3 10 8 20 11
Headache/
mi-
graine
74 42 20 13 95 49 97 43 48 31 40 29 412 229 264 146
Im-
po-
tence
1 1 0 0 5 4 17 5 0 0 0 0 6 5 17 5
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Table 9. Most commonly occurring adverse events continued (trials providing detailed individual participant data) (Contin-
ued)
In-
creased/
wors-
ened
seizures
1 1 0 0 29 21 41 25 86 35 58 27 136 75 107 60
Kid-
ney/
uri-
nary
prob-
lems
4 3 2 2 4 3 10 8 16 16 18 17 47 42 38 35
Mem-
ory
prob-
lems
4 4 3 3 38 23 71 34 7 6 7 7 67 47 87 49
Men-
strual
prob-
lems
15 9 13 7 4 4 3 2 0 0 0 0 22 16 37 26
Mood/
be-
havioural
change
5 5 4 1 32 22 56 34 2 2 6 5 61 46 82 55
Nau-
sea/
vom-
iting
21 15 15 11 38 23 54 35 30 23 37 24 179 132 163 107
Pain 18 15 1 1 14 9 15 12 55 28 28 20 162 103 71 53
Pins
and
nee-
dles/
tin-
gling
3 2 0 0 13 13 23 13 4 4 3 3 27 25 29 18
Rash/
skin
prob-
lems
33 26 17 14 65 36 99 65 23 20 39 32 258 183 269 191
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Table 9. Most commonly occurring adverse events continued (trials providing detailed individual participant data) (Contin-
ued)
Sleep
prob-
lems/
dreams
27 19 3 2 46 32 24 12 19 18 10 9 132 104 54 33
Throat/
tonsil
in-
fec-
tion
13 10 1 1 2 2 1 1 6 4 4 3 54 43 23 21
Tremor/
twitch
7 6 0 0 28 12 13 10 16 8 10 9 53 28 27 22
Vi-
sual
dis-
tur-
bance/
nys-
tag-
mus
6 4 7 5 34 22 33 22 13 10 8 4 71 50 70 47
Weight
gain
1 1 0 0 21 13 42 21 4 4 3 3 34 25 49 28
Table of most commonly occurring adverse events split into two for formatting reasons.
Events = number of adverse events reported; Ppts = number of participants reporting the adverse event (a participant could report the
same type of adverse event multiple times).
LTG = lamotrigine; CBZ = carbamazepine
Most common adverse events are defined as events reported 10 or more times in at least one of the seven trials (Brodie 1995 A; Brodie
1995 B; Brodie 1999; Nieto-Barrera 2001; Reunanen 1996; SANADA 2007; Werhahn 2015). Less commonly reported adverse events
are not summarised in this table but details are available on request from the review authors. General terminology for the type of adverse
events was defined by the review authors based on the individual participant data provided.
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A P P E N D I C E S
Appendix 1. Epilepsy Specialized Register search strategy
The following was used for the latest update.
1. epilepax or lamictal or lamotrigin* AND INREGISTER
2. MeSH DESCRIPTOR Carbamazepine Explode All AND INREGISTER
3. biston or carbamazepin* or carbatrol or cbz or epitol or equetro or neurotop or tegretal or tegretol or teril or timonil AND
INREGISTER
4. #2 OR #3 AND INREGISTER
5. #1 AND #4 AND INREGISTER
6. ((adjunct* or “add-on” or “add on” or adjuvant* or combination* or polytherap*) not (monotherap* or alone or singl*)):TI AND
INREGISTER
7. (#5 NOT #6) AND >31/07/2014:CRSCREATED AND INREGISTER
8. (epilepax or lamictal or lamotrigin*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
9. MeSH DESCRIPTOR Carbamazepine Explode All AND CENTRAL:TARGET
10. (biston or carbamazepin* or carbatrol or cbz or epitol or equetro or neurotop or tegretal or tegretol or teril or timonil):
AB,KW,MC,MH,TI AND CENTRAL:TARGET
11. #9 OR #10 AND CENTRAL:TARGET
12. #8 AND #11 AND CENTRAL:TARGET
13. ((adjunct* or “add-on” or “add on” or adjuvant* or combination* or polytherap*) not (monotherap* or alone or singl*)):TI AND
CENTRAL:TARGET
14. (#12 NOT #13) AND >31/07/2014:CRSINCENTRAL AND CENTRAL:TARGET
15. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
16. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
17. epilep* OR seizure* OR convuls* AND CENTRAL:TARGET
18. #15 OR #16 OR #17 AND CENTRAL:TARGET
19. #14 AND #18 AND CENTRAL:TARGET
20. #7 OR #19
Appendix 2. CENTRAL via CRSO search strategy
For the latest update, the following was used to search CENTRAL via the Cochrane Register of Studies Online (CRSO).
#1 epilepax OR lamictal OR lamotrigin*
#2 MESH DESCRIPTOR Carbamazepine EXPLODE ALL TREES
#3 biston OR carbamazepin* OR carbatrol OR cbz OR epitol OR equetro OR neurotop OR tegretol OR teril OR timonil
#4 #2 OR #3
#5 #1 AND #4
#6 (epilep* OR seizure* OR convuls*):TI,AB,KY
#7 MESH DESCRIPTOR Epilepsy EXPLODE ALL TREES
#8 MESH DESCRIPTOR Seizures EXPLODE ALL TREES
#9 #6 OR #7 OR #8
#10 eclampsia:TI
#11 #9 NOT #10
#12 #5 AND #11
#13 ((adjunct* OR “add-on” OR “add on” OR adjuvant* OR combination* OR polytherap*) NOT (monotherap* or alone or singl*)):
TI
#14 #12 NOT #13
#15 (“Conference Abstract”):PT AND INEMBASE
#16 #14 NOT #15
#17 * NOT INMEDLINE AND 03/12/2015 TO 17/10/2016:CD
#18 #16 AND #17
Earlier versions of this review used the following to search CENTRAL in the Cochrane Library.
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#1 (lamotrigine OR lamictal)
#2 MeSH descriptor Carbamazepine explode all trees
#3 carbamazepine or tegretol
#4 (#1 AND ( #2 OR #3 ))
#5 MeSH descriptor Epilepsy explode all trees
#6 MeSH descriptor Seizures explode all trees
#7 epilep* or seizure* or convulsion*
#8 (#5 OR #6 OR #7)
#9 (#4 AND #8)
Appendix 3. MEDLINE search strategy
The following was used for the latest update. It is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised
trials in MEDLINE (Lefebvre 2011).
1. (lamotrigin$ or lamictal or epilepax).tw.
2. exp carbamazepine/ or (biston or carbamazepin$ or carbatrol or cbz or epitol or equetro or neurotop or tegret?l or teril or timonil).tw.
3. 1 and 2
4. exp Epilepsy/
5. exp Seizures/
6. (epilep$ or seizure$ or convuls$).tw.
7. 4 or 5 or 6
8. exp *Pre-Eclampsia/ or exp *Eclampsia/
9. 7 not 8
10. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
11. clinical trials as topic.sh.
12. trial.ti.
13. 10 or 11 or 12
14. exp animals/ not humans.sh.
15. 13 not 14
16. 3 and 9 and 15
17. ((adjunct$ or “add-on” or “add on” or adjuvant$ or combination$ or polytherap$) not (monotherap$ or alone or singl$)).ti.
18. 16 not 17
19. limit 18 to ed=20140731-20180226
20. 18 not (1$ or 2$).ed.
21. 20 and (2014$ or 2015$ or 2016$ or 2017$ or 2018$).dt.
22. 19 or 21
23. remove duplicates from 22
Earlier versions of this review used the following search strategy, based on the previous Cochrane Highly Sensitive Search Strategy for
MEDLINE as set out in Appendix 5b of the Cochrane Handbook for Systematic Reviews of Interventions (version 4.2.5, updated May
2005) (Higgins 2005).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. exp Randomized Controlled Trials/
4. exp Random Allocation/
5. exp Double-Blind Method/
6. exp Single-Blind Method/
7. clinical trial.pt.
8. Clinical Trial/
9. (clin$ adj trial$).ab,ti.
10. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ab,ti.
11. exp PLACEBOS/
12. placebo$.ab,ti.
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13. random$.ab,ti.
14. exp Research Design/
15. or/1-14
16. (animals not humans).sh.
17. 15 not 16
18. lamotrigine.tw.
19. carbamazepine/ or carbamazepine.tw.
20. exp epilepsy/ or epilep$.tw.
21. exp seizures/ or seizure$.tw.
22. convulsion$.tw.
23. 18 and 19
24. 20 or 21 or 22
25. 23 and 24 and 17
WH A T ’ S N E W
Last assessed as up-to-date: 26 February 2018.
Date Event Description
26 February 2018 New citation required but conclusions have not
changed
Conclusions are unchanged.
26 February 2018 New search has been performed Searches updated 26 February 2018; no new studies
have been included.The term ’partial’ has been replaced
by ’focal’, in accordance with the most recent classifi-
cation of epilepsies of the International League Against
Epilepsy (Scheffer 2017).
H I S T O R Y
Protocol first published: Issue 1, 1998
Review first published: Issue 1, 2006
Date Event Description
26 April 2017 Amended Declarations of interest updated.
17 October 2016 New search has been performed Searches updated 17 October 2016; eight new studies
have been included
17 October 2016 New citation required but conclusions have not
changed
Conclusions are unchanged.
11 August 2009 Amended Contact details updated.
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(Continued)
27 August 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
SJ Nevitt assessed studies for inclusion in the review update, obtained individual participant data from trial investigators for the review
update, assessed risk of bias in all included studies, performed analyses in Stata version 14, added survival plots and a ’Summary of
findings’ table, and updated the text of the review.
C Tudur Smith provided statistical supervision and was involved with data analysis in the original review.
AGMarson independently assessed studies for inclusion, obtained individual participant data from trial investigators, provided guidance
with the clinical interpretation of results, assessed eligibility and methodological quality of individual studies, and co-wrote the original
review.
J Weston independently assessed risk of bias in all included studies.
D E C L A R A T I O N S O F I N T E R E S T
SJ Nevitt: none known.
J Weston: none known.
AG Marson was Chief Investigator of SANAD A 2007. A consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma)
funded the National Audit of Seizure Management in Hospitals (NASH) through grants paid to the University of Liverpool. Professor
Tony Marson is part funded by National Institute for Health Research Collaboration for Leadership in Applied Health Research and
Care North West Coast (NIHR CLAHRC NWC).
C Tudur Smith was involved in the statistical analysis of SANAD A 2007.
S O U R C E S O F S U P P O R T
Internal sources
• University of Liverpool, UK.
External sources
• National Institute for Health Research (NIHR), UK.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For the 2018 update, ’Time to withdrawal of allocated treatment’ was re-defined as ’Time to treatment failure’ due to feedback received
from the Cochrane Editorial Unit regarding potential confusion regarding ’withdrawal’ as a positive or negative outcome of anti-
epileptic monotherapy.
Additional analyses of ’Time to treatment failure’ (due to lack of efficacy and due to adverse events) following feedback on published
anti-epileptic drug monotherapy reviews that these sub-outcomes would be useful for clinical practice.
The term ’partial’ has been replaced by ’focal’, in accordance with the most recent classification of epilepsies of the International League
Against Epilepsy (Scheffer 2017).
For the 2016 update, in a posthoc change, ’Summary of findings’ tables were added to the review
December 2014: the title was changed to specify that the review uses individual participant data.
N O T E S
Sarah J Nolan (lead author of the 2016 update) is now Sarah J Nevitt.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [adverse effects; ∗therapeutic use]; Carbamazepine [adverse effects; ∗therapeutic use]; Epilepsies, Partial [∗drug therapy];
Epilepsy, Generalized [drug therapy]; Epilepsy, Tonic-Clonic [∗drug therapy]; Randomized Controlled Trials as Topic; Recurrence;
Triazines [adverse effects; ∗therapeutic use]; Withholding Treatment
MeSH check words
Adult; Child; Humans
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